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Antibiotic discovery and the emergence of antibiotic resistance 
Antibacterial chemotherapy is an important component of modern medicine and it has 
drastically improved human health and life expectancy worldwide, bringing benefits to the 
individual and society as a whole [1].  Use of antibiotics in livestock and poultry, initially 
mainly for growth promotion but also to control endemic disease among increasingly larger 
groups of animals, has also revolutionized animal production agriculture [2]. This started 
with the discovery and development of sulphonamides and penicillin during the first half 
of the twentieth century, followed by the so called Golden Era of drug discovery, which 
accelerated the discovery of many novel classes of antibiotics [3] (Figure 1).
However, extensive (over- and mis-) use of antibacterial drugs over the past decades have 
favoured the selection and spread of resistant bacteria [4]. The high level of antibiotics 
utilized in the livestock and poultry industry is considered to have contributed to the global 
spread of antibiotic resistance [5]. As a consequence, there are plans to further reduce 
antibiotic use in livestock across Europe [6]. Nevertheless, resistance of clinically relevant 
bacteria to commonly used antibiotics combined with the current void in discovery and 
market approval of successful novel antibacterial drugs remains a global health emergency 
[7, 8]. The rising prevalence of antibiotic resistance in bacteria is a leading healthcare priority 
worldwide, with drug resistant pathogens causing increased morbidity, mortality and overall 
healthcare costs in both human and veterinary medicine [8, 9]. Annually, 25.000 Europeans 
and 23.000 Americans are estimated to die as a direct result of infections with multidrug-
resistant bacteria [8, 10]. Although it is difficult to estimate, bacterial antimicrobial resistance 
has been reported to cost the European Union economy approximately €1.5 billion and the 
US health-care system between $21 billion to $34 billion per year [7, 11]. Yet, it is not so much 
the current impact of antibiotic resistance but the potential future implications that are 
worrisome. Antibiotic resistance is expected to lead to increased morbidity and mortality, 
with an associated exorbitant increase in health-care costs and indirect economic impacts 
worldwide [7, 9, 12].
Compounds that were found in the Golden Era of antibiotic discovery (1940s to 1960s) or 
derivatives of these compounds encompass practically all currently used antibiotics and 
despite the enormous high-tech discovery efforts which started in the 1990s only two new 
classes of antimicrobials have been approved in the last 20 years [3, 13] (Figure 1). History has 
shown that the introduction of every new antibiotic was rapidly followed by the emergence 
of resistance in the target microorganism, and the required steady flow of novel classes of 
antibiotics and derivatives has been outpaced by the emergence and spread of antibiotic 
resistance [13, 14]. Although there are hundreds of essential proteins in bacteria, the number 
of targets of currently used antibiotics is relatively small [13]. The most successful antibiotics 
hit only three targets or pathways: the ribosome (affecting protein synthesis), DNA gyrase or 
DNA topoisomerase (affecting DNA synthesis), or cell-wall synthesis. Other antibiotics target 
RNA synthesis, folic acid metabolism pathways and the bacterial cell membrane (Figure 2).
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Figure 1. History of antimicrobial drug discovery, showing the “Golden Era” of antimicrobial drug discovery from 
~1945 – 1976.  Market approval of different classes of antibiotics per decade are indicated above the timeline. 
The principal strategies employed in antimicrobial drug discovery are displayed below the timeline (HTS: High-
Throughput Screening, SBDD: Structure-Based Drug Discovery, FBDD: Fraction-Based Drug Discovery, VHTS: Virtual 
High-Throughput Screening). Figure is adapted from [15] and [14].
Antibiotic resistance is a normal ecological phenomenon which is widespread in the 
environment. Over billions of years bacteria have evolved to resist the action of naturally 
occurring antibacterial compounds [16]. It has been shown that antibiotic resistance in 
bacteria already existed before the modern selective pressure caused by human use of 
antibiotics was introduced [17, 18]. It is this dramatic increase of selective pressure caused 
by the extensive use of antibiotics over the last 70 years that has accelerated the evolution 
and spread of bacteria that are resistant to antibiotics. Although antibiotic resistance is a 
complex phenomenon, its mechanisms can be classified in three categories, namely intrinsic, 
acquired and adaptive resistance. Some common antibiotic targets and mechanisms 
associated antibiotic resistance are shown in Figure 2.
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Figure 2. Antibiotic targets and mechanisms of resistance. Figure adapted from Wright (2010)[19] and Lewis (2013)
[13].
Alternatives to conventional antibiotics
The alarming problem of antibiotic resistance has prompted renewed interests in alternative 
strategies to combat pathogenic microbes, such as the use of bacteriophages [20], synthetic 
antimicrobial peptides and peptoids [21-24], and naturally occurring bacteriocins [25-
27]. Renewed optimism about natural product discovery and the overwhelming number 
of uncharacterized biosynthetic gene clusters (BGCs) has also accelerated efforts to find 
novel antimicrobial secondary metabolites from microbes [28-30]. Vaccination, often being 
relatively cheap and highly effective, is another historically successful strategy against bacteria 
causing infectious disease. Although new tools and vaccination strategies are continuously 
being developed, still a myriad of challenges remain, such as persistent, highly variable and/
or novel pathogens, complex (e.g. polymicrobial) infections, and target populations that 
are difficult to reach [31]. The work in this thesis will focus on antimicrobial peptides as an 
alternative strategy to reduce the risk of infections by pathogenic bacteria.
Antimicrobial peptides
As mentioned above, the use of antimicrobial peptides (AMPs) is one of the alternatives to 
conventional antibiotics that is currently being explored and which has received considerable 
interest from the scientific community. Peptides with antibacterial and antifungal activity 
have a very ancient evolutionary origin and are widely distributed throughout all domains 
of life; currently, sequences of 2692 antimicrobial peptides originating from six kingdoms 
are deposited in the Antimicrobial Peptide Database (http://aps.unmc.edu/AP/) [32]. Their 
efficacy in antimicrobial activity against pathogens has likely contributed to their ubiquity 
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throughout many lifeforms. AMPs have been found in numerous multicellular organisms, 
and are an essential component of innate immunity and form a first line of defence against 
pathogenic microbes [33]. In mammals, cathelicidins and defensins are two major classes 
of AMPs that are often produced by epithelial cells, circulating neutrophils, and tissue 
macrophages which are important in protecting against pathogenic invasion. For example, 
studies in knockout mice have shown that the murine cathelicidin-related antimicrobial 
peptide (mCRAMP) mediates defense against intestinal colonisation with epithelial adherent 
pathogens such as Citrobacter rodentium [34]. The protective role of human defensin 5 was 
demonstrated by its expression in Paneth cells of transgenic mice, which led to increased 
resistance to oral challenge with virulent Salmonella typhimurium [35]. Expression of human 
antimicrobial peptides is greatly reduced in skin lesions of patients suffering from atopic 
dermatitis, which is characterized by increased bacterial, fungal and viral skin infections [36]. 
Similarly, amphibian skin AMPs have been shown to effectively inhibit skin infections by the 
pathogenic fungus Batrachochytrium dendrobatidis [37].
Being an integral component of innate immunity, AMPs usually act non-specifically (broad-
spectrum activity) and rapidly (within minutes) [38]. There is an enormous diversity of known 
peptide sequences and typically little sequence similarity is seen between peptides isolated 
from different species [33]. This thesis is mostly centred around the antimicrobial activity 
of AMPs. However, in addition to direct pathogen killing, many AMPs have been shown to 
possess other activities such endotoxin neutralization, immune cell recruitment, modulation 
of cytokine production, suppression of potentially harmful inflammation, induction of cell 
differentiation, and enhancement of adaptive immune responses, cell survival, wound 
healing and angiogenesis (Figure 3), and thus are also commonly referred to as host-defense 
peptides (HDPs) [21, 39-41].
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Figure 3. Multiple functions of antimicrobial peptides in host defense. Source: Lai & Gallo (2009)[40]
Structures of AMPs
Over the last two decades multiple peptide databases have been established in an attempt 
to classify the wide range of AMPs based on characteristics such as origin, secondary 
structure, mode of action, or post-translational modification [42]. Traditionally, AMPs are 
categorized regarding the most common three-dimensional secondary structures: α-helices 
(e.g. LL-37, magainin, cecropin), β-strands having multiple stabilizing disulphide bridges (e.g. 
human α- and β-defensin, protegrin), loop structures with one internal disulphide bridge 
(e.g. bactenecin), and extended structures rich in glycine, proline, tryptophan arginine, or 
histidine (e.g. indolicidin)[39] (Figure 4).
A commonly found and widely studied class of HDPs is cationic α-helical AMPs. Such linear 
AMPs often appear in aqueous solution as unorganized coils, but they can adopt an active 
secondary α-helix structure in the presence of phospholipid membranes [43]. In this shape, 
clusters of cationic and hydrophobic amino acid residues are organised three-dimensionally 
in separate clusters of the molecule, resulting in an amphipathic structure. Often, in amphibian 
skin secretions several cationic α-helical AMPs can be found, such as the magainins being 
among the first HDPs to be described [44]. The antimicrobial and cytolytic activity of these 
peptides is determined by cationicity, hydrophobicity, α-helicity and amphipathicity [45], 
parameters that can be altered by amino acid substitution to change antimicrobial potency 
or specificity [46]. In this thesis, naturally occurring amphibian AMPs and analogues thereof 
have been tested for their activity and selectivity against pathogenic bacteria, and the human 
cathelicidin LL-37 was used as a model cationic peptide.
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Figure 4. Three-dimensional structures of selected AMPs, showing the structural diversity. Pink colour highlights 
α-helical motifs, while β-sheets are shown in yellow colour. Protein Data Bank ID of the displayed models is given 
in parentheses.
Bacteriocins
Ribosomally synthesized AMPs from prokaryote origin are generally known as bacteriocins 
and they have been proposed as potential alternatives to or synergistic complementary 
agents with conventional antibiotic therapy [26, 47]. They are usually classified based on 
their post-translational modification; Class I peptides (e.g. nisin, thuricin CD, bottromycin 
A2) are modified, whereas class II peptides (e.g. pediocin PA-1, epidermicin NI01, enterocin 
AS-48) are largely unmodified or cyclic in their active form [26, 48]. Bacteriocins target some 
pathways or processes in common with conventional antibiotics, such as the inhibition of cell 
wall biosynthesis and DNA or protein synthesis. Additionally, many bacteriocins have been 
found to disrupt membrane integrity (see below) [47]. In general, bacteriocins have narrow-
spectrum activity against a limited set of species that are phylogenetically closely related to 
the producer and are therefore thought to modulate the composition of bacterial species 
colonizing a niche without dramatically disrupting the microbiota [26, 49]. Production of 
such AMPs is widespread among bacteria and is regarded to contribute to bacterial fitness, 
colonization capacity, and probiotic functionality by having multiple ecological functions 
[49]. Commensal production of AMPs specifically targeted against pathogens in situ is 
LL-37 (2K6O)
Protegrin-3 (2MZ6)
Magainin (2LSA)
Human beta-defensin (1KJ6)
Indolicidin (1G89)
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considered an attractive strategy to prevent infectious disease [26, 50]. For example, a Bacillus 
thurigiensis isolate from human faeces was found to produce the two-peptide bacteriocin 
thuricin CD that displays narrow-spectrum antimicrobial activity against Clostridium difficile, 
without significantly disrupting the resident microbiota which might lead to recurrence of C. 
difficile associated diarrhoea [49, 51]. 
Non-ribosomal peptide biosynthesis
In addition to ribosomally synthesized peptides, many microbes have the ability to produce 
secondary metabolites of wide structural diversity, including peptide antibiotics, using large 
multifunctional enzymes encoded by BGCs. One class of BGC is formed by non-ribosomal 
peptide synthetases (NRPSs), which consist of a linear arrangement of modules, each 
of which are further subdivided into separate catalytic domains [52, 53]. Each module is 
responsible for the incorporation of one building block (e.g. amino or hydroxy acid) into the 
growing peptide chain, with the separate domains catalysing specific substrate activation, 
covalent binding, and peptide bond formation. In this sense, the NRPS comprises both the 
assembly machinery as well as the specific template for biosynthesis of the product [52]. The 
structural diversity of NRPS derived molecules is enormous, because the possible building 
blocks are not limited to the 20 canonical amino acids [53].  To date more than 530 possible 
monomers and 1179 different non-ribosomally derived peptides have been identified [54]. 
Many pharmaceutically valuable antimicrobial compounds that are used in the clinic today 
are microbial NRPS products or derivatives thereof [55]. Vancomycin, belonging to the 
glycopeptide class of antibiotics, is a potent drug against Gram-positive bacteria and was 
already isolated and described in the early 1950’s [56]. The cyclic lipopeptide daptomycin 
was discovered in fermentations of Streptomyces roseosporus and is now used as a last-
resort antibiotic, for instance against Gram-positive skin infections [57, 58].
AMP modes of action
Although AMPs lack evolutionary conservation of primary sequences and thus have a 
wide variety of three-dimensional structures, they usually share common features such as 
cationicity, amphipathicity and short length, which are important for their mode of action 
[39]. AMPs display a higher specificity to bind and insert into the plasma membrane of 
bacteria and fungi compared to the membranes of higher eukaryotes. This is primarily due 
to the higher content of anionic phospholipids exposed on the outer leaflet of bacterial and 
fungal plasma membranes compared to plasma membranes of plants and animals, where 
the negatively charged headgroups of the phospholipids are mainly located on the inner 
leaflet [59]. Other negatively charged components, such as lipopolysaccharide (LPS) or wall- 
and lipoteichoic acids (WTA, LTA), are also only present on bacterial but not on eukaryotic 
cell surfaces [60]. Electrostatic interaction between these negatively charged cell envelope 
components and positively charged amino acids is generally believed to be a main driver 
for AMP binding and accumulation on membrane surfaces [60-62]. Additionally, a range of 
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other factors may be involved in the selectivity and activity of AMPs, such as differences in 
transmembrane potential and the presence of cholesterol in the target membrane altering 
membrane fluidity and stability [59]. 
Different models to describe the molecular mode of lethal action of AMPs have been 
proposed, although the exact mechanisms are not yet fully understood. However, all models 
agree on the initial key event of stoichiometric accumulation of AMPs on the outer leaflet of 
the plasma membrane by their binding to phospholipids, and once a threshold is reached, 
plasma membrane permeabilization is induced [63]. Traditionally accepted models describe 
permeabilization by micellization (“carpet” model) [64], by formation of pores composed 
exclusively by peptides organised perpendicularly to the membrane (“barrel-stave” 
pore model) [65], by accumulation of peptides parallel to the membrane surface causing 
phospholipid folding and bending leading to mixed peptide-phospholipid pores (“toroidal” 
pore model) [66] (Figure 5) [63]. Regardless of the mechanism, severe disruption of the 
internal homeostasis ensues, with a lethal outcome for the targeted microbe [33]. 
Figure 5. Suggested models for phospholipid membrane disruption by AMPs. Initially, a threshold concentration of 
AMPs on the membrane interface is required. a) Barrel-stave pore, b) carpet model, c) toroidal pore, d) disordered 
toroidal pore. Source: Melo et al. (2009)[63].
It recently became clear that the importance of the non-specific interaction of AMPs with the 
phospholipid membrane and subsequent membrane disruption might be overestimated, 
and that the bactericidal activity of many AMPs might be due to interaction with other 
specific targets [62, 67, 68]. One example is nisin, a lantibiotic produced by strains of 
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Lactococcus lactis  [69] that has been widely used as a food preservative for more than 
40 years. Nisin interacts with the membrane-bound cell wall precursor lipid II, thereby 
inhibiting peptidoglycan synthesis. Additionally, nisin forms membrane pores that consist 
of lipid II and nisin molecules, causing dissipation of the membrane potential, and rapid 
efflux of small metabolites [70, 71]. Many defensins from multiple sources have been shown 
to directly target the bacterial cell wall building block lipid II, thereby specifically inhibiting 
cell wall biosynthesis [67]. For example, the fungal defensin plectasin showed very potent 
antimicrobial activity against Gram-positive pathogens, and was able to cure mice from S. 
pneumoniae induced peritonitis and pneumonia without evidence of toxicity to the host [72]. 
This antibacterial activity is entirely due to lipid II binding and blocking of the peptidoglycan 
synthesis pathway, without compromising bacterial membrane integrity [73].
Bacterial resistance mechanisms to AMPs
Rapid development of microbial resistance against AMPs due to their mechanism of killing 
has often been claimed to be unlikely, because bacteria would have to alter the composition 
and/or organisation of conserved structures like the membrane and cell-wall causing adverse 
consequences [33]. This notion  was until recently supported by the absence of reports of 
bacterial resistance to AMPs [33, 62] and was one of the reasons for the considerable amount 
of scientific attention they have received [39]. The enticing idea of developing AMPs as 21st 
century novel antibiotics that would circumvent the global antibiotic resistance problem now 
has to be reconciled with recent evidence for several of resistance mechanisms against AMPs 
[74]. The various mechanisms of resistance to AMP-mediated killing most likely evolved in 
bacteria due to the selective pressure resulting from exposure to environmental bacteriocins 
and host AMPs, and include surface charge modification, active efflux, alteration of membrane 
fluidity, proteolytic digestion, and entrapment by surface proteins and polysaccharides [74]. 
The current knowledge about strategies employed by bacteria to counteract the lethal action 
of AMPs is extensively described in recent reviews by Joo et al. [75] and Cole & Nizet [74]. 
Here, some key resistance mechanisms are briefly discussed (Figure 6). 
Given that many AMPs are cationic, a well-described resistance mechanism in both Gram-
positive and Gram-negative bacteria is modification of anionic cell surface constituents 
to decrease electrostatic attraction of such peptides [75]. In Gram-positives, the cell-wall 
components LTA and WTA usually have an overall negative charge, but the gene products 
of the dlt operon confer a positive charge by the incorporation of d-alanyl esters [76]. This 
reduces the susceptibility of the bacterium to cationic AMPs by electrostatic repulsion [77] 
and by increasing cell wall density that sterically hinders AMP access to the membrane due to 
altered conformation of LTA [76]. Another electrostatic repulsion mechanism found in both 
Gram-positives and Gram-negatives involves the modification of the anionic membrane 
phospholipid phosphatidylglycerol (PG) by the multipeptide resistance factor (MprF), adding 
a l-lysine or l-alanine residue, which results in a net-positively charged PG [75, 78, 79]. 
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Secreted or membrane-bound proteases can provide another simple, yet effective 
resistance strategy against AMPs, by effectively cleaving and inactivating them [75]. For 
example, proteases  from  several clinically important human pathogens, such as elastase 
of Pseudomonas aeruginosa, were able to break down the human cathelicidin LL-37 and 
increase bacterial survival in an ex vivo wound fluid model [80].
Aforementioned lipid II is an essential and well conserved component of peptidoglycan 
biosynthesis pathway required for cell wall formation in eubacteria. Lipid II offers several 
binding sites for many structurally unrelated antibiotics and AMPs, and their interaction often 
leads to defunct cell wall biosynthesis with severe adverse effects to the target bacterium 
[60, 68]. Bacteria may modify lipid II to alter the overall cell surface charge and reduce 
the binding affinity of AMPs [60]. In contrast to the regulated resistance caused by surface 
charge modification of proteolytic AMP degradation, structural modifications to the cell wall 
components is usually constitutive [60].
These and other common mechanisms of resistance to AMPs are highlighted in Figure 6.
Figure 6. Overview of Gram-positive and Gram-negative resistance mechanisms to cationic AMPs (CAMP). Different 
counteracting strategies are 1) proteolytic degradation; 2) sequestration; 3) electrostatic repulsion by d-alanylation 
of teichoic acids; 4) electrostatic repulsion by amino-acylation of membrane phospholipids; 5) modification of lipid 
II to prevent binding; 6) AMP removal via efflux transporters; 7) proteolytic degradation by membrane bound or 
intracellular proteases; 8) sequestration or steric hindrance by the polysaccharide chain of LPS; 9) electrostatic 
repulsion by amine-compound modification of lipid A; 10) increased membrane by addition of extra acyl chains into 
lipid A. Source: Joo et al. (2016)[75]
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Interestingly, AMPs have been proposed to serve as environmental cues to elicit virulence 
gene expression in the host, leading to bacteria gaining a more “invasive phenotype” [81-
85]. Additionally, these AMP induced changes in gene expression could lead to increased 
adaptive resistance towards conventional antibiotics, such as macrolides, fluoroquinolones, 
or aminoglycosides [84, 86]. Surprisingly, acquisition of adaptive DNA mutations leading to 
increased bacterial mucoidy and rifampin resistance were observed upon exposure to sub-
inhibitory concentrations of LL-37 [87]. The therapeutic use of AMPs may also compromise 
natural innate immunity, one example being the exposure of Staphylococcus aureus to 
pexiganan, a synthetic analogue of magainin, leading to cross-resistance to human 
defensin-1 [88].
Other limitations of AMPs as therapeutic agents
Despite the scientific enthusiasm about AMPs as potent new antibiotic drug candidates and 
the increasing amount of patents claiming such therapeutic potential, many AMPs do not 
make it to the market due to failure in clinical trials [62, 89]. This could be due to a number 
of reasons, such as absorption, low in situ peptide stability and proteolytic degradation, 
haemolytic and cytotoxic activities in patients, or bacterial resistance mechanisms (see 
below). This emphasizes that there is a gap in fully understanding their plethora of biological 
functions, the mode of antibacterial activity and the resistance mechanisms developed by 
bacteria. Thus, there are some major issues that remain to be solved before therapeutic use 
of AMPs can be achieved.
Initially, two methods were available for obtaining antimicrobial peptides: isolation from 
the host organism or chemical synthesis. Isolation of these defense molecules from host 
tissues such as frog skins [44] and insect lymph fluid [90] required several fractionation 
and purification steps, followed by microbiological tests to determine their bactericidal 
properties. Using this approach many cationic peptides from various species have been 
discovered. Nevertheless, this method of AMP isolation is tedious, requires large quantities 
of source material, usually has low yields, and is therefore not suitable for clinical trials 
[62, 91]. On the other hand, the chemical peptide synthesis using the established solid-
phase techniques is faster, easy to automate, and requires simpler purification steps. This 
technique allows studies on structure-activity relationships without biological restrictions 
due to toxicity. It also has the possibility of incorporating unnatural amino acids, whereas 
peptides generated by ribosomes are limited to a subset of α-amino acids and α-hydroxy 
acids [23, 92].  However, the limitation of chemical AMP synthesis is the high cost and difficulty 
to incorporate complex posttranslational modifications. For example, the production of 
peptides containing multiple disulphide bonds and thus complex secondary structures, will 
substantially increase production costs [91]. 
Alternatively, the heterologous expression of eukaryotic AMPs by microorganisms, such 
as lactic acid bacteria, could be a cost-effective tool for functional and clinical research. 
Production of AMPs by genetically modified microorganisms is interesting due to the low 
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costs, rapid growth on inexpensive substrates, controllable laboratory conditions, and the 
generally well-characterized genetic backgrounds and availability of a wide range of vectors 
and host strains [93]. The use of fusion proteins is common in the production of small, labile 
AMPs to provide stabilization, shield the AMP from intracellular proteolytic degradation, 
increase expression and facilitate downstream purification processes, but more importantly 
to mask the intrinsic toxicity of these peptides to the expression host [91, 94, 95]. However, 
there are technical problems that currently still persist in optimizing bacteria as AMP 
producing cell-factories, such as their intrinsic antibacterial activity, lack of post-translational 
modification machinery in heterologous producers, contamination with bacterial LPS, and 
the inefficient expenditure of energy and protein synthesis machinery caused by the fusion 
protein strategy [62]. Despite the feasibility of isolating AMPs, or producing them by chemical 
synthesis or microbial cell-factories, the cost of manufacturing sufficient quantities for 
therapeutic use greatly exceeds the costs of currently used antibiotics [62].  
From a pharmacological standpoint, AMPs don’t follow the Lipinski “Rule of Five” for drug-
likeness that predicts good absorption and permeation [96]. Additionally, many natural AMPs 
are sensitive to enzymatic degradation in vivo by host or bacterial (see below) proteases and 
peptidases. Another limitation of many AMPs is their systemic toxicity and haemolytic activity 
preventing their use to treat systemic invasive disease.  For these reasons AMPs currently 
hold most promise as topical treatments for skin and wound infections [97, 98]. 
The importance of the microbiota 
Although for several decades there was a strong scientific focus on antibiotic resistance 
development in specific pathogenic bacteria, there is now concern about collateral effects of 
the extensive use of broad-spectrum antibiotics on commensal bacteria [99]. Furthermore, 
the accumulation of antibiotic resistance genes (i.e. the resistome) in commensal microbes 
and their potential horizontal transfer to opportunistic or pathogenic bacteria is of 
concern [100]. The diverse and complex communities of commensal microbes that inhabit 
mammalian external surfaces, such as the gastrointestinal tract, the oral cavity or the skin, 
are collectively known as the microbiota [101]. The microbiota composition may differ widely 
between individuals as well as between different niches within an individual [102], and is the 
result of shared co-evolution, co-adaptation and codependency with the host [103].
It was as early as 1907 that Élie Metchnikoff  theorized that beneficial properties of 
certain commensal lactic acid bacteria could be used to enhance health by manipulating 
the intestinal microbiota [104]. Methods to study and characterize the microbiota are 
continuously improving, and especially the advent of cultivation-independent methods, 
such as the ones targeting the bacterial 16S rRNA gene sequence and random metagenomic 
DNA approaches, have considerably accelerated scientific research in this field over the last 
decades [105]. Next generation sequencing (NGS) technologies that allow high-throughput 
data collection, such as 454 pyrosequencing and Illumina sequencing, have been broadly 
adopted for microbiota profiling as costs of (outsourced) sequencing continues to decrease. 
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In addition, studies in gnotobiotic mice have significantly advanced our understanding of 
the important role of microbiota in the intestinal development and homeostasis and the 
function of the immune system [106-108].
We now know that the microbiota is involved in various processes that are beneficial 
to the host [109], such as fermentation and conversion of food or feed components [110, 
111], production of essential nutrients and metabolites [109, 112, 113], maturation and 
modulation of the immune system [107, 114], and colonization resistance against pathogens 
(see below)[50]. On the other hand, dysbiosis of the gut microbiota and the sudden increase 
in abundance of specific intestinal pathobionts have been shown to contribute to the 
pathophysiology of both intestinal and extra-intestinal disorders, such as inflammatory 
bowel disease, obesity and type II diabetes [115]. 
It has also become clear that the composition and function of the microbiota can indeed be 
influenced by environmental factors, and that this may alter the health status of the host. 
It has been shown that nutrition is an important factor in the modulation of the intestinal 
microbiota, particularly dietary fibres and probiotics [116, 117]. Several studies have shown 
that antibiotic chemotherapy can adversely impact on the composition and diversity of 
the microbiota [118, 119]. Increased susceptibility to pathogenic infections due to loss of 
colonization resistance after exposure to antibiotics was already demonstrated almost 60 
years ago [120, 121] and this phenomenon is now well-accepted [50, 122].
Colonisation resistance
Stable and diverse microbial communities may provide colonisation resistance against 
pathogenic species by two major mechanisms that are mediated via a variety of molecular 
microbe-microbe interactions (direct colonisation resistance) and/or microbe-host 
interactions (indirect colonisation resistance) [122]. It is mutually beneficial to the host and 
commensal bacteria to reduce or inhibit the establishment of pathogenic bacteria. Such 
cooperation prevents severe inflammation, tissue damage and associated reduced nutrient 
uptake for the host and it preserves the balanced niche in which the commensal bacteria 
thrive [123].
Direct colonisation resistance (i.e. microbial antagonism) may occur through several different 
mechanisms, including competitive exclusion, nutritional competition and production of 
metabolites and bacteriocins, thereby conferring a benefit to the host [50, 122, 124] (Figure 
7). Competitive exclusion refers to direct bacterial competition for mucosal adherence sites 
in which several bacterial surface structures, such as adhesins and fimbriae, have been 
proposed to play an important role [125, 126], although the exact mechanisms behind this 
remain unclear. Commensal bacteria can also limit the availability of carbon sources and/
or micronutrients; for example, Bacteroides thetaiotaomicron outcompetes the pathogen 
Citrobacter rodentium for consumption of carbohydrates [127]. Bacterial antimicrobial 
peptides or compounds might (1) confer a competitive advantage to the producer to facilitate 
colonization of a specific niche, (2) directly kill or inhibit growth of pathogenic bacteria, and 
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(3) be involved in signalling within bacterial communities or with the host [25]. Additionally, 
some commensal microbes are able to neutralize host epithelium damaging toxins secreted 
by pathogens, such as a protease from Saccharomyces boulardii that inactivates toxin A that 
is produced by Clostridium difficile [128]. 
As briefly mentioned earlier, the host itself is also an crucial environmental factor shaping 
local microbial communities, as some bacteria are better adapted than others to withstand 
the generally non-specific host defenses. Indirect (or immune-mediated) colonisation 
resistance refers to the microbiota enhancing the mucosal barrier and/or modulating innate 
and adaptive immunity of the host, which results in reduced susceptibility to (invasive) 
pathogens [50, 122]. In the intestine, commensal microbes can trigger the secretion of 
cytokines, chemokines and antimicrobial HDPs [50, 129]. A prime example that illustrates 
the complexity of such host-microbiota interplay is the secretion of REGIIIγ, a bactericidal 
C-type lectin peptide. REGIIIγ expression by epithelial cells is upregulated upon exposure 
to bacterial stimuli, such as LPS, through the Toll-like receptor-MYD88 signalling pathway. 
Moreover, the cytokine IL-22, which is secreted by innate lymphoid cells (ILCs) and elicits 
several immune responses essential for mucosal homeostasis and protection against 
infections, is also required for REGIIIγ expression [130, 131]. Expression of IL-22, in turn, has 
been shown to be enhanced by activation of the aryl hydrocarbon receptor (Ahr) in ILCs by 
bacterial metabolites, such as indole-3-aldehyde produced by certain Lactobacillus species, 
like L. reuteri [132]. Increased expression of REGIIIγ in the large intestine is dependent on 
colonization with commensal bacteria, e.g. B. thetaiotaomicron, and through the above 
mentioned regulatory mechanism, REGIIIγ protects the intestinal mucosal barrier against 
infections by the pathogens, like Listeria monocytogenes [133-135]. 
The increasing knowledge about the molecular mechanisms underlying the beneficial 
effects of commensal or probiotic bacteria and their inhibition of proliferation of pathogenic 
microbes, opens up the way to the development of next-generation probiotics to exploit 
natural colonization resistance and control potential pathogens [136]. 
Probiotics
Probiotics are defined as “live microorganisms, which when consumed in adequate amounts, 
confer a health benefit on the host” [137]. Frequently used probiotic agents include strains 
of lactic acid bacteria, bifidobacteria, bacilli, non-pathogenic Escherichia coli, and yeasts 
[25]. The beneficial properties of these probiotics may be due to one or more colonisation 
resistance mechanisms that are described in the previous section, and in this context it has 
been proposed that bacteriocin production is an important probiotic trait [25]. Currently, the 
potential to use of (mixtures of) probiotic strains to reduce the risk of infections in humans 
and animals as an alternative to conventional antibiotic therapy is receiving great scientific 
and commercial interest [136]. 
For example, Lactobacillus reuteri can produce reuterin (3-hydroxypropionaldehyde), a 
secondary metabolite with broad-spectrum antimicrobial activity that can modulate the 
GENERAL INTRODUCTION
25
Ch
ap
te
r 1
microbiota composition as well as directly inhibit enteric pathogens [138, 139]. In addition, 
L. reuteri may have immunomodulatory effects by enhancing the intestinal production of 
IL-22 [132], and by suppressing the production of proinflammatory cytokines such as TNF-α 
and IL-12 in macrophages, monocytes, and dendritic cells, which can contribute to tolerance 
and reduction of intestinal inflammation in colitis [139]. Several strains of L. reuteri are 
currently commercially available as food supplements that claim to reduce the incidence 
and the severity of diarrhea, prevent enterocolitis or reduce infantile colic. Also in livestock, 
lactobacilli, such as L. reuteri, are widely used as probiotics [140, 141]. In pigs, especially 
neonatal or post-weaning piglets, L. reuteri is applied to increase performance (weight gain), 
prevent of diarrhea, and reducing oxidative stress [141]. While in specific situations probiotic 
supplementation could reduce or replace antibiotic chemotherapy, in most studies with pigs, 
the exact underlying mechanism and the specific location where L. reuteri exerts its activity 
are not yet clear. Nevertheless, considering the planned reduction of veterinary antibiotic 
use, applications of probiotic or commensal bacteria to prevent or minimize infections of 
piglets by bacterial pathogens would be very valuable for the swine industry. The work in this 
thesis focusses on alternative strategies against the porcine pathogen Streptococcus suis.
Figure 7. Direct colonization resistance mechanisms. Source: Sassone-Corsi & Raffatellu (2015) [50]
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The porcine pathogen Streptococcus suis
Streptococcus suis is an encapsulated Gram-positive facultative anaerobic microbe, 
frequently present as a member of the porcine microbiota of the oro- and nasopharynx, 
and the intestinal and genital tracts [142-144]. S. suis is considered to be an important swine 
pathogen, causing morbidity and mortality in all countries where pigs are reared on a large 
scale. As such, infections by S. suis cause large economic losses to the global swine industry 
[145]. Carriage of S. suis in adult pigs varies widely among herds, with possible rates of up to 
80% of the herd, and is usually asymptomatic, whereas young pigs during weaning (weeks 
4 to 12) are most at risk from invasive disease [146, 147]. Disease symptoms such as acute 
sepsis, meningitis, endocarditis, pneumonia and arthritis are often reported, although in 
acute cases sudden death may also occur without appearance of obvious symptoms [148, 
149]. S. suis also contributes to polymicrobial upper respiratory tract infections which may 
increase susceptibility to subsequent invasive S. suis infections [150, 151]. Morbidity due to 
invasive disease is estimated to be between 1% and 50% although it rarely exceeds 5% when 
treated promptly, while mortality can increase dramatically up to 20% without rapid and 
appropriate antibiotic treatment [145]. 
Aside from causing invasive disease in swine, S. suis is also considered an emerging zoonotic 
pathogen [152]. The first human infection was recorded in Denmark in 1968 [153], and since 
then around 1600 clinical cases have been documented [154, 155]. There have probably 
been considerably more cases of human infection in countries where S. suis is endemic, such 
as Asian countries with extensive small-scale pig rearing, due to a lack of disease awareness 
or diagnostic capabilities. Occupational exposure to infected pigs or pork products (a hazard 
for pig farmers, abattoir workers and butchers) has been shown to be associated with S. 
suis infections in humans [156-158]. Another important risk factor for human infection is the 
consumption of raw or undercooked pork products, such as meat, blood and organs, which 
is common in some parts of Asia [157]. 
S. suis is normally encapsulated and based on the antigenic diversity of the surface-associated 
capsular polysaccharides (CPS) 35 different serotypes have so far been described. However, 
it remains unclear whether all serotypes actually belong to S. suis; recent analysis of 16S 
rRNA and cpn60 genes sequences suggested that serotypes 32 and 34 were phylogenetically 
more closely related with S. orisratti [155, 159]. S. suis prevalence is common but the known 
serotypes seem to have a different geographical distribution worldwide [155]. Mainly serotype 
2, but also serotypes 1, 7, 9, and 14, are most frequently isolated from clinical samples of 
diseased pigs in Europe. Serotype 9 in particular is being increasingly isolated and associated 
with diseased pigs [160], while serotype 2 strains often are more virulent in pigs and generally 
considered to be the most common serotype infecting humans [155, 161]. 
The clinical manifestations of invasive disease by S. suis are similar in pigs and humans, 
with meningitis (68%) being the most common clinical symptom followed by sepsis (25.0%), 
arthritis (12.9%), endocarditis (12.4%), and endophthalmitis (4.6%), although these reported 
values may vary per country and depend on study design and used methods [154]. Presence 
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of S. suis serotype 2 is most often confirmed in cases of human infection (74.7%), followed by 
unknown or unconfirmed serotypes (23%) and serotype 14 (2%) [155]. 
Challenges in prevention and treatment of S. suis
Antibacterial chemotherapy is currently an important tool to treat and control S. suis 
infections in the swine industry. Prompt treatment of animals diagnosed with or suspected 
of S. suis infection with penicillin G, amoxicillin, trimethoprim/sulfamethoxazole, gentamicin, 
and ceftiofur is recommended [162]. In some countries S. suis is the primary cause of mortality 
and morbidity in young pigs and the most frequent reason to prescribe antibiotics of the 
amino-penicillin group as a preventative measure. Thus S. suis infections on farms indirectly 
contribute to the spread of antibiotic resistance. Of major concern is the emergence of 
strains causing more rapid and severe disease [154, 163] and the risk that the burden of both 
zoonotic and porcine disease will increase as plans for continued reduction of antibiotic 
use in livestock are implemented across Europe [6]. Prudent use of antibiotics for S. suis is 
essential to preserve the therapeutic efficacy of broad-spectrum compounds and to minimize 
selection of resistant S. suis strains [162]. Studies have suggested a direct link between the use 
of the antibiotics tylosin and tetracycline and the prevalence of bacterial resistance to these 
compounds in pigs [164]. Currently, resistance to macrolides, lincosamides, tetracyclines, 
and sulphonamides has been reported for up to 85% of S. suis isolates in many countries 
[162]. There are also strong indications that S. suis could act as a reservoir contributing to 
the spread of antibiotic resistance to other major streptococcal pathogens, presumably via 
mobile resistance genetic elements [152].
Despite the considerable efforts to develop vaccines against S. suis over the last decade, there 
is currently no efficacious and cross-protective vaccine on the market. Vaccines with heat- or 
formalin killed bacteria are used in the field with some degree of success and recent studies 
with CPS specific glycoconjugate vaccines show promising results [165-169]. However, the 
use of these preventative measures is very limited because protection is restricted to a 
specific serotype. 
For the above mentioned reasons, alternative strategies to control S. suis are needed. 
Bacteriophages, phage lysins [170] [171] and plant extracts [172] are among the alternatives 
that have been investigated to date. Recently, the production of bacteriocins by selected 
avirulent strains of S. suis that can inhibit virulent S. suis of different sequence types was 
described as a similar strategy [173-175].
Rationale and approach undertaken in this thesis
This thesis studies the potential of naturally occurring host AMPs as therapeutic alternatives 
against pathogenic bacteria, with focus on Streptococcus suis in particular. In order to 
cause disease, S. suis first has to successfully colonize the host’s mucosal surfaces, niches 
that are rich in both host- and microbe-derived AMPs. Hence, it was assumed that S. suis is 
continuously exposed to attack by AMPs, and as a result has likely evolved mechanisms to 
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defend itself or might sense host-derived AMPs as an environmental cue leading to enhanced 
colonisation or infection capacity. Another promising approach to reduce S. suis infections in 
pigs could be via administration of bacteria producing AMPs in situ to prevent colonization or 
suppress sudden post-weaning blooming by S. suis [123]. Such a strategy may be particularly 
suitable in young pigs, which are most susceptible to S. suis infections after weaning and in 
which the microbiota is still developing. The feasibility of such an approach was shown for a 
mixture of five candidate probiotic strains from the porcine intestine that inhibited Salmonella 
enterica in vitro and ameliorated diarrhoea when administered to  S. enterica infected pigs. 
The protective effect was proposed to be due to the production of a bacteriocin by one of the 
isolates [176-178]. As such, the hypothesis was that commensal bacteria displaying (direct) 
microbial antagonism against S. suis may be found in the microbiome of the niches that S. 
suis inhabits. Such AMP producing antagonists could potentially be effective colonisers of 
these niches and protect against S. suis infection when applied early in the life of young pigs.
Eukaryotic AMPs
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Figure 8. Schematic overview of the approach and the chapters of this thesis.
Aims and outline of this thesis
The therapeutic use of AMPs has been proposed as a promising alternative to combat 
multidrug resistant (MDR) pathogenic bacteria. The first aim of this thesis was to investigate 
to what extent naturally occurring AMPs could be effective for treating skin or wound infections 
caused by specific pathogenic bacteria. Chapter 2 describes the testing of a selection of 
amphibian skin peptides and analogues thereof with different physicochemical properties 
in antimicrobial assays to determine their effect on a collection of Gram-positive and Gram-
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negative probiotic, commensal and pathogenic bacteria. We observed a 3- to 9-fold lower MIC 
for five natural peptides and a 5- to 6.5-fold lower MIC for three analogues against selected 
pathogens than against commensal or probiotic Gram-positive bacteria. We propose that 
these peptides could be a good starting point for future research into use their for topical 
applications, based on their differential antimicrobial effect against certain skin associated 
multi-drug resistant pathogenic bacteria and their low cytotoxicity to mammalian cells.
Although many studies have focussed on identifying or synthesizing novel potent 
antimicrobial peptides, some bacteria may have evolved inducible resistance mechanisms 
against HDPs and bacteriocins and may even use their presence as an environmental cue to 
trigger a more virulent phenotype. Moreover the induced resistance mechanism may cause a 
degree of cross-resistance to antibiotics [84, 86, 87]. With these concepts in mind, the second 
aim of this thesis was to study the resistance and response of S. suis to a model cationic AMP. 
Chapter 3 investigates the generic and adaptive resistance mechanisms in S. suis in response 
to the human cathelicidin LL-37 and the potential for this peptide to be recognised as a host 
cue for regulation of adaptive virulence mechanism. A microarray transcriptome analysis of 
S. suis S10, which is a virulent strain of serotype 2 that can be carried in pigs and humans, was 
performed upon short-term exposure to sub-lethal concentrations of LL-37. A significantly 
altered expression of genes associated with two-component signalling, membrane transport 
and carbohydrate uptake was identified. In addition, genes involved in pilus formation, cell 
surface protein anchoring and adhesion were strongly upregulated upon exposure to LL-37. 
Understanding the adaptive response of S. suis to an important host defense peptide may 
highlight putative novel targets for antimicrobial drug development.
The hypothesis was that the endogenous microbiota could play an important role in 
colonisation resistance against S. suis in piglets. To investigate this, a third aim of this thesis 
was to characterise the bacteria that are part of the natural microbiome of S. suis, which 
might enable us to propose commensal bacteria from the porcine microbiota with inhibitory 
activity against S. suis as well as pathogens that may promote S. suis virulence. Chapter 
4 describes the composition of the tonsillar and small intestinal microbiota from healthy 
piglets. Bacterial taxa that positively or negatively correlated with S. suis abundance were 
identified using the LEfSE pipeline, Pearson correlations and CoNET. Lactobacillus reuteri 
was found to have a strong significant negative correlation with the abundance of S. suis 
and other porcine pathogens. This chapter demonstrates that the microbiota from the same 
niche that is inhabited by S. suis contains endogenous bacteria that might display direct or 
indirect antagonism against S. suis together with a network of porcine pathogens that may 
promote S. suis virulence and its infection of piglets. 
With this knowledge in mind, the goal was to find individual bacteria belonging to the porcine 
tonsillar and small intestinal microbiomes that displayed potent narrow-spectrum growth-
inhibiting activity towards S. suis through the production of AMPs or secondary metabolites. 
Chapter 5 describes the isolation and high-throughput screening of bacteria from the porcine 
tonsil and small intestine for growth inhibiting activity against clinically relevant serotypes of 
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S. suis. The isolation and identification of a commensal strain of S. pasteuri  that produces 
two α-helical delta-lysins is reported. These peptides share high sequence similarity with 
and have comparable physicochemical properties to other Staphylococcal delta-lysins. In 
addition to previously attributed cytotoxic and haemolytic activity, these delta-lysins display 
narrow-spectrum antimicrobial activity against multiple serotypes of S. suis. Another example 
is given in Chapter 6, which focusses on the detailed characterization of a commensal Rothia 
nasimurium strain isolated from the porcine tonsil, producing the ionophore valinomycin. 
This chapter describes the molecular characterisation of the valinomycin encoding BGC, 
highlighting its potential recent acquisition by R. nasimurium, and shows that valinomycin 
may have antimicrobial, cytotoxic and immunomodulatory effects, thereby impacting the 
host as well as other microbes. 
Finally, Chapter 7 summarizes the research undertaken in this thesis and discusses its 
contribution to the scientific knowledge of S. suis occurrence in pigs and the role of the 
endogenous microbiota in that regard, as well as potential avenues towards alternative 
strategies to reduce porcine infections by this pathogenic bacterium.
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Abstract 
Cationic, amphipathic, α-helical host-defense peptides (HDPs) that are naturally secreted 
by certain species of Anura possess potent broad-spectrum antimicrobial activity and show 
therapeutic potential as alternatives to treat infections by multi-drug resistant pathogens. 
Fourteen amphibian skin peptides and twelve analogues of temporin-1DRa were studied 
for their antimicrobial activities against clinically relevant pathogens with emphasis on 
opportunistic bacteria isolated from human or animal skin infections. For comparison, their 
potencies against a range of probiotic Lactobacilli were determined. The ISO-certified VITEK 
2 system was used to define a profile of antibiotic susceptibility for the bacterial isolates 
used in this study. The minimal inhibitory concentration (MIC) values of the naturally 
occurring temporin-1DRa, CPF-AM1, alyteserin-1c, hymenochirin-2B, and hymenochirin-
4B for pathogenic bacteria were 3- to 9-fold lower than the values for the tested probiotic 
strains. Similarly, temporin-1DRa and its [Lys4], [Lys5] and [Aib8] analogues showed 5- to 6.5-
fold greater potency against the pathogens tested compared with the probiotic bacteria. 
In the case of PGLa-AM1, XT-7, temporin-1DRa and its [D-Lys8] and [Aib13] analogues, no 
apoptosis or necrosis was detected in human peripheral blood mononuclear cells even at 
concentrations above the MIC. Given the differential activity against commensal bacteria 
and pathogenic strains, some of the tested peptides are considered promising candidates 
for further development into antimicrobial agents for topical treatment of human or animal 
skin infections with multi-drug resistant bacteria.
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Introduction
The alarming increase in incidence of multidrug-resistant (MDR), pathogenic bacteria together 
with the decreasing discovery rates for new antibiotics represents a major societal problem 
and threat to human and animal health. This situation has heightened interest in naturally 
occurring host defense peptides (HDPs), including antimicrobial peptides (AMPs), as potential 
novel therapeutics [1, 2]. A widely studied class of HDPs is cationic amphipathic α-helical 
peptides, many of which are originally isolated from skin secretions of species belonging 
to the Anura order of amphibians (frogs and toads). Amphibians are, for a large part of their 
lifecycle, confined to warm and moist environments with high exposure to bacteria and fungi. 
However, frogs and toads possess excellent immunity to defend themselves against invasion 
by microorganisms. It is currently believed that as part of their innate immune system many 
species, but not all, produce and secrete a wide variety of HDPs via specialized glands in the 
skin [3, 4]. Amphibian peptides were amongst the first HDPs described nearly three decades 
ago [5, 6] and they form a highly diverse group of peptides comprising between 8 and 48 
amino acid residues and generally a net charge between +2 and +6 at pH 7 [7]. Production 
of amphibian skin peptides seems to be evolutionarily conserved, presumably due to their 
role in preventing infection by pathogenic microbes although some skin peptides may also 
have autocrine or chemotactic functions [4, 8]. Previously, certain frog skin peptides have 
been proposed as candidates to treat infections on the basis of their potent and broad-range 
antimicrobial activity against pathogenic bacteria, fungi and protozoa [9, 10]. 
A disadvantage of many of these candidate HDPs in a therapeutic setting is their hemolytic 
activity and cytotoxicity, although this is typically observed at concentrations significantly 
higher than the minimal bactericidal concentration (MBC). However, it is possible to 
selectively reduce the cytotoxicity of HDPs through systematic amino acid substitutions 
to alter physiochemical properties, while retaining their potency and broad-spectrum 
antimicrobial activity [11]. For the above-mentioned reasons, HDPs currently show most 
promise as topical treatments for skin and wound infections rather than for systemic 
applications to treat invasive disease [2, 10, 12]. 
The aim of this study was to test a range of amphibian skin peptides and analogues of 
temporin-1DRa with different physicochemical properties in antimicrobial assays. We 
determined their effect on a selection of pathogens including opportunistic bacteria isolated 
from human or animal skin infections and MDR strains. We included several probiotic, 
commensal strains in the assays to investigate the spectrum of activity and selectivity of 
the amphibian HDPs. To benchmark the efficacy of these skin peptides, we also determined 
susceptibility of the selected bacteria to commonly used antibiotics using an ISO-certified 
assay platform. 
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Material and methods
Bacteria and culture conditions
Table 1 lists the bacterial strains used in this study and their source. Nine probiotic Lactobacilli 
were previously isolated from commercially available products [13]; Lactobacillus plantarum 
WCFS1 is a single colony isolated from L. plantarum NCIMB8826, which was originally 
derived from human saliva [14]. Lactobacillus casei Shirota (Yakult®, Japan) was originally 
isolated from the human intestine, Lactobacillus reuteri ATCC55730 was originally isolated 
from human breast milk [15]. Streptococcus suis S10 [16] was obtained from the Central 
Veterinary Institute (CVI, Lelystad, The Netherlands), Staphylococcus pseudintermedius and 
Pseudomonas aeruginosa (strains 26228 and 25467) were obtained from skin infections in 
dogs and were obtained from University of Copenhagen (KU, Copenhagen, Denmark). The 
Enterococcus faecium, Staphylococcus aureus, Acinetobacter baumannii and P. aeruginosa 
strains MDR1 and MDR2 were isolated from clinical samples were obtained from the Erasmus 
University Medical Centre Rotterdam (EMC, Rotterdam, The Netherlands). Lactobacilli were 
cultured and assayed in de Man, Rogosa and Sharpe (MRS) broth (VWR International) at 
37°C under anaerobic conditions. All other strains were cultured in Müller-Hinton (MH) broth 
(Oxoid Ltd, Basingstoke, UK) at 37°C under aerobic conditions. 
Bacterial species strain source
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ic Lactobacillus plantarum WCFS1 TIFN
Lactobacillus rhamnosus LGG Valio
Lactobacillus salivarius subsp. salicinius DSM20554 DSMZ
Lactobacillus salivarius FortaFit Ls-33 Danisco
Lactobacillus casei R0215 Rossell
Lactobacillus casei Shirota Yakult
Lactobacillus johnsonii LC-1 Nestle
Lactobacillus reuteri ATCC55730 BioGaia
Lactobacillus acidophilus LA5 Chr Hansen
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Streptococcus suis S10 3881 CVI [16]
Staphylococcus aureus DMS 20231 DSMZ
Staphylococcus aureus Sens 8325.4 EMC 
Staphylococcus aureus MRSA B33424 EMC
Staphylococcus pseudintermedius E138 KU 
Staphylococcus pseudintermedius E139 KU
Staphylococcus pseudintermedius E140 KU
Staphylococcus pseudintermedius S70E2 KU
Staphylococcus pseudintermedius S70E8 KU
Staphylococcus pseudintermedius S70F3 KU
Pseudomonas aeruginosa 26228 KU
Pseudomonas aeruginosa 25467 KU
Pseudomonas aeruginosa  Sens1 PA01 EMC
Pseudomonas aeruginosa  Sens2 ATCC27853 EMC
Pseudomonas aeruginosa  MDR1 B38084 EMC
Pseudomonas aeruginosa  MDR2 B31770 EMC
Enterococcus faecium Sens S1 EMC
Enterococcus faecium Sens S2 EMC
Enterococcus faecium VanA R39 EMC
Enterococcus faecium VanB R44 EMC
Acinetobacter baumannii MDR Bangl 027 EMC
Table 1. Bacteria used in this study. 
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Bacterial antibiotic susceptibility testing
The profile of antibiotic susceptibility of a panel of bacterial isolates was determined by 
the micro broth dilution test using the ISO-certified VITEK® 2 system (bioMérieux Benelux 
BV, Boxtel, The Netherlands) [17, 18]. The following antibiotic cards were used: AST-P633 
(cefoxitin, benzylpenicillin, oxacillin, gentamicin, kanamycin, tobramycin, ciprofloxacin, 
levofloxacin, erythromycin, clindamycin, linezolid, teicoplanin, vancomycin, tetracycline, 
fosfomycin, fusidic acid, mupirocin, chloramphenicol, rifampicin, and trimethoprim/
sulfamethoxazole), AST-N199 (piperacillin/tazobactam, ceftazidime, cefepime, imipenem, 
meropenem, gentamicin, tobramycin, ciprofloxacin, colistin), and AST-P586 (ampicillin, 
sulbactam, cefuroxime, cefuroxime axetil, imipenem, gentamycin, streptomycin, moxifloxacin, 
erythromycin, clindamycin, quinupristin/dalfopristin, linezolid, teicoplanin, vancomycin, 
tetracycline, tigecycline, nitrofurantoin, trimethoprim/sulfamethoxazole). Bacteria were 
inoculated from glycerol stocks on appropriate growth medium agar plates using sterile 
plastic loops and incubated at 37°C overnight, after which single colonies were picked for 
analysis. 
Peptides
The frog skin peptides (Table 2) and the temporin-1DRa analogues (Table 3) used in this study 
were chemically synthesized and purified as previously described [11, 19-27]. The identities 
of all peptides were confirmed by electrospray mass spectrometry and their purity was >98%. 
Lyophilized peptides were reconstituted in 20 µL 0.1% HCl and stock solutions were made at 
1 or 2.5 mg/mL in sterile PBS and kept at -20°C until use. 
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Table 2. The naturally occurring peptides and temporin-1DRa analogues used in this study and their source species. 
PGLa-LM1 was found in a hybrid frog of X. laevis and X. muelleri (1.1.2)[27]. The grand average of hydropathy (GRAVY) 
is defined as the sum of all hydropathy values divided by the length of the sequence [28].  The α-helicity predictions 
were made using AGADIR [29]. Aib = α-aminoisobutyric acid, Orn = ornithine, DAB = diaminobutyric acid, TML = 
trimethyllysine, nd = not determined, † = decreased α-helicity.
 
source /  peptide length amino acid sequence net charge 
at  pH 7.0 
GRAVY � -hel icity  
1. Pipidae 
1.1. Xenopus 
1.1.1. Xenopus amieti 
    Magainin-AM1 23 aa GIKEFAHSLGKFGKAFVGGILNQ +2 +0.2 Non-helical 
    PGLa-AM1  22 aa GMASKAGSVLGKVAKVALKAAL.NH2 +4 +0.83 9-22 
    CPF-AM1  17 aa GLGSVLGKALKIGANLL.NH2 +2 +1.03 5-14 
1.1.2. X. laevis x X. muelleri 
    PGLa-LM1 21 aa GMASKAGSVAGKIAKFALGAL.NH2 +4 +0.805 9-18 
1.2. Silurana 
1.2.1. Silurana tropicalis 
    XT-7 (CPF-ST3)  18 aa GLLGPLLKIAAKVGSNLL.NH2 +2 +1.12 5-13 
1.3. Hymenochirus 
1.3.1. Hymenochirus boettgeri 
    Hymenochirin-1B 29 aa IKLSPETKDNLKKVLKGAIKGAIAVAKMV.NH2 +6 +0.169 5-27 
    Hymenochirin-2B 29 aa LKIPGFVKDTLKKVAKGIFSAVAGAMTPS +4 +0.466 8-16 
    Hymenochirin-4B 28 aa IKIPAFVKDTLKKVAKGVISAVAGALTQ +4 +0.664 7-16 
2. Alytidae 
2.1. Alytes 
2.1.1. Alytes obstetricans 
    Alyteserin-1c 23 aa GLKEIFKAGLGSLVKGIAAHVAS.NH2 +3 +0.748 2-8; 10-21 
    Alyteserin-2a 16 aa ILGKLLSTAAGLLSNL.NH2 +2 +1.275 9-14 
3. Ranidae 
3.1. Rana 
3.1.1. Rana draytonii 
    Temporin-1DRa 14 aa HFLGTLVNLAKKIL.NH2 +3 +0.879 5-14 
      [Lys4]temporin-1DRa  HFLKTLVNLAKKIL.NH2 +4 nd 4-14 
      [Lys5]temporin-1DRa  HFLGKLVNLAKKIL.NH2 +4 nd 4-14 
      [D-Lys4]temporin-1DRa  HFLDKTLVNLAKKIL.NH2 +4 nd † 
      [D-Lys5]temporin-1DRa  HFLGDKLVNLAKKIL.NH2 +4 nd † 
      [D-Lys8]temporin-1DRa  HFLGTLVDKLAKKIL.NH2 +4 nd † 
      [Aib8]temporin-1DRa  HFLGTLV[Aib]LAKKIL.NH2 +4 nd 5-14 
      [Aib9]temporin-1DRa  HFLGTLVN[Aib]AKKIL.NH2 +4 nd 5-14 
      [Aib10]temporin-1DRa  HFLGTLVNL[Aib]KKIL.NH2 +4 nd 5-14 
      [Aib13]temporin-1DRa  HFLGTLVNLAKK[Aib]L.NH2 +4 nd 5-14 
      [Orn7]temporin-1DRa  HFLGTL[Orn]NLAKKIL.NH2 +4 nd nd 
      [DAB7] temporin-1DRa  HFLGTL[DAB]NLAKKIL.NH2 +4 nd nd 
      [TML7] temporin-1DRa  HFLGTL[TML]NLAKKIL.NH2 +4 nd nd 
3.1.2. Rana boylii 
    Brevinin-1BYa 24 aa FLPILASLAAKFGPKLFCLVTKKC +4 +1.07 4-12 
3.2. Hylarana 
3.2.1. Hylarana erythraea 
    B2RP-Era 19 aa GVIKSVLKGVAKTVALGML.NH2 +3 +1.25 13-16 weak 
4. Hylidae 
4.1. Pseudis 
4.1.1 Pseudis paradoxa 
    Pseudin-2 24 aa GLNALKKVFQGIHEAIKLINNHVQ.NH2 +3 -0.008 2-19; 14-19 
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Antimicrobial assays
The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of 
the peptides were determined by standard dilution assays in 96-well microtiter plates in two 
independent experiments [30]. Serial dilutions of peptide in the appropriate growth medium 
(25 µL) were mixed with bacterial suspension (75 µL) to obtain an inoculum of 5 x105 CFU/mL. 
Bacteria were incubated at 37°C for 18-22 hours, after which bacterial growth was measured 
by absorption at 600 nm using a spectrophotometer (Spectramax M5, Molecular Devices, 
Sunnyvale CA, USA). The MIC was determined as the lowest concentration at which no visible 
growth was observed. MBC was determined as the lowest concentration of peptide at which 
no viable bacteria could be detected, following plating of serial dilutions of suspensions from 
the wells on agar plates. Heatmaps were generated using the Multiple Experiment Viewer 
software [31], using Euclidean Distance with Average Linkage for Hierarchical Clustering of 
the data. 
Human peripheral blood mononuclear monocyte (PBMC) cytotoxicity assay 
PBMCs were isolated as previously described [32] with modifications. Buffy coats from 
peripheral blood of three healthy donors were obtained from the Sanquin Blood Bank, 
Nijmegen, The Netherlands. Isolated PBMCs were washed and resuspended in Iscove’s 
Modified Dulbecco’s Medium (IMDM) + Glutamax (Gibco, Thermo Fischer Scientific) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin and 
100 μg/mL streptomycin (Invitrogen, Breda, The Netherlands) at a final concentration of 
1 × 106 cells/mL and seeded (100 µL per well) in 96-well tissue culture plates. PBMCs were 
exposed to peptides at final concentrations of 1, 10 and 100 μg/mL. Exposure to LPS (1 μg/
mL) was used as a positive control. After exposure for 24 h, cells were incubated with Annexin 
V-APC and propidium iodide (eBiosciences, Vienna, Austria) and, using flow cytometry (FACS 
Canto II, BD Biosciences), the proportions of live (unstained), dead (PI only), early-apoptotic 
(Annexin V only) and late-apoptotic (Annexin V + PI) cells were determined (BD FACSDiva). 
Data are presented as mean values ± SD.
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Results
Antibiotic resistance of a panel of selected probiotic and pathogenic microbes
We used the bioMerieux VITEK®2 system to assay microbial resistance to commonly used 
antibiotics [33] for which the mode of action and bacterial target is given in Supplemental 
Table 1. The VITEK®2 system was chosen as it represents a widely used and well-standardized 
ISO-certified platform used in hospitals and medical centers to assess antibiotic resistance 
of clinically sampled microbes. Many Lactobacillus species were not able to grow under 
the incubation conditions of the VITEK®2 system; therefore, it was impossible to obtain an 
antibiotic susceptibility profile for these strains. The data for antibiotic resistance of each 
bacterium (Table 3) was used for benchmarking against each of the frog antimicrobial 
peptides. In the first row the number of antibiotics to which a strain was resistant is depicted 
by a color scheme: brighter red colors correspond to increased antibiotic resistance and 
brighter blue correspond to susceptibility to the tested antibiotics (Table 3). These data 
provide the baseline susceptibility of a selected set of bacteria to antibiotics, classifying 
certain strains as multi-drug resistant (MDR). The reference dataset of antibiotic resistance 
was then compared to a dataset of the MIC and MBC values for frog antimicrobial peptides 
and synthetic analogues tested against the same strains.
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# of antibiotics w/ resistances
resistance to % of tested 
antibiotics 
Cefoxitin screen
Benzylpenicillin
Oxacillin
Gentamicin
Kanamycin
Tobramycin
Ciproﬂoxacin
Erythromycin
Clindamycin
Linezolid
Teicoplanin
Vancomycin
Tetracycline
Fosfomycin
Fusidic Acid
Mupirocin
Chloramphenicol
Rifampicin
Trimethoprim/ Sulfamethoxazole
Piperacillin/ Tazobactam
Ceftazidime
Cefepime
Imipenem
Meropenem
Colistin
Amoxicillin/ Clavulanic Acid
Azithromycin
Ampicillin
Ampicillin/ Sulbactam
Cefuroxime
Cefuroxime Axetil
Streptomycin
Moxiﬂoxacin
Quinupristin/ Dalfopristin
Tigecylcine
Nitrofurantoin
Fluconazole
Cefoxitin
Cefotaxim
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Table 3. Antibiotic resistance profile for bacteria used in this study, as determined by the VITEK®2 system. Multiple 
antibiotics cards were used, differing in antibiotics depending on the target species. Profiles for those Lactobacilli 
that required anaerobic culture conditions were not obtained. Resistance phenotype per antibiotic was scored as 
sensitive (green), intermediate (orange) or resistant (red) according to the EUCAST species specific breakoff points 
based on MIC values [33]. The total number of antibiotics scored as resistant is depicted in the second column, 
shaded from resistance to no (dark blue) to 16 (dark red) antibiotics. See Supplemental Table 1 for an overview of 
mode of actions of each antibiotic. nd =not determined. 
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Potency of frog skin peptides against probiotic and pathogenic microbes
Fourteen frog skin peptides were tested for their antimicrobial activity against a panel of 
bacteria. Antimicrobial activities were determined using a standard micro broth dilution 
assay and are presented as minimum inhibitory concentration (MIC) (Figure 1 B) and minimal 
bactericidal concentration (MBC) (Supplemental Table 2).  Figure 1B represents the MIC 
values obtained for the naturally occurring frog skin peptides as a hierarchically clustered 
heatmap, with bright green colors corresponding to values of <8 µg/mL and bright red colors 
corresponding to values of >256 µg/mL. The heatmap shows that temporin-1DRa and XT-7 
were effective at low concentration (<8 μg/mL) while magainin-AM1 and pseudin-2 showed 
no inhibition of any of the strains tested. With the exception of magainin-AM1 and pseudin-2, 
all the native frog peptides tested, inhibited all strains of Staphylococcus pseudintermedius at 
MIC = 8 µg/mL. The three hymenochirin peptides clustered together based on the observed 
MIC values, showing activity against Gram-positive MDR S. pseudintermedius, vancomycin-
resistant Enterococcus faecium and the Gram-negative MDR Acinetobacter baumanii. The 
PGLa peptides also clustered together, based on their low MIC against all S. pseudintermedius 
strains. The strains of Pseudomonas aeruginosa were relatively insensitive to the frog 
peptides tested, except for the MDR2 isolate. For the Gram-positive bacteria  (see Table 1) 
we compared the MIC of selected frog peptides against 9 different species of Lactobacilli 
(Figure 1A, green bars) and 13 pathogenic strains (excluding S. suis) (Figure 1A, orange bars) 
and measured the fold-difference in MIC value between these two bacterial groups (Figure 
1A, purple bars). We found that the Gram-positive pathogens were 5.5-fold to 9-fold more 
susceptible to inhibition by CPF-AM1, temporin-1DRa and alyteserin-1c than the probiotic 
Lactobacilli. 
ANTIMICROBIAL ACTIVITY OF FROG SKIN HOST-DEFENSE PEPTIDES
55
Ch
ap
te
r 2
Figure 1. A) MIC values of a selection of naturally occurring frog skin peptides against 9 Gram-positive lactic acid 
bacteria (green) and 13 Gram-positive pathogenic bacteria (orange). The fold difference in MIC between the two 
groups is depicted as purple bars on the secondary axis. Average values ± SEM are shown. B) Heatmap representation 
of all MIC values of the tested frog skin peptides, including for each peptide its net charge at pH=7 and grand average 
of hydropathy (GRAVY). The gray color indicates MIC was not determined.
Temporin-1DRa, a peptide, first isolated from Rana draytonii [21], showed most promise 
for therapeutic activity against a range of Gram-positive pathogens including methicillin-
resistant  strains of S. pseudointermedius which are a major cause of recurring skin and wound 
infections in dogs [34]. Additionally, the MIC values for temporin-1DRa were approximately 
3.5-fold lower for pathogens than probiotic species (Figure 1A). 
Antimicrobial activities of analogues of temporin-1DRa 
To investigate whether the antimicrobial activity of temporin-1DRa against pathogenic 
species could be increased by appropriate amino acid substitutions, we tested 14 different 
analogues, having single residue modifications to alter parameters such as cationicity, 
hydrophobicity and α–helicity [11] (Table 2). The effect of these amino acid substitutions 
on the physicochemical properties of α-helical peptides and the subsequent effect on 
cytotoxicity and antimicrobial potency has been described previously [11, 22, 35-37]. We 
observed MIC values that ranged from <8 to >64 µg/mL for these temporin-1Dra analogues, 
although multiple isolates of the same species showed similar sensitivities to a given 
peptide (Figure 2, Supplemental Table 3). Figure 2A shows that the analogues had altered 
activity against bacteria, with [Aib8]temporin-1DRa having the largest fold-change (6.5) in 
activity between the grouped Gram-positive pathogenic and probiotic bacteria, followed by 
the [Lys4], [Lys5] and [Aib9] analogues. Incorporation of α-aminoisobutyric acid (Aib) into a 
peptide generally promotes the formation of an α- or 310-helix or stabilizes an existing helical 
conformation [37].
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Figure 2. A) MIC values of temporin-1DRa analogues against 9 Gram-positive lactic acid bacteria (green) and 13 
Gram-positive pathogenic bacteria (orange). The fold difference in MIC between the two bacterial groups is depicted 
as purple bars on the secondary axis.  Average values ± SEM are shown. B) Heatmap representing the MIC values of 
temporin-1DRa analogues against the panel of tested bacteria. The gray color indicates MIC was not determined.
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Cytotoxic effects of selected frog peptides and temporin-1DRa analogues 
In order to determine the cytotoxic activities of those peptides that showed promising 
antimicrobial activity against pathogenic bacteria (PGLa-AM1, XT-7, temporin-1DRa and its 
[D-Lys8] and [Aib13] analogues, we exposed human PBMCs to the peptides and quantified 
apoptosis and necrosis using flow-cytometry. Figure 3 shows that none of the peptides 
tested had a significant effect on the viability of PBMCs during a 24 h exposure to final peptide 
concentrations of 1, 10 and 1000 µg/mL. 
0%
25%
50%
75%
100%
live cells early apoptotic cells late apoptotic cells dead cells dead cells
Figure 3. Human PBMCs obtained from three healthy donors were exposed for 24 h to 100, 10 or 1 µg/mL of PGLa-
AM1, XT-7, temporin-1DRa, [d-Lys8]temporin-1DRa, and [Aib13]temporin-1DRa after which cells were stained with 
Annexin V and PI and analyzed using flow cytometry for the quantification of cell apoptosis and necrosis. Relative 
percentages of cells are shown, error bars depict SD of live cells between averaged values of all three donors.
CHAPTER 2
58
Discussion
Many Anurans secrete host-defense peptides (HDPs) into the outer skin mucosa [3, 4], that 
may have potent and broad-range antimicrobial activity against bacteria, fungi and protozoa. 
Consequently, they are interesting candidates for antimicrobial therapeutic applications [9, 
10]. The amphipathic peptides we tested can limit growth of several multidrug-resistant 
Gram-positive and Gram-negative pathogens. We found that the Pseudomonas aeruginosa 
strains were relatively insensitive to the action of the peptides. This is possibly due to the 
secretion of extracellular proteases that aid in their resilience towards peptide antimicrobials 
[38, 39].
The MIC and MBC values obtained for PGLa-AM1, PGLa-LM1, CPF-AM1, alyteserin-1c, 
hymenochirin-2B, and hymenochirin-4B and the [Aib8], [Lys4], [Lys5] and [Aib9] temporin-
1DRa analogues showed promising differential activity against the pathogenic bacteria 
Staphylococcus pseudintermedius, Enterococcus faecium, and Acinetobacter baumanii 
compared to the probiotic strains of Lactobacilli (Figures 1 and 2) . In a recent study it was 
shown that PGLa-AM1 and CPF-AM1 
have potent antimicrobial activity against a selection of oral pathogens [40]. We showed 
that the Gram-positive lactic acid bacteria, which are often present in probiotic supplements 
or food products, are not susceptible at peptide concentrations that are bactericidal  to 
these oral pathogens [40]. This highlights the potential of these peptides for selective 
antimicrobial therapy against such oral pathogenic bacteria. Furthermore, the multi-drug 
resistant S. pseudintermedius and vancomycin-resistant E. faecium strains did not show a 
markedly different sensitivity from the antibiotic-sensitive strains, suggesting there is no 
cross-resistance mechanism to cationic amphipathic AMPs. 
We also tested the potential cytotoxicity of selected peptides against human PBMCs, as 
it would be important not to inhibit the defensive immune response of the host if these 
peptides were used as topical applications to treat infections. We found that concentrations 
of peptides that effectively inhibited bacteria did not cause necrosis or apoptosis against 
human PBMCs. 
Based on this study, we propose that peptides alyteserin-1c, PGLa-AM1, PGLa-LM1, CPF-AM1, 
temporin-1DRa and its [Lys4], [Lys5], [Aib8], and [Aib9] analogues are interesting candidates for 
further research into potential use as novel topical therapeutics for treatment of skin infections 
caused by antibiotic resistant bacteria. Based on the observed MIC values, temporin-1DRa 
shows great promise to be used to treat canine skin infections by S. pseudintermedius, a 
bacterium that causes high morbidity and seriously lower the quality of life of affected dogs 
[34]. Moreover, the hymenochirin-2B and -4B peptides displayed high potency against multi-
drug resistant A. baumannii, pathogens that cause severe wound infections [41] and are an 
important cause of difficult to treat nosocomial infections [42]. The differential activity of 
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these antimicrobials against several pathogenic bacteria but not lactic acid bacteria might be 
advantageous as many commensal species of bacteria including Lactobacilli are considered 
beneficial and potentially contribute toward colonization resistance against pathogenic 
bacteria [43, 44]. 
Recently, several biotechnological tools have become available that open up avenues to 
develop promising applications for AMPs, including the peptides described in this study 
[45]. Tethering and display of AMPs on nanoparticles, fibers or polymers for localized and 
controlled delivery, increased stability and enhanced activity are examples of possible 
therapeutic applications of AMPs against MDR pathogenic bacteria in the future.
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Supplemental Table 1. VITEK antibiotic resistance profile for bacteria used in this study. The number of antibiotics 
for which each tested bacterial strain was classified as resistant based on the detected MIC value and clinical 
breakpoints are listed and colored from highest (red) to lowest (blue) number of antibiotic resistances. Additionally, 
the general mode of action of the corresponding antibiotics to which resistance was observed are listed.
CHAPTER 2
64
Supplemental Table 2. MIC and MBC values of frog skin peptides against a panel of bacteria, as determined by 
micro broth dilution assay. Experiments were performed in duplicate, average values are shown.
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Supplemental Table 3. MIC and MBC values of temporin-1DRa analogues against a panel of bacteria, as determined 
by micro broth dilution assay. Experiments were performed in duplicate, average values are shown.
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Abstract
Many bacteria have evolved inducible resistance mechanisms to resist the action of 
antimicrobial peptides (AMPs) and may even use their presence as environmental cues to 
regulate virulence-associated genes. The aim of this study was to investigate if generic and 
adaptive resistance could be induced in S. suis upon exposure to sub-lethal dosages of a 
model cationic AMP, the human cathelicidin LL-37. A flow cytometric assay for live and dead 
bacteria was used to determine that the lethal concentration of LL-37 for S. suis was 2.5 µM, 
which is similar to that determined for Bacillus subtilis. The susceptibility of S. suis to LL-37 was 
not affected by the presence of a capsule as shown by the use of a capsule-negative mutant 
J28. However, S. suis strain 8039 (serotype 7) appeared to be slightly less susceptible to LL-37 
killing at concentrations below the MBC than strains S10 (serotype 2) or 8067 (serotype 9). 
Microarray gene expression profiling of S. suis exposed to 1 and 0.25 uM LL-37 for 10 and 30 
min revealed a complex stress response consisting of a general stress response, including 
increased expression of the heat shock operons. Putative peptide antibiotic sensing and 
transporter systems found to play a role in other Gram-positive bacteria in export of specific 
cell-envelope acting peptide antibiotics were also highly induced upon exposure to LL-37. 
The S. suis deletion mutant of TCS SSU0827/28, which is located downstream of the induced 
putative peptide transporter gene cluster, was equally sensitive to LL-37. Although the dlt 
operon has been shown in other bacteria increase resistance to cationic AMPs, a deletion 
mutant of dltA was not more susceptible than the wt strain to LL-37. Additionally, we found 
that exposure to LL-37 substantially increased expression of 11 genes encoding (putative) 
surface proteins or exported proteins, some of which are proposed to be involved in virulence. 
This work shows that S. suis appears to possess a transcriptional response program that 
regulates tolerance to sub-lethal concentrations of the cationic AMP LL-37. Understanding 
these key processes in bacterial defense responses to host immune mediators may provide 
leads to novel strategies to combat S. suis in pig husbandry.
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Introduction
Streptococcus suis is an encapsulated Gram-positive facultative anaerobe and opportunist 
pathogen, frequently present as a member of the porcine microbiota on the mucosal 
surfaces of the oro- and nasopharynx, and the intestinal and genital tracts [1-4]. Carriage 
of S. suis in adult pigs is usually asymptomatic whereas young pigs post-weaning (weeks 4 
to 12) are most at risk from invasive disease [5, 6], with symptoms such as acute sepsis and 
meningitis, endocarditis, pneumonia and arthritis often being reported [7, 8]. S. suis is also a 
zoonotic pathogen and human infections worldwide have increased in the past years, with 
most cases originating in Southeast Asia [9] [10]. Currently, no efficacious, cross-protective 
vaccines exist to protect animals against infection by S. suis [11, 12]. It is worrisome that 
resistance of S. suis to macrolides, lincosamides, tetracyclines, and sulphonamides has been 
reported for up to 85% of isolates in many countries throughout the world [13]. Of concern 
are the recent emergence of highly virulent strains causing more rapid and severe disease 
[14] and the risk that the burden of both zoonotic and porcine disease will increase due to 
European Union policies on reducing veterinary antibiotic use [15]. Consequently several 
alternatives are being considered for disease prevention in livestock animals [16] including 
applications of eukaryotic antimicrobial peptides (AMPs) and their analogues which have 
been been proposed as new treatment strategies for multi-drug resistant pathogens [17, 18]. 
For S. suis and many other pathogens, successful colonization of the host mucosa is a 
prerequisite to invasive disease. Host AMPs, (also known as host-defense peptides (HDPs)) 
are an important component of the innate defense against pathogens and are expressed at 
mucosal sites either constitutively or in an induced manner by pattern recognition receptor-
mediated recognition of microbes [19, 20]. One important family of HDPs are the cathelicidins, 
comprising a wide variety of peptides of varying length and structure, but all containing a 
C-terminal cationic antimicrobial domain that becomes active after being freed from the 
conserved N-terminal cathelin domain of the holoprotein [21, 22].  In humans cathelicidin 
hCAP-18 is produced as an inactive 18-kDa pre-pro-protein that is proteolytically cleaved to 
generate the active carboxy-terminal 37 amino acid γ–helical peptide LL-37 [21, 23, 24]. 
Most AMPs are cationic and amphipathic and mediate bacterial killing through the 
aggregation of peptide monomers to form transmembrane channels or upon insertion of the 
peptides into the cell membrane to disrupt the native integrity of cell membrane [17, 25, 26]. 
This leads to dissipation of the ion gradient, transmembrane potential and cell death. AMPs 
have also been identified with other modes of action including inhibition of cell replication 
or transcriptional processes [27-30].
LL-37 is produced by epithelial cells and neutrophils at several body sites and has been shown 
to possess a plethora of functions, such as antimicrobial, cytotoxic, immunomodulatory, 
wound-healing and endotoxin-binding activities [22, 31, 32]. Human LL-37 and the porcine 
cathelicidin PR-39 are produced in the oral cavity and respiratory tract [33-37], two body sites 
which can be colonized by S. suis [2]. The alimentary and respiratory tracts are also inhabited 
by other microbes, many of which are capable of producing AMPs, including ribosomally 
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synthesized bacteriocins and non-ribosomally synthesised secondary small molecule 
metabolites, to improve their competitiveness [38, 39]. As a result, the mucosal surfaces that 
can be colonised by S. suis may contain multiple host- or microbe-derived AMPs.
Given the role of cationic AMPs, such as LL-37, in innate immunity, many bacteria have 
evolved to develop redundant strategies to counter and survive regular exposure to such 
peptides [40, 41]. Such bacterial mechanisms for detection, electrostatic repulsion, enzymatic 
degradation, and active efflux of cationic AMPs were recently reviewed elsewhere [40, 41].  We 
hypothesize that S. suis strains that are commonly carried in pigs might possess mechanisms 
of resistance towards specific cationic AMPs [40], and these mechanisms could be cross-
protective against other host- or microbe-derived AMPs considering their comparative mode 
of membrane-disruptive action [42]. 
Interestingly, host AMPs have been proposed to serve as environmental cues to elicit virulence 
gene expression in pathogenic bacteria colonising host mucosal surfaces, leading to bacteria 
gaining a more “invasive phenotype” [43-47]. Additionally, AMP-induced changes in gene 
expression could lead to increased adaptive resistance towards conventional antibiotics, 
such as macrolides, fluoroquinolones, or aminoglycosides [46, 48]. Surprisingly, acquisition 
of adaptive DNA mutations leading to increased bacterial mucoidy and rifampin resistance 
were observed upon exposure to sub-inhibitory concentrations of LL-37 [49]. 
The aim of this study was to investigate if generic and adaptive resistance could be induced 
in S. suis upon exposure to sub-lethal dosages of LL-37, and the potential for this cationic 
peptide to be recognised as a host cue for regulation of virulence gene expression in S. suis. 
We performed a transcriptome analysis of S. suis S10, a virulent strain of serotype 2 that can 
be carried in pigs and humans and is the major cause of invasive disease [9], upon short-
term exposure to sub-inhibitory concentrations of LL-37. The aims of this study were to 
search for inducible mechanisms of resistance to AMPs as well as induction of virulence gene 
expression upon exposure to AMPs, in order to gain insights into host-derived factors that 
might mediate S. suis pathogenesis. If such resistance- or virulence-mediating mechanisms 
would exist, interfering with them may provide leads to novel strategies to combat S. suis in 
pig husbandry.
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Materials and Methods
Bacteria and culture conditions
The virulent S. suis serotype 2 strain S10, originally isolated from the tonsil of a healthy pig [50], 
and S. suis strains 8039 (SS7) [51], and 8067 (SS9) [52], were obtained from Central Veterinary 
Institute (Lelystad, Netherlands). The genome of S. suis S10 is genetically highly similar 
(>99%) to the sequenced S. suis serotype 2 reference strain p1/7 [53] (unpublished Genome 
Announcement). All Streptococcus strains were cultured without agitation at 37°C with 5% 
atmospheric CO2 in Todd-Hewitt Broth (THB) (Oxoid, Basingstoke, UK), supplemented with 
100 µg mL-1 spectinomycin (Invitrogen) when required. 
Generation of S. suis mutants
Insertional deletion mutants of the TCS genes SSU0827/0828 and SSU1930/1931, were made 
in S. suis strain S10 using Gene Splicing Overlap Extension PCR and allelic replacement as 
described previously [54]. A mutant lacking the dltA gene (SSU0596) was made similarly, by 
transformation of S. suis with linear DNA containing a spectinomycin resistance cassette (aad9) 
between upstream and downstream regions of dltA. The plasmid p5ΔdltA [55] was used as a 
template for the amplification of the linear DNA fragment using the oligonucleotide primer pair 
dlt_fw (5’-GGTGCATGCTGAAGAGAAAG-3’) and dlt_rev (5’-GACCGACCGAAACGTTAAATAAG-3’). 
S. suis strains were grown overnight in THB broth at 37°C under 5% CO2. The overnight 
culture was diluted 1:40 into pre-warmed media, and grown at 37°C until OD600 nm of 0.035 
(Spectramax M5, Molecular Devices, Sunnyvale CA, USA). The bacterial suspension (100 µL) 
was incubated with 200 ng donor DNA together with 250 µM competence inducing peptide 
[56] for 2 hours at 37°C in 1.5 ml Eppendorf Safe Lock Tubes™, after which the samples were 
diluted and plated onto THB agar media containing 100 µg mL-1 spectinomycin.
Bactericidal effect of LL-37 determined by Live/Dead staining and flow cytometry
All media and buffers were filtered prior to use with 0.2 μm syringe filters (Merck 
Millipore,  Darmstadt, Germany). THB was inoculated 1:1000 from a frozen glycerol stock 
of S. suis, and incubated at 37°C with 5% CO2 for 4 h to obtain a culture with an OD600 nm 
of ~0.2. Bacteria were collected by centrifugation at 6000 x g for 5 min, and the pellet was 
resuspended in PBS (supplemented with 0, 1, 5, or 10% v/v THB) to obtain an inoculum 
containing ~5 x 105 CFU ml-1. In 96-well microtiter plates, bacterial suspension (90 µL) was 
added to each well containing peptide dilutions in PBS (10 µL). Bacteria were exposed 
to peptide for 30 or 60 min at 37°C with 5% CO2, and then stained using the LIVE/DEAD® 
BacLight™ Bacterial Viability and Counting Kit (Molecular Probes, Leiden, The Netherlands) 
according to manufacturer’s instructions. Briefly, 150 μL 0.85% NaCl was added to each well, 
and the total volume was transferred to a flow-cytometry tube containing 0.75 μL of dye A + B 
mix. Tubes were vortexed shortly and after 15 min incubation at RT in the dark samples were 
analysed using flow cytometry (FACS Canto II, BD Biosciences). The proportions of live (SYTO 
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9 positive) and dead (propidium iodide positive) bacteria were determined (BD FACSDiva) 
and data were represented as percentage live bacteria (# live/(# live + # dead)) x 100).
Experimental design and RNA extraction
A volume of 5 mL THB was inoculated from a frozen glycerol stock of S. suis S10 and was 
incubated overnight at 37°C with 5% CO2. This culture was diluted 1:40 in pre-warmed THB 
and grown for approximately 3 h until an OD600 nm of 0.25 was reached. Cells were collected 
by centrifugation for 5 min at 5000 x g, and the pellet resuspended in an equal volume of 
fresh, pre-warmed THB. In a 50 mL Falcon tube, 2.5 mL of this cell suspension was added 
to 47.5 mL of pre-warmed sterile PBS, immediately followed by addition of LL-37 to a final 
concentration of 0.1 µM or 0.25 µM. Bacteria were incubated at 37°C for 5 or 25 min and 
collected by centrifugation for 5 min at 8000 x g at 30°C. Supernatant was carefully discarded 
and the pellets were resuspended in 2.5 mL PBS plus 5 mL RNAprotect Bacteria Reagent 
(Promega) by vortexing and incubated for 5 min at RT. The bacteria were collected by 
centrifugation and the pellet immediately frozen in liquid nitrogen and stored at -80°C until 
further handling. The frozen pellet was redissolved in 110 µL of TE containing protease K (1.25 
µg mL-1) and lysozyme (15 µg mL-1) by thorough vortexing and incubated at RT for 10 min. 
Then, 700 μL RLT buffer (Promega) containing 7 μL of freshly added γ-mercaptoethanol was 
added and the whole volume was transferred to FastPrep matrix B tubes and run for 40 sec 
at 6.0 m sec-1 on a FastPrep-24 (MP Biomedicals, Solon, OH) for mechanical disruption of the 
bacteria. Total RNA was purified from the obtained bacterial lysate using the RNeasy Mini Kit 
(Qiagen) following manufacturer’s instructions. The quality, concentration and integrity of 
RNA were assessed using the Experion System (Bio-Rad) and by spectrometric analysis of the 
A260/A280 ratio (NanoDrop 8000 UV-Vis). cDNA was synthesized with a SuperScript III Reverse 
Transcriptase Kit (Invitrogen) using Aminoallyl-UTP and purified with the Illustra CyScribe 
GFX Purification Kit (GE Healthcare). The aminoallyl-cDNA was labelled using the CyDye Post-
Labelling Reactive Dye Pack (GE Healthcare). 
Microarray transcriptome analysis
An S. suis oligonucleotide array (Array Express Accession: A-MEXP-1916) containing in situ 
synthesized 60-mers (8 x 15K) was produced by Agilent Technologies (Santa Clara, USA), 
based on the genome sequence of S. suis p1/7 [53]. A total of 7651 unique 60-mers having 
a theoretical melting temperature of approximately 81°C and representing 1960 ORFs were 
selected as described [57]. Genes were represented by 4 (91%), 3(4%), 2(2%), or 1(3%) 
probe(s). Twenty-five putative genes were not represented because no unique probes could 
be selected that met the selection criteria. Co-hybridization with Cy3- and Cy5-labelled 
cDNA probes was performed on these oligonucleotide arrays for 16 h at 65°C in GEx HI-RPM 
Hybridisation buffer (Agilent). The slide was washed in Gene Expression Wash Buffer (Agilent) 
1 (2x) and then in Wash Buffer 2 (1x) and air-dried in an ozone-free environment. The slide 
was scanned in a ScanArray Express 4000 (Perkin Elmer, Wellesley, MA) subsequently at three 
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different photomultiplier (PMT) values. Data were normalized using Lowess normalization 
[58] as available in MicroPrep [59] and corrected for inter-slide differences on the basis of 
total signal intensity per slide using PostPrep [59]. Significance of differential gene expression 
was based on false discovery rate (FDR) values lower than 0.05. (Data will be deposited in the 
NCBI GEO database, accession #)
Transcriptome data mining
Short Time-series Expression Miner (STEM) [60] was used for clustering and comparing gene 
expression intensities across different peptide concentrations. The Bonferroni correction 
method for multiple hypothesis testing of model profiles was used, with a significance level 
of 0.05. Significant models that showed a correlation of more than 0.6 were clustered. 
Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm) was used to 
filter the data for the most statistically significant differentially expressed genes with the 
following parameters: standard deviation (gene vector): 300; ≥ 4 observations with absolute 
value higher than 20; subtraction between maximum and minimum value: ≥ 200.
Heatmaps displaying normalised expression values or log-transformed intensity ratios were 
generated using the Multiple Experiment Viewer (MeV) version 4.9.0 (http://www.tm4.org/
mev.html) [61].
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Results
Assays to determine the minimum inhibitory and bactericidal concentrations of LL-37
As an initial step towards the investigation of adaptive responses to LL-37 we determined the 
minimal inhibitory concentrations (MIC) of LL-37 for different strains and serotypes of S. suis. 
Initially we performed the MIC assay for LL-37 in Todd-Hewitt Broth (THB), a rich medium 
commonly used for laboratory growth of S. suis, or a complex medium (CM) supplemented 
with 1% (v/v) glucose or maltotriose [62]. However, the peptide concentrations that were 
required to achieve inhibition of growth (25 – 50 µM) resulted in peptide precipitation with 
media components, which interfered with optical assessment of bacterial growth (data 
not shown). To overcome the problem of components in THB broth interfering with LL-37 
or promoting its precipitation we used a less rich medium and a rapid fluorescence-based 
flow cytometry assay for enumeration of live or dead bacteria and the determination of the 
minimal bactericidal concentration (MBC) of LL-37. In PBS supplemented with 0, 1, 5 or 10% 
(v/v) of THB,  almost complete killing of S. suis was observed after 1 h in the presence of 2.5 
µM LL-37 (Figure 1 A) which was 10-fold lower than for the peptide in undiluted THB (data 
not shown). These less rich growth conditions probably reflect better the nutrient availability 
in vivo, which will typically be more growth restrictive than rich laboratory medium due to 
competition between other microorganisms and rapid absorption of digested food by the 
host. S. suis S10 appeared to be more susceptible to killing by LL-37 in PBS alone compared 
to exposure in PBS supplemented with 1, 5 or 10 % (v/v) THB, although this difference was 
not statistically significant (Figure 1A).  
Recovery experiments
After 1 h exposure to 0, 0.25, 1.0 or 2.5 μM LL-37 the bacteria were resuspended in fresh, pre-
warmed THB medium and cultured for a further 6 hours, while growth was monitored by 
measuring the optical density of the culture (Figure 1B). The goal here was to determine 
the extent to which cells exposed to LL-37 (Figure 1A) can recover and grow normally. No 
growth of S. suis was observed when the bacteria had been previously incubated in PBS or 
in PBS plus 1% (v/v) THB with 2.5 µM LL-37, whereas slight increase in turbidity was seen 
between 5 and 7 hours in bacteria exposed to 2.5 µM LL-37 in PBS supplemented with 5 or 10 
% (v/v) THB.  This may be due to the effect of interfering compounds in the rich medium as 
mentioned above. Prior incubation of S. suis with 1.0 or 0.25 µM LL-37 allowed growth in fresh 
THB medium, although there was a LL-37 concentration-dependent effect on the length of 
the lag phase (Figure 1 B). 
Influence of capsule on inhibition by LL-37
As the S. suis capsule is an important virulence factor and a stereotypic marker of strains 
associated more commonly with invasive disease, we investigated the sensitivity of strains 
8039 (serotype 7) and 8067 (serotype 9), S10 (serotype 2) and its un-encapsulated isogenic 
mutant J28, to LL-37 in PBS containing 5% THB. Overall the sensitivity of the strains to LL-
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37 was similar with viability decreasing to zero between 1 and 2.5 µM (Figure 1C). However 
strain 8039 (SS7) appeared to be more resistant than S10 and 8067 to 1 µM LL37, with 40% of 
bacteria remaining viable after 1 hour. After 1 hour exposure to1 μM LL-37, only about 10% of 
strains S10, J28 (unencapsulated), and 8067 (SS9) were viable, suggesting that the capsule 
itself does not confer significant protection against this AMP. 
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Figure 1. Bacterial viability as measured by Live/Dead staining and flow cytometry analysis of A) S. suis S10 exposed 
for 60 min to LL-37 in PBS or PBS supplemented with 1%, 5%, or 10% THB. B) Recovery (growth measured as optical 
density at 600 nm) of S. suis S10 after resuspension in fresh THB following exposure to LL-37 for 60 min in either PBS 
or PBS supplemented with 1%, 5%, or 10%  C) Viability of S. suis strains S10, J28, 8039 (SS7), and 8067 (SS9) after 60 
min exposure to LL-37 in PBS with 5% THB, determined by Live/Dead staining and flow cytometry analysis. 
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Effect of D-alanylation of teichoic acids and two-component systems on sensitivity to 
LL-37 
The d-alanylation of teichoic acids has previously been shown to contribute to the resistance 
of Gram-positive bacteria to cationic antimicrobial peptides by electrostatic repulsion [63]. 
The gene products of the dltABCD operon incorporate d-alanyl esters in lipoteichoic acid 
(LTA) and wall-teichoic acid (WTA), which is considered to decrease the negative charge of the 
bacterial surface and to increase the cell wall density due to altered conformation of LTA which 
sterically hinders AMP access to the membrane [64]. We generated a deletion mutant of dltA 
in S. suis S10 and tested its sensitivity to LL-37 (Figure 2AB). Additionally, we investigated the 
role of two previously uncharacterised two-component systems (TCS) mutants on sensitivity 
to LL-37 as these mutants were less virulent in vivo and more sensitive to neutrophil killing 
[54].  Using the flow cytometry assay for live/dead staining described above we found that 
the wt S10 was not markedly more resistant to LL-37 than the dltA mutant when exposed for 
60 min in PBS plus 5% (v/v) THB. Also after 30 min exposure to 2.5 μM LL-37 S10 and the dltA 
mutant were completely killed (Figure 2AB).
Surprisingly, the strain with a deletion of TCS SSU1930/31 was less susceptible to killing 
by LL-37 compared to the wild-type S10. However, this difference in susceptibility was only 
observed at LL-37 concentrations lower than the minimal bactericidal concentration (2.5 µM) 
at which complete killing of the bacteria was observed. For example, at 0.25 µM 90% of TCS 
mutant SSU1930/31 were viable after 60 min whereas only 60% bacteria of S10 remained 
alive (Figure 2B). In contrast the sensitivity of the second TCS mutant SSU0827/28 was not 
significantly different to S10 (Figure 2B). 
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Figure 2. Bacterial viability after LL-37 exposure in PBS with 5% THB as measured by Live/Dead staining and FACS. 
A) 30 min or B) 60 min exposure of S. suis S10 (wt) and isogenic mutant ΔdltA. C) 60 min exposure of S. suis S10 (wt) 
and TCS mutants Δ1930/31 and Δ0827/28.
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Transcriptome responses to sub-lethal concentrations of LL-37 – STEM analysis
To investigate the stress response and potential induction of defence mechanisms in S. suis 
exposed to LL-37, we prepared RNA from S. suis incubated with sub-lethal (below the MIC) 
concentrations of 0.1 or 0.25 µM LL-37 in PBS + 5% THB for 10 or 30 min (see Figure 1). As a 
control RNA was also prepared from S. suis incubated without LL-37. To gain insights in the 
altered global biological processes associated with exposure to sub-lethal concentrations 
of LL-37, we used STEM [60] to categorise specific concentration dependent profiles of gene 
expression. Figure 3 shows the STEM profiles of genes that were significantly differentially 
expressed with increasing LL-37 concentrations after 10 min or 30 min exposure.
Figure 3. Differentially expressed genes with increasing LL-37 concentration were assigned to model profiles by 
STEM, similar profiles are clustered and have the same colour shading. All profiles for exposure time of A) 10 min 
(top) and B) 30 min (bottom) are shown. (profile number in top left corner, p-value of enrichment in bottom left 
corner and number of genes assigned in top right corner). C) Venn diagram representing the number of differentially 
genes present within profiles 1 and 2 of both time points.
STEM profiles 1 and 2 for both the 10 min and 30 min time point indicate gene transcripts that 
were significantly decreased with increasing concentrations of LL-37. STEM also provides the 
gene ontology (GO) terms associated with the genes within each profile. The GO terms that 
were enriched, i.e. statistically significantly overrepresented, in the clustered profile 1 and 2 
for time point 10 min and 30 min are listed in Table 1 and Table 2, respectively. These results 
indicate a concentration-dependent decrease in transcripts of genes related to biological 
processes involved in transmembrane transport of ions and/or carbohydrates.
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Profile 10 contains genes that were continuously being induced. GO term enrichment 
calculation of the profile 10 genes after 30 min exposure to LL-37 (Figure 3B) showed that 
these genes were enriched for GO terms associated with signal transduction, suggesting that 
exposure of S. suis to increasing concentrations of LL-37 increases signal transduction.
 
Profile 1 and 2 GO terms – 10 min 
Category ID Category Name #Genes 
Category 
#Genes 
Assigned 
#Genes 
Expected 
#Genes 
Enriched 
p-value Corrected 
p-value 
Fold
GO:0006810 transport 194 50 20.9 29.1 2.90E-10 <0.001 2.4 
GO:0051234 establishment of localization 196 50 21.1 28.9 4.30E-10 <0.001 2.4 
GO:0071702 organic substance transport 75 27 8.1 18.9 2.80E-09 <0.001 3.3 
GO:0044765 single-organism transport 139 38 15 23 1.10E-08 <0.001 2.5 
GO:0022891 substrate-specific transmembrane transporter act. 90 29 9.7 19.3 1.30E-08 <0.001 3 
GO:1902578 single-organism localization 141 38 15.2 22.8 1.60E-08 <0.001 2.5 
GO:0022892 substrate-specific transporter activity 94 29 10.1 18.9 4.00E-08 <0.001 2.9 
GO:0022857 transmembrane transporter activity 123 33 13.3 19.7 1.90E-07 <0.001 2.5 
GO:0008643 carbohydrate transport 53 19 5.7 13.3 8.10E-07 <0.001 3.3 
GO:0008982 protein-N(PI)-phosphohistidine-sugar PTS activity 31 14 3.3 10.7 9.40E-07 <0.001 4.2 
GO:0009401 phosphoenolpyruvate-dependent sugar PTS system 36 15 3.9 11.1 1.30E-06 <0.001 3.9 
GO:1901476 carbohydrate transporter activity 38 15 4.1 10.9 3.10E-06 <0.001 3.7 
GO:0015144 carbohydrate transmembrane transporter activity 38 15 4.1 10.9 3.10E-06 <0.001 3.7 
GO:0016021 integral component of membrane 165 36 17.8 18.2 1.10E-05 0.002 2 
GO:0031224 intrinsic component of membrane 165 36 17.8 18.2 1.10E-05 0.002 2 
GO:0044425 membrane part 171 36 18.4 17.6 2.70E-05 0.004 2 
GO:0022804 active transmembrane transporter activity 95 24 10.2 13.8 3.20E-05 0.004 2.3 
GO:0015075 ion transmembrane transporter activity 72 19 7.8 11.2 1.20E-04 0.03 2.4 
GO:0016773 phosphotransferase act., alcohol group as acceptor 74 19 8 11 1.80E-04 0.04 2.4 
GO:0015294 solute:cation symporter activity 26 10 2.8 7.2 1.90E-04 0.04 3.6 
GO:0015293 symporter activity 26 10 2.8 7.2 1.90E-04 0.04 3.6 
GO:0015171 amino acid transmembrane transporter activity 7 5 0.8 4.2 2.40E-04 0.054 6.6 
GO:0015291 secondary active transmembrane transporter activity 34 11 3.7 7.3 5.30E-04 0.078 3 
GO:0005342 organic acid transmembrane transporter activity 8 5 0.9 4.1 5.90E-04 0.086 5.8 
GO:0046943 carboxylic acid transmembrane transporter activity 8 5 0.9 4.1 5.90E-04 0.086 5.8 
GO:0008324 cation transmembrane transporter activity 59 15 6.4 8.6 9.80E-04 0.122 2.4 
GO:0051119 sugar transmembrane transporter activity 26 9 2.8 6.2 1.00E-03 0.126 3.2 
GO:0008514 organic anion transmembrane transporter activity 9 5 1 4 1.20E-03 0.154 5.2 
GO:0071705 nitrogen compound transport 9 5 1 4 1.20E-03 0.154 5.2 
GO:0005402 cation:sugar symporter activity 24 8 2.6 5.4 2.50E-03 0.26 3.1 
GO:0005351 sugar:proton symporter activity 24 8 2.6 5.4 2.50E-03 0.26 3.1 
GO:0015295 solute:proton symporter activity 24 8 2.6 5.4 2.50E-03 0.26 3.1 
GO:0016772 transferase activity 158 28 17 11 4.10E-03 0.336 1.6 
GO:0005886 plasma membrane 106 20 11.4 8.6 7.40E-03 0.488 1.8 
 
Table 1. Gene Ontology (GO) terms enriched in STEM profile 1 and 2, after 10 min exposure to LL-37. GO categories 
depicted in bold font were also enriched for the 30 min timepoint profiles (Table 2).
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Profile 1 and 2 GO terms – 30 min 
Category ID Category Name #Genes 
Category 
#Genes 
Assigned 
#Genes 
Expected 
#Genes 
Enriched 
p-value Corrected 
p-value 
Fold
GO:0006810 transport 194 67 28.6 38.4 1.90E-13 <0.001 2.3 
GO:0051234 establishment of localization 196 67 28.9 38.1 3.30E-13 <0.001 2.3 
GO:0008643 carbohydrate transport 53 27 7.8 19.2 3.10E-10 <0.001 3.5 
GO:0044765 single-organism transport 139 48 20.5 27.5 9.70E-10 <0.001 2.3 
GO:1902578 single-organism localization 141 48 20.8 27.2 1.70E-09 <0.001 2.3 
GO:0022891 substrate-specific transmembrane transporter act. 90 35 13.3 21.7 7.00E-09 <0.001 2.6 
GO:0071702 organic substance transport 75 31 11.1 19.9 9.80E-09 <0.001 2.8 
GO:0009401 phosphoenolpyruvate-dependent sugar PTS system 36 20 5.3 14.7 1.00E-08 <0.001 3.8 
GO:0008982 protein-N(PI)-phosphohistidine-sugar PTS activity 31 18 4.6 13.4 2.20E-08 <0.001 3.9 
GO:0022892 substrate-specific transporter activity 94 35 13.9 21.1 2.70E-08 <0.001 2.5 
GO:1901476 carbohydrate transporter activity 38 20 5.6 14.4 3.50E-08 <0.001 3.6 
GO:0015144 carbohydrate transmembrane transporter activity 38 20 5.6 14.4 3.50E-08 <0.001 3.6 
GO:0022857 transmembrane transporter activity 123 41 18.1 22.9 6.30E-08 <0.001 2.3 
GO:0016021 integral component of membrane 165 46 24.3 21.7 3.50E-06 0.002 1.9 
GO:0031224 intrinsic component of membrane 165 46 24.3 21.7 3.50E-06 0.002 1.9 
GO:0044425 membrane part 171 46 25.2 20.8 1.00E-05 0.002 1.8 
GO:0015075 ion transmembrane transporter activity 72 25 10.6 14.4 1.30E-05 0.002 2.4 
GO:0022804 active transmembrane transporter activity 95 30 14 16 1.50E-05 0.004 2.1 
GO:0051119 sugar transmembrane transporter activity 26 13 3.8 9.2 2.10E-05 0.004 3.4 
GO:0005886 plasma membrane 106 31 15.6 15.4 6.00E-05 0.012 2 
GO:0016773 phosphotransferase act., alcohol group as acceptor 74 24 10.9 13.1 7.10E-05 0.018 2.2 
GO:0071944 cell periphery 121 33 17.8 15.2 1.60E-04 0.026 1.8 
GO:0005402 cation:sugar symporter activity 24 11 3.5 7.5 2.50E-04 0.036 3.1 
GO:0005351 sugar:proton symporter activity 24 11 3.5 7.5 2.50E-04 0.036 3.1 
GO:0015295 solute:proton symporter activity 24 11 3.5 7.5 2.50E-04 0.036 3.1 
GO:0015294 solute:cation symporter activity 26 11 3.8 7.2 5.80E-04 0.1 2.9 
GO:0015293 symporter activity 26 11 3.8 7.2 5.80E-04 0.1 2.9 
GO:0019200 carbohydrate kinase activity 7 5 1 4 1.10E-03 0.182 4.8 
GO:0008324 cation transmembrane transporter activity 59 18 8.7 9.3 1.30E-03 0.198 2.1 
GO:0016772 transferase activity 158 37 23.3 13.7 1.70E-03 0.216 1.6 
 
Table 2. Gene Ontology (GO) terms enriched in STEM profile 1 and 2, after 30 min exposure to LL-37. Bold GO 
categories depicted in bold were also enriched for the 10 min timepoint profiles (Table 1).
Although the STEM analysis gave insight into global biological processes that were altered 
in S. suis upon exposure to sub-lethal concentrations of LL-37, we were also interested in the 
individual genes that were differentially expressed. The most differentially expressed genes 
were identified by pre-filtering of the gene expression intensity data using Cluster 3.0 (see 
Methods). A total of 97 genes remained after filtering and manual removal of genes encoding 
ribosomal proteins. These genes were clustered using Multiple Experiment Viewer (MeV) 
using Euclidean distance and average linkage, and are displayed in Figure 4.
Eight genes associated with bacterial general stress response were upregulated with 
increasing LL-37 concentrations: these genes included the heat shock response transcriptional 
regulator HrcA, heat shock protein GrpE, chaperone protein DnaK and DnaJ, heat shock 
protein 60 family chaperone GroEL (60 kDa chaperonin) and co-chaperone GroES (10 kDa 
chaperonin) (Figure 4). The chaperones encoded by these genes associate with proteins to 
prevent misfolding and to assist in proper folding [65, 66]. 
One cluster of genes that were strongly upregulated after exposure to LL-37, especially 0.1 
µM for 30 minutes, included the genes SSU0831 to SSU0836 which form a putative operon 
that is predicted to be involved in lantibiotic transport or immunity. The genes SSU0832 
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and SSU0835 are annotated as ABC transporter ATPase, and SSU0831 and SSU0834 are 
annotated as ABC transporter permease. The downstream genes SSU0827/28 encoding a TCS 
were also slightly, but not significantly, upregulated upon exposure to LL-37. This resembles 
the organisation of the antibiotic peptide sensing and transporter systems that have been 
described for some Gram-positive bacteria [67-70], where sensing of the antimicrobial 
peptide through a TCS histidine kinase induces expression of upstream ABC transporter 
genes which actively remove the peptide.
This cluster of upregulated genes also contains 11 putative membrane, surface-associated, 
or exported proteins with unknown function (Figure 4). 
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Figure 4. Heatmap displaying the 96 most differentially expressed genes after filtering with Cluster 3.0 (see Methods), 
clustered using average linkage and Euclidean distance. 
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Effect of exposure to LL-37 on the expression of known or putative virulence-
associated genes
We examined the effect of LL-37 exposure on the transcription of genes known to be associated 
with virulence and pathogenesis of S. suis [71]. Exposure to LL-37 at concentrations below 
the MIC for 10 and 30 minutes, moderately increased relative transcription of 23 virulence-
associated genes including, neuraminidase, fibronectin-binding protein, suilysin, subtilisin-
like protease, amylopullulanase, and heparinase (Figure 5). Highly upregulated in response 
to LL-37 were transcripts of genes encoding serum opacity factor (9.3- to 31-fold), adhesin 
SadP (4.3- to 16.5-fold), a pilus-encoding operon (SSU1885-89) (1.9- to 102.8-fold), and an 
unknown cell wall anchored protein (SSU1201) (11.9- to 35-fold). The fact that these genes, 
located at different loci dispersed across the chromosome, were expressed in such a similar 
manner suggested that LL-37 might induce a regulatory mechanism for the expression of 
these genes. Transcription of several regulatory genes was increased in response to LL-37, 
including the TCS-like regulator revSC21 which is thought to control expression of virulence-
associated genes [72]. 
Multiple TCS are reported to be important for sensing and responding to antibiotic- or AMP-
induced envelope stress [69]. The TCS response regulator CovR, belonging to the CovRS 
(CsrRS) TCS that plays a role in resistance to exposure of LL-37 in streptococci [43, 47], was 
induced significantly (p<0.01) upon LL-37 exposure to 0.25 μM LL-37 for 10 and 30 min and 0.1 
µM for 30 min. Similarly, the gene encoding response regulator CiaR, belonging to the CiaHR 
TCS which is involved in responses to cell-envelope associated stress [73, 74], showed modest 
(but not significant) increased transcript levels at 10 min exposure to LL-37, and significant 
(p<0.01) upregulation at the 30 min timepoint. TCS WalKR has been shown to be involved in 
response to antibiotic induced stress in Bacillus anthracis [75], and the orthologous genes 
(SSU1190/91) were also upregulated significantly (p<0.01) in S. suis. Genes encoding three 
other TCS (SSU0387/88 (LiaSR), SSU0827/28, SSU1471/72) were also upregulated in a LL-37 
concentration-dependent manner at both time-points, although this was only statistically 
significant (p<0.01) for SSU0387/88 across all timepoints and LL-37 concentrations, for 
SSU0827/28 at 30 min with 0.1 µM LL-37 and for SSU1471/72  30 min with 0.25 µM LL-37 (data 
not shown).
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Figure 5. Clustered heatmap showing fold-change in expression of genes that are potentially associated with 
virulence, adhesion and invasion. Colours indicate fold-change compared to the control (dark blue -5 and yellow 
+5), with 23 values (marked with *) being off-scale above the upper limit. 
* * *
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Discussion
Antimicrobial peptides (AMPs) are attractive alternatives to antibiotic therapy for the control 
of pathogenic microbes. Unfortunately, several pathogenic bacteria have been shown to 
activate cellular pathways mediating tolerance to AMPs, or even, induce microbial virulence 
mechanisms together with AMP survival pathways. In this study, we investigated if, and to 
what extent and through which pathways, exposure of S. suis to the human cationic AMP 
LL-37 induced tolerance in S. suis In the MIC assay we found that LL-37 precipitated at 
concentrations at which no continued S. suis growth occurred when using standard THB 
culture medium. This precipitation interfered with optical assessment of bacterial growth and 
likely affected the actual concentration of bioactive peptide. However, in PBS supplemented 
with up to 10% (v/v) of THB the observed MIC was approximately 10-fold lower and using flow 
cytometry we were able to measure rapid killing of the entire inoculum of S. suis at a LL-37 
concentration of 2.5 μM. Recovery experiments in fresh medium after 1 h incubation with LL-
37 confirmed complete killing of S. suis at 2.5 µM and continued growth at concentrations of 
1 and 0.25 μM, although the length of the lag phase was influenced by initial concentration 
of LL-37. The MBC of 2.5 µM is similar to that determined for Bacillus subtilis (between 2 and 
4 μM), which has a cationic peptide sensing and detoxification mechanism consisting of a 
two-component system and an ABC transporter [76]. 
The polysaccharide capsule forms the outermost surface of many Gram-positive bacteria, 
and is the first structural bacterial component that cationic AMPs encounter. Unencapsulated 
streptococci were found to have increased susceptibility to cationic AMPs [77-79]. In our 
flow cytometry killing assay, the susceptibility of S. suis to LL-37 was not affected by the 
presence of a capsule as shown by the use of a capsule-negative mutant J28. We also 
evaluated differential sensitivity of different S. suis serotypes and did not observe a difference 
in MBC. However, S. suis strain 8039 (serotype 7) appeared to be slightly more tolerant to 
the bactericidal effects of LL-37 at concentrations below the MBC than strains belonging to 
serotype 2 or serotype 9. Serotype 7 strains are more often found in the lungs compared 
to other serotypes, whereas serotype 2 and serotype 9 are mostly found brains, hearts and 
joints, among others [51]. It would be of interest to investigate if different cationic AMPs in 
the different organs may correlate with differential sensitivity S. suis serotypes to the different 
AMPs and thus, differential organ colonisation.
We also tested if mutants of genes involved in cell wall composition and charge showed 
differential sensitivity to LL-37. Although the dlt operon has been shown in some Gram-
positive bacteria to confer increased resistance to cationic peptides like LL-37 [63, 80-82] 
we found the dltA mutant of strain S10 to be not more sensitive to LL-37 than the wt strain 
(Figure 2 AB). Previously, upregulation of transcription of all four genes of the dlt operon was 
described in Streptococcus pneumoniae upon exposure to ~1 µM LL-37 [44], but in S. suis we 
did not observe a significant change in expression of genes belonging to the dlt operon.
LL-37 permeabilizes the cytoplasmic membrane, which at effective concentrations causes 
loss of membrane integrity and leakage of small molecules and ions from the cytoplasm into 
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the surrounding medium. In previous studies with Bacillus subtilis, LL-37 was shown to lead 
to membrane permeabilisation that could be measured by Sytox Green uptake within 5 min. 
This implies that the membrane will also be permeable to protons resulting in a dissipation 
of the proton-motive force (PMF) [83]. As ATP synthesis is linked to the generation of a PMF, 
LL-37 was predicted to inhibit energy requiring processes including protein synthesis. Loss 
of membrane integrity, even at sub-lethal concentrations of LL-37, may be one of the factors 
underlying the general stress responses that resulted in increased transcription of the heat 
shock response regulons including HrcA, heat shock protein GrpE, chaperone protein DnaK 
and DnaJ, heat shock protein 60 family chaperone GroEL (60 kDa chaperonin) and co-
chaperone GroES (10 kDa chaperonin). 
In other streptococci, TCS have been shown to regulate the transcriptional programs that 
mediate a bacterial stress response to AMPs. We tested two TCS deletion mutants for 
their sensitivity to LL-37 because these strains were more susceptible to in vitro killing by 
neutrophils and less virulent than the parent strain in a zebrafish larvae infection model 
[54]. Surprisingly a mutant of the TCS-encoding genes SSU1930/31 was less susceptible to 
sub-lethal concentrations of LL-37 (Figure 2C) and expression of the genes encoding this TCS 
are slightly (not statistically significant, p>0.01) downregulated upon peptide exposure, in 
contrast to many upregulated other TCS genes (data not shown). The regulon of the S. suis 
TCS SSU1930/31 is presently unknown, as are the pathways regulated by this TCS. Follow-up 
transcriptomics studies could be performed to determine if exposure of this mutant to the 
used concentrations of LL-37 induces lower induction of genes involved in bacterial stress 
pathways.
The second TCS mutant SSU0827/28 lies downstream of a cluster of genes that are 
strongly upregulated after exposure to LL-37. These genes SSU0832 and SSU0835 are both 
annotated as ABC transporter ATPases, and SSU0831 and SSU0834 are both annotated as 
ABC transporter permeases. The locus organization resembles that of the peptide antibiotic 
sensing and transporter systems found in some other Gram-positive bacteria [69, 76], which 
are involved in sensing cell envelope stress (e.g. exerted by cell wall active antibiotics or 
AMPs) and regulate genes important for cell envelope integrity, detoxification, and virulence. 
Although a deletion mutant of TCS encoding genes SSU0827/28 was not more susceptible to 
killing by LL-37, we could not rule out a role for the induced transporter in removing specific 
classes of AMPs affecting the cell envelope integrity as as shown for the BceSR system of B. 
subtilis which regulates expression of an ABC transporter to remove bacitracin [84, 85]. The 
investigation of the role of these transporters and the other TCS differentially expressed upon 
exposure to LL-37 will be the subject of future genetic and biochemical studies. 
This work has shown that in S. suis, there appears to be a transcriptional response program 
that regulates tolerance of these bacteria to sub-lethal concentrations of the cationic AMP 
LL-37. Among the genes that showed differential expression upon exposure to LL-37 were 
transcriptional regulators that mediate general bacterial stress responses including the heat-
shock response, suggesting that S. suis may indeed use conserved pathways to endure sub-
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lethal concentrations of AMPs. Of course, at later time-points that were not measured here, 
more specific stress response and damage control pathways may be induced, for instance 
DNA damage pathways that include the induced Holliday junction resolvase or cell wall 
integrity pathways that include the induced enolase. Importantly, the S. suis response to sub-
lethal concentrations of LL-37 also appears to modulate its lifestyle, altering the expression 
9 of the 17 virulence genes that can be upregulated by carbohydrate catabolite control [86] 
were significantly induced upon exposure to LL-37 in at least two tested conditions. From this, 
it can be hypothesised that in vivo exposure of S. suis bacteria that are colonising mucosal 
surfaces to increasing concentrations of cationic AMPs, such as LL-37, might induce virulence 
genes in these bacteria. Induction of these virulence genes might promote host invasion. It is 
therefore of interest to investigate effects of increasing accumulations of human or porcine 
host- or microbiota-derived AMPs at mucosal surfaces on S. suis adhering to the same 
mucosal surfaces, using in vitro invasion models. Paradoxically, it might be that a stronger 
innate immune response, including secretion of AMPs at mucosal surfaces, is correlating with 
higher virulence of colonising S. suis bacteria.
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Abstract 
Streptococcus suis is an opportunistic porcine pathogen, mainly causing invasive disease in 
post-weaned piglets. The microbial communities that colonise piglets are thought to play an 
important role in abundance of S. suis and the development of invasive disease. This study 
aimed to gain insight into which bacterial taxa positively or negatively correlated with S. 
suis abundance, in order to identify putative antagonists of S. suis. Microbiological samples 
from the tonsil and small intestine of healthy piglets were collected and 454 pyrosequencing 
was applied for compositional profiling of the microbiota. Several bacterial species and 
taxa with strong co- and anti-occurrences with S. suis were identified within these microbial 
communities: pathogenic species from the genera Actinobacillus, Actinomyces, Fusobacterium 
and Streptococcus showed strong co-occurrence with S. suis, whereas Lactobacillus spp., and 
Lactobacillus reuteri in particular, were found to be strongly negatively associated with S. suis 
abundance. This study supports the ideas that a network of other pathobionts may support 
the occurrence and pathogenicity of S. suis, and that specific groups or species of bacteria 
that display microbial antagonism against S. suis (and its co-occurring pathogens) can be 
found in the microbiota of niches that are colonised by this pathogen.
COMPOSITIONAL PROFILING OF PORCINE MICROBIOTA
97
Ch
ap
te
r 4
Introduction
Streptococcus suis is a pathogen of swine and one of the most important causes of bacterial 
mortality in piglets worldwide. Clinical infections are seen mainly in piglets 2-5 weeks after 
weaning and in growing pigs, but less frequently in suckling piglets and adult animals. 
Healthy pigs can carry multiple serotypes of S. suis, many of which are considered a low risk 
for causing invasive disease [1]. The porcine niche where S. suis occurs at highest densities is 
the upper respiratory tract of pigs, more particularly the nasal cavities and the tonsils [1, 2]. 
S. suis is also found in the small intestine of asymptomatic pigs [2, 3] albeit at lower relative 
abundances than in the tonsils. Due to its prevalence in domestic pigs, S. suis is considered a 
normal inhabitant of the microbiota of these niches [1, 4]. 
The porcine palatine tonsils, secondary lymphoid organs in the oral cavity, are part of the 
mucosa-associated lymphoid tissue and are the site of microbial sampling by the pig and of 
colonisation, replication and invasion of bacterial pathogens [5-7]. Piglets can also become 
colonized with S. suis from vaginal secretions during parturition and while nursing or by 
contact with colonized sows. S. suis is usually transmitted nasally or orally; transmission 
between herds occurs by the movement and mixing of healthy carrier pigs and may lead to 
the introduction of a highly virulent strain into a herd resulting in invasive disease in weaning 
and growing pigs [5]. 
Some herds may suddenly develop serious S. suis clinical disease, which is considered 
to be due to predisposing factors such as overcrowding, poor ventilation, excessive 
temperature fluctuations, and coinfections with other pathogens such as porcine influenza 
or reproductive and respiratory syndrome virus [5, 8, 9]. Still, other environmental factors 
may promote outgrowth of S. suis as well. Previously, we have shown that the carbohydrate 
source determines expression of S. suis virulence genes [10], suggesting that a change in 
nutrient composition towards more complex carbohydrates, including starch from the pig’s 
feed, might promote the transition from a commensal to a pathogenic mode of S. suis. The 
microbial community is likely to strongly influence disease occurrence, for example by the 
antagonism or promotion of S. suis by other bacteria. Respiratory disease in pigs is often 
polymicrobial in nature, and although one pathogen may dominate, other species in the 
microbial community may contribute to pathogen colonization and pathological processes in 
the host [11]. These interactions are complex and understanding them requires quantitative 
information about the organization and principles that govern the associations of the 
different species with S. suis. Approaches using Pearson’s correlation and other correlation 
measures have been recently used to reconstruct molecular ecological networks in soil [12] 
marine  [13] and gut [14] microbial communities. The aim of this study was to gain insights 
into the correlative population structure of S. suis with other species in the tonsil and small 
intestine. 
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In this microbiota profiling study, we wanted to achieve: (1) gain insight into the bacterial 
taxa that show positive (possible symbionts of S. suis) and negative (possible antagonists) 
correlations with S. suis abundance; (2) find out if some of the taxa showing anti-correlation 
with S. suis abundance could be considered candidate natural antagonists of S. suis; and 
(3) find out if bacteria that co-occur with S. suis could promote S. suis virulence. In other 
words, we wanted to explore the idea that S. suis is part of a consortium of opportunistic 
porcine pathogens that co-occur in the intestine and/or the palatine tonsils. Since S. suis is 
also considered a respiratory pathogen that is commonly sampled in the upper respiratory 
tract, we hypothesised that taxa co-occurring with S. suis in the tonsillar areas might also be 
respiratory pathogens. In two separate groups of healthy piglets around the age of weaning, 
we have sampled the microbiota from the palatine tonsils and/or small intestine. We applied 
barcoded 454 FLX pyrosequencing of the 16S rRNA genes to describe the composition and 
diversity of the microbial community of these sampled niches. 
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Material and Methods
Animals and sample collection
Two separate groups of piglets were used for the collection of biological samples from the 
tonsil and small intestine. 
Tonsil samples: Piglets (breed TEEZN, Table S1, Figure S1) were bred and housed under specific 
pathogen free (SPF) conditions at Varkens Innovatie Centrum (Sterksel, The Netherlands). 
Animals were weaned between 21 and 29 days of age, with an average of 24 days for the 
sampled pigs. Tonsil swabs were obtained from 20 piglets at days 9 and 30 post-weaning, by 
brushing both palatine tonsils thoroughly for 20s with a sterile toothbrush.  The top of the 
toothbrush was cut off and transferred to a tube containing 4 mL sterile, cold phosphate-
buffered saline (PBS) and kept at 4°C. The samples were homogenized by thorough vortexing 
and divided into 1 mL aliquots, either with or without 20% (v/v) glycerol. Samples were stored 
at -80°C within 4 hours of collection. 
Intestinal content and tonsil tissue: Piglets (breed Topigs20 F1, all boars, Table S2) were raised 
on a SPF farm (Van Beek Varkens BV, Lelystad, The Netherlands). Animals were weaned at 
28 days of age. When aged 3 – 5 weeks, piglets were anaesthetized and killed, after which 
the abdominal cavity was opened and ~20 cm sections of three different locations of the 
small intestine (duodenum, jejunum, ileum) were clamp-closed and removed. The luminal 
content (~2 mL) from the intestinal sections was collected by gentle squeezing and split into 
two cryotubes, either with or without 20% glycerol. All samples were directly frozen in liquid 
nitrogen and stored at -80°C. 
DNA extraction, and 16S rRNA gene sequence-based microbiota composition profiling
For the oropharyngeal samples 1 mL aliquots from tonsil-brushed material were freeze-
dried prior to DNA extraction. For the small intestinal content samples, approximately 0.2 
gram of material was used. Total DNA was extracted from these samples using the Repeated 
Bead Beating method as described in [15] using a FastPrep-24 instrument (MP-Biomedicals, 
France), purified using the QIAmp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) and stored 
at -20°C.
Amplicons from the V3 to V6 region of the 16S rRNA genes were generated by 
PCR using forward primer 338F (5’-ACTCCTACGGGAGGCAGCAG-3’) 5’-extended 
with a ‘NNNNNN’ barcode sequence and the titanium sequencing adapter A 
(5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG-3’) at the 5’ end. The ‘NNNNNN’ barcode is a 
unique six nucleotide sequence used for each separate sample. Each reaction was performed 
using the reverse primer 1061R (5’-crrcacgagctgacgac-3’) 5’-extended with the titanium 
sequencing adapter B (5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3’) at the 5’ end.
PCR reactions were performed using a thermocycler in a total reaction volume of 50 µL 
containing 1x buffer, 5 μL dNTP mix, 3 μL MgSO4, 1 unit of KOD Hot Start DNA polymerase 
(Novagen, Toyobo, Japan), 200 nM of forward and reverse primer, and 2 µL of undiluted or 
10x diluted template DNA. The amplification program comprised an initial denaturation 
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step at 95°C for 2 min, and 35 cycles of: denaturation at 95°C for 20 s, annealing at 55°C for 
10 s, elongation at 70°C for 15 s. The size of the amplicons (789 bp) was confirmed by gel 
electrophoresis. Both negative and positive control PCR reactions were run alongside the 
amplification, and yielded no amplicon and an amplicon of the expected size, respectively. 
PCR products were purified using MSB® Spin PCRapace columns (Stratec Molecular GmbH, 
Berlin, Germany) and the PureLink® PCR Purification kit (Invitrogen) with high cut-off buffer B3 
to remove fragments <300 bp. Yield and purity of the DNA was determined using a NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
All PCR amplicons were mixed in equimolar concentrations to 31 ng µL-1 and 5 internal standard 
controls were included. The pooled PCR amplicons were subjected to pyrosequencing, using 
half a picotiterplate on the Genome Sequencer FLX in combination with titanium chemistry 
(GATC-Biotech, Konstanz, Germany).
Pyrosequencing data were analysed with a workflow based on QIIME v1.2 [16], using settings 
as recommended in the QIIME 1.2 tutorial, with the following exceptions: reads were filtered 
for chimeric sequences using Chimera Slayer [17] and OTU clustering was performed with 
settings as recommended in the QIIME newsletter of 17 December 2010 [18] using an identity 
threshold of 97%. Diversity metrics were calculated as implemented in QIIME 1.2. Hierarchical 
clustering of samples was performed using UPGMA with weighted UniFrac as a distance 
measure as implemented in QIIME 1.2. The Ribosomal Database Project classifier version 2.2 
was performed for taxonomic classification [19]. Additional data handling, including manual 
examination of proper species assignment, was done using in-house developed Python and 
Perl scripts (NIZO Food Research, Ede, The Netherlands).
Microbiome data mining: searching for microbial biomarkers using LEfSE
To investigate if bacterial taxa were enriched in a specific microbiota sample group, Linear 
Discriminant Analysis (LDA) effect sizes were determined and statistically compared between 
groups by LEfSE [20]. Briefly, bacterial abundance data were normalized by dividing each 
single abundance in each sample by the sum of (total) abundances in the sample and 
multiplying the obtained fraction by 1 million. The non-parametric factorial Kruskal-Wallis 
(KW) sum-rank test was used to detect bacterial taxa with significant differential abundance 
with respect to location (small intestine vs. tonsil) or S. suis load (binned into “high”, “low” or 
“none”, based on the median of 16S abundance) of individual piglets. Significant statistical 
interactions between location (main classifier) and piglet S. suis load (subclassifier) were 
subsequently determined by pairwise tests using the unpaired Wilcoxon rank-sum test. 
Finally, LEfSE used LDA to estimate the effect size of each differentially abundant microbial 
taxon, whereby statistical significance is coupled to biological relevance (here, LDA measures 
the strength of the enrichment of a given bacterial taxon by only selecting those taxa that are 
most contrasting between the two locations or the three S. suis load bins).
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Microbiome data mining: co-occurrence analysis using Pearson correlations and CoNET
We used two different methods to obtain bacterial co-occurrence networks. The first method 
used the Pearson correlations based on the 16S abundance data of all microbial taxa from 
all locations and animals. We chose to combine animals and locations in order to achieve 
highest statistical support, with the knowledge that we could annotate the resulting network 
when needed, e.g. to plot microbes enriched in animals with higher or lower S. suis load. 
Although frequently used in microbiome analysis, using Pearson correlations has some 
disadvantages including sensitivity to outliers. To have the possibility to evaluate microbial 
co-occurrences in different, stricter ways, CoNET was used in addition. CoNet [14] is a 
microbiome-data-handling tool that offers ensemble-based network construction, offering 
the advantage to combine multiple similarity measures into a single network calculation. 
Rare taxa were discarded by lumping all taxa that were present in < 20 samples into a 
garbage taxon and converting counts into relative abundances. Five methods: Pearson, 
Spearman, Mutual Information, Bray Curtis and Kullback-Leibler dissimilarity, were selected 
for ensemble inference. Instead of specifying their thresholds manually, for each method, 
the top 300 positive correlations (edges) were calculated together with the top 300 negative 
correlations (edges).
The permutations output to compute p-values included randomisation, shuffling of rows 
to resample initial results of ensemble inference, and renormalisation to compensate 
for compositionality biases were stored in a file prior to method- and edge-specific 
permutation.  This permutation file was used to obtain bootstrap score distributions to 
compute final p-values, merging all five method-specific p-values of an edge into one single 
p-value. The resulting network data were transformed into a network using Cytoscape 2.8.3 
[21], showing edges that corresponded to p-values < 0.05. 
Antimicrobial assay
S. suis strains S10 (SS2), 8039 (SS7), 8067 (SS9), or 13730 (SS14) were grown in Todd-Hewitt 
Broth (THB) (Oxoid Ltd, Basingstoke, UK) at 37°C with 5% CO2. Reuterin (3-hydroxypropanal) 
was purchased (Matrix Scientific, Columbia SC, USA) as a 1 M solution in water. Standard 
dilution assays in 96-well microtiter plates were used to determine the minimal inhibitory 
concentration (MIC) of reuterin in two independent experiments. Ten-fold serial dilutions of 
reuterin in PBS (20 µL) were mixed with bacterial suspension in THB (180 µL) to obtain an 
inoculum of 5 x105 CF mL-1. Plates were incubated at 37°C with 5% CO2 for 22 hours, after 
which bacterial growth was measured by absorption at 600 nm using a spectrophotometer 
(Spectramax M5, Molecular Devices, Sunnyvale CA, USA). The MIC was determined as the 
lowest concentration at which no visible growth was observed. Bacteria were exposed to 100 
µg/mL streptomycin (Invitrogen) or PBS as controls. All conditions were assayed in duplicate.
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Ethical statement
All animal experiments were approved by the ethical committee of Wageningen UR, The 
Netherlands, in accordance with the Dutch law on animal experiments.
Results
Bacterial abundance enrichment analysis using LEfSE
The first objective was to gain insight into differential abundance of bacterial taxa in the 
piglets’ tonsils and small intestine. Using the statistical LEfSE pipeline (see Methods), we 
found that out of a total of 313 identified taxa, 142(45%) were statistically more abundant 
in the tonsil (49 samples), and 20 (6%) in the small intestine (32 samples, of which 10 from 
duodenum, 11 from jejunum, and 11 from ileum). To make biological interpretations more 
pertinent, the enriched taxa are shown at the taxonomically terminal species level in Table 1; 
the enriched taxonomically “deeper”  taxa (from genus to phylum level) are not shown. QIIME 
taxonomic classifications of OTUs to species level were evaluated by manual inspection 
using in-house scripts (NIZO Food Research, Ede, The Netherlands), graphics calling and 
expert evaluation.
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Table 1. Enrichment of bacterial taxa in porcine tonsils and small intestine. The LDA score is displayed as logarithmic 
LDA score. Taxa are only shown at species level, and taxa are alphabetically ordered for each location.
 
Taxon region LDA score p-value (Kruskal-Wall is)  
Actinobacillus equuli tonsil 3.889323 0.006833 
Actinobacillus indolicus tonsil 4.774283 5.88E-13 
Actinobacillus minor tonsil 3.721275 7.65E-06 
Actinobacillus porcinus tonsil 4.935675 2.79E-11 
Actinobacillus rossii tonsil 3.545464 1.39E-07 
Actinomyces denticolens tonsil 3.585802 1.41E-08 
Actinomyces hyovaginalis tonsil 4.550342 1.02E-12 
Arcanobacterium pyogenes tonsil 4.445029 3.10E-11 
Arcobacter cryaerophilus tonsil 3.485532 0.041107 
Atopobium minutum tonsil 3.58961 0.000128 
Bacteroides coprocola tonsil 4.794031 2.13E-14 
Bacteroides denticanoris tonsil 3.32526 0.014113 
Campylobacter mucosalis tonsil 3.611075 9.13E-12 
Catenibacterium mitsuokai tonsil 3.611318 1.93E-09 
Collinsella aerofaciens tonsil 3.276762 0.002941 
Coprococcus catus tonsil 3.440239 0.005338 
Corynebacterium diphtheriae tonsil 3.333376 9.52E-06 
Deinococcus xinjiangensis tonsil 3.451583 0.041107 
Dorea formicigenerans tonsil 3.645955 0.001153 
Dorea longicatena tonsil 3.404981 0.000235 
Faecalibacterium prausnitzii tonsil 3.728934 1.54E-08 
Filifactor alocis tonsil 3.96707 0.016915 
Filifactor villosus tonsil 3.447888 6.53E-07 
Fusobacterium necrophorum tonsil 4.248722 1.44E-14 
Fusobacterium nucleatum tonsil 3.594978 9.77E-10 
Fusobacterium ulcerans tonsil 4.058233 2.66E-14 
Granulicatella adiacens tonsil 3.699811 4.10E-11 
Klebsiella pneumoniae tonsil 3.476566 0.005181 
Kurthia gibsonii tonsil 3.310304 0.002686 
Megasphaera elsdenii tonsil 3.467616 0.007516 
Mycoplasma hyorhinis tonsil 3.072899 0.002686 
Pasteurella aerogenes tonsil 3.672429 1.54E-11 
Prevotella copri tonsil 4.036657 1.44E-11 
Prevotella ruminicola tonsil 3.59596 0.041107 
Ruminococcus bromii tonsil 3.582797 0.000132 
Selenomonas sputigena tonsil 3.778899 0.0043 
Streptococcus dysgalactiae tonsil 4.208334 4.05E-12 
Streptococcus ferus tonsil 3.73773 4.09E-07 
Streptococcus hyointestinalis tonsil 3.987304 3.49E-05 
Streptococcus orisratti tonsil 3.480155 0.00022 
Streptococcus porcinus tonsil 3.734663 1.24E-06 
Streptococcus ratti tonsil 3.285496 0.006833 
Streptococcus suis tonsil 3.654945 6.71E-11 
Subdoligranulum variabile tonsil 3.651386 7.40E-08 
Tannerella forsythensis tonsil 3.624986 1.15E-05 
Treponema pedis tonsil 3.673888 4.28E-08 
Treponema vincentii tonsil 3.900779 0.001664 
Veillonella parvula tonsil 3.551059 2.12E-08 
Clostridium butyricum intestine 3.784249 0.006223 
Lactobacillus acidophilus intestine 3.301214 2.64E-05 
Lactobacillus coleohominis intestine 3.318533 2.10E-05 
Lactobacillus crispatus intestine 3.468845 0.013017 
Lactobacillus gasseri intestine 3.674634 4.30E-06 
Lactobacillus johnsonii intestine 5.134426 4.63E-12 
Lactobacillus pontis intestine 3.42111 9.45E-05 
Lactobacillus reuteri intestine 5.338082 7.04E-14 
Lactobacillus ultunensis intestine 4.799174 0.010893 
Lactobacillus vaginalis intestine 3.29626 1.44E-09 
Lactococcus raffinolactis intestine 3.873204 0.004554 
Streptococcus parasanguinis intestine 3.950966 0.026922 
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Table 1 shows that S. suis and other streptococci are significantly more abundant in the tonsil, 
together with other porcine respiratory pathogens including Actinobacillus spp., Arcobacter 
cryaerophilus, Klebsiella pneumoniae and Pasteurella aerogenes. In the small intestine, 
Lactobacillus spp. are significantly more abundant, together with butyrate-producing 
commensal Clostridium butyricum and the symbiont Streptococcus parasanguinis [22].
Because it is unknown if piglet infection by S. suis is a consequence of its abundance, it 
is of interest to look at the distribution of S. suis across individual piglets (Figure 1A). Two 
piglets were positive for S. suis in the intestine, of which one showed substantial abundance. 
Although S. suis was clearly more abundant on the tonsils, three piglets were negative for S. 
suis and 5 piglets showed relatively low abundance. The 16S rRNA gene abundance data of 
S. suis (Figure 1B) showed that piglets could, relative to the median, be divided into three 
groups or “bins”, characterised by “high”, “low” or “none” S. suis 16S sequence, interpreted 
as the “S. suis load” of a piglet. Figure 1B shows the abundance of S. suis per bin for the 
individual piglet samples of all the intestinal and tonsil samples combined.
Figure 1. A) Abundance of S. suis in the small intestine and tonsil per individual piglet sample. B) Abundance of S. 
suis in each of three bins (groups) based on high, low or no abundance of 16S rRNA gene sequences of S. suis. Bins 
were generated across the small intestine and the tonsil samples. Horizontal lines represent the mean, and the 
dotted lines the median abundance.
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We were interested to see if specific bacterial taxa were enriched in each bin, since co-
occurrence and anti-occurrence of bacteria with S. suis is a first step to suggest which bacteria 
might be symbionts (bacteria enriched when S. suis counts are high) or antagonists (bacteria 
enriched when no S. suis was present). Table 2 shows the enrichment of bacteria in the three 
bins across all piglets. LEfSE analysis found that out of the 313 identified taxa, 34 (11%) were 
enriched in piglets with high S. suis load, 3 (1%) were enriched in piglets with low S. suis 
load, and 10 (3%) were enriched when no S. suis was present. LEfSE analysis shows that on 
the tonsils and in the small intestine, piglets with a high S. suis load also showed relatively 
high abundance of other potentially pathogenic bacteria including Actinobacillus spp., 
Corynebacterium diphteriae, Pasteurella aerogenes, Fusobacterium ulcerans, and several 
Streptococcus species. In contrast, Lactobacillus spp. and Treponema pedis were enriched in 
piglets with no S. suis.
 
Taxon S.  suis  load LDA score p-value (Kruskal-Wall is)  
Lactobacillus johnsonii none 5.084389 2.44E-05 
Lactobacillus reuteri none 5.270496 2.72E-06 
Treponema pedis none 3.516628 8.13E-06 
Prevotella copri low 3.989732 1.68E-06 
Actinobacillus indolicus HIGH 4.849962 4.38E-10 
Actinobacillus minor HIGH 3.041014 0.000108 
Actinobacillus porcinus HIGH 4.949623 8.24E-09 
Actinomyces denticolens HIGH 3.530911 3.82E-07 
Corynebacterium diphtheriae HIGH 3.265174 2.52E-06 
Fusobacterium ulcerans HIGH 4.026356 5.09E-09 
Granulicatella adiacens HIGH 4.386953 8.72E-08 
Pasteurella aerogenes HIGH 3.780639 1.78E-09 
Streptococcus ferus HIGH 3.869253 5.63E-07 
Streptococcus orisratti HIGH 3.118125 1.63E-05 
Streptococcus porcinus HIGH 3.920725 6.94E-07 
Streptococcus suis HIGH 3.830303 2.37E-16 
Veillonella parvula HIGH 3.93556 2.35E-06 
 
 
Table 2. Enrichment of bacterial taxa in tonsils and small intestine of piglets with high, low or no S. suis load. The 
LDA score is displayed as logarithmic LDA score. Taxa are only shown at species level, and taxa are alphabetically 
ordered per bin.
The data in Table 2 suggest some negative correlation or anti-occurrence between 
Streptococci including S. suis and Lactobacillus spp.. Although many Lactobacilli can occur 
at multiple sites of the upper gastro-intestinal (GI) tract, from the oral cavity to the small 
intestine [23], it is also possible that anti-occurrence of Lactobacilli and Streptococci is caused 
by them occupying different niches. It was therefore of interest to inspect enrichment of S. 
suis per GI region. We first checked for differential abundance of bacteria across the three 
sampled regions of the small intestine: duodenum (10 samples), jejunum (11 samples) and 
ileum (11 samples). LEfSE analysis did not find any taxa that were enriched in any region (not 
shown) so the 32 intestinal samples from the three regions were pooled in further analyses. 
We also checked if there was a differential abundance of taxa across the small intestine with 
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the three S. suis bins as first classifier and intestinal region as subclassifier; that did show a 
significant result for the bins, but the effect of intestinal region of subclass did not contribute 
substantially as S. suis was only marginally present in 2 piglets (not shown).
In the small intestine, LEfSE analysis found that out of the total of 313 identified taxa, 32 
(10%) were enriched in the intestine of piglets with high S. suis load, 28 (9%) were enriched 
in the intestine of piglets with low S. suis load, and 6 (3%) were enriched in the intestine of 
piglets with no S. suis. Piglets with a high S. suis load also showed relatively high abundance of 
other potentially pathogenic taxa including Actinobacillus spp., Corynebacterium diphteriae, 
Pasteurella aerogenes, Fusobacterium ulcerans and Streptococcus spp.. The species 
Lactobacillus coleohominis, isolated from healthy humans [24], was enriched in piglets with 
no S. suis in the intestine.
 
Taxon S.  suis  load LDA score p-value (Kruskal-Wall is)  
Lactobacillus coleohominis none 3.402267 0.0286 
Bacteroides coprocola low 4.609421 0.000826 
Bifidobacterium animalis low 4.061458 0.039291 
Campylobacter mucosalis low 3.503331 0.039523 
Fusobacterium necrophorum low 3.974706 0.037646 
Actinobacillus indolicus HIGH 4.550149 3.42E-05 
Actinobacillus porcinus HIGH 5.121409 4.24E-05 
Actinobacillus rossii HIGH 4.45799 0.005552 
Actinomyces denticolens HIGH 4.222156 0.001707 
Actinomyces hyovaginalis HIGH 4.97434 0.004376 
Corynebacterium diphtheriae HIGH 3.624362 0.001038 
Fusobacterium ulcerans HIGH 4.169602 0.00095 
Howardella ureilytica HIGH 3.777632 0.018069 
Pasteurella aerogenes HIGH 3.966449 0.001575 
Streptococcus dysgalactiae HIGH 4.514429 0.000623 
Streptococcus orisratti HIGH 4.524303 0.012721 
Streptococcus pasteurianus HIGH 4.959211 0.027218 
Streptococcus suis HIGH 4.217685 4.72E-09 
 
 
Table 3. Enrichment of bacterial taxa in small intestine of piglets with “high”, “low” or “none” S. suis load. The LDA 
score is displayed as logarithmic LDA score. Taxa are only shown at species level, and taxa are alphabetically ordered 
per bin.
We were also interested to inspect which bacteria were co-occurring with S. suis in the tonsil 
areas of piglets with high, low or no S. suis load. LEfSE analysis found that out of the total of 
313 identified taxa, 6 (2%) taxa were enriched in the tonsil areas of piglets with a high S. suis 
load, and 3 (1 %) taxa were enriched in the tonsil areas of piglets with no S. suis. LEfSE analysis 
showed that the porcine pathogens Arcobacter cryaerophilus, Actinobacillus indolicus and S. 
porcinus [25-27] were enriched in the tonsil areas of piglets with high S. suis load.
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Table 4. Enrichment of bacterial taxa in tonsils of piglets with high, low or no S. suis load. The LDA score is displayed 
as logarithmic LDA score. Taxa are only shown at species level, and taxa are alphabetically ordered per bin.
Network co-occurrence analysis of bacteria that show positive or negative 
correlation with S. suis abundance
The LEfSE analyses showed that several microbial pathogens are positively correlated with 
higher S. suis abundance, whereas symbiotic Lactobacilli showed anti-correlation with 
higher S. suis abundance. To further explore correlations between presence or absence data 
of bacterial taxa with S. suis load, a network view was constructed where nodes represent 
bacterial taxa and edges represent positive or negative Pearson correlations. In order to 
obtain highest statistical support, Pearson correlations representing the microbiome co-
occurrence data of all piglets were pooled and only edges representing p-values lower than 
0.001 were used; positive p-values representing positive correlations or co-occurrence are 
displayed in black, and negative p-values representing anti-correlation are displayed in red. 
To annotate the network, we coloured the nodes representing bacterial taxa enriched in 
piglets with high, low or no S. suis load (Figure 2).
 
Taxon S.  suis  load LDA score p-value (Kruskal-Wall is)  
Arcobacter cryaerophilus HIGH 3.5882 0.03641 
Actinobacillus indolicus HIGH 4.5851 0.0356 
Streptococcus porcinus HIGH 3.9163 0.01206 
Streptococcus suis HIGH 3.8617 2.85E-08 
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Figure 2. Co-occurrence network representing positive (edges displayed in black) and negative (edges displayed in 
red) Pearson correlations between abundance data of bacterial taxa. The edges represent p-values lower than 0.001. 
Where possible, nodes are coloured based on enrichment of the respective taxa in piglets with no (blue), low (green) 
or high (red) S. suis load (see Table 2).
From this network in Figure 2, it is clear that S. suis appears to be part of a consortium 
of opportunist pathogens that include species belonging to the genera Actinobacillus, 
Actinomyces, Pasteurella, Streptococcus, and Fusobacterium that were also observed in 
LEfSE enrichment analysis. Several Lactobacillus species show negative correlations with 
this pathogen consortium. The network analysis thus supports the notion that S. suis may be 
part of a consortium of pathogens that are also relevant respiratory pathogens.
Although Pearson correlations are commonly used in ecological research to infer co-
occcurrence of taxa, it is useful to explore additional correlation metrics that are less 
sensitive to outliers. The CoNET software tool has been developed to this goal and was 
used here to combine 5 different similarity measures including the Pearson correlation (see 
Methods). Exporting the CoNET correlation data to Cytoscape resulted in a co-occurrence 
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network where nodes represent microbial taxa and edges represent positive and negative 
correlations. (Figure 3).
Figure 3. Co-occurrence network representing positive (edges displayed in green) and negative (edges displayed in 
red) correlations between abundance data of bacterial taxa, calculated using CoNET. The node representing S. suis 
is coloured red.
Inspection of the above network shows that the strongest positive correlations exist 
between S. suis and pathogenic species belonging to the genera Actinobacillus, Actinomyces, 
Fusobacterium and Streptococcus; the strongest negative correlations exist between S. suis 
and the positively correlated pathogenic taxa on the one hand, and species belonging to 
the genera Lactobacillus spp. (especially Lactobacillus reuteri) and Enterococcus faecium 
on the other hand. When considering only the data from the tonsil samples, the CoNET co-
occurrence network looks slightly different (Figure 4). Using only the tonsil data to generate 
the species co-occurrence network that is displayed in Figure 4, it can be seen that S. suis 
was strongly directly positively correlated with Streptococcus porcinus and Granulicatella 
adiacens,  two pathogenic microbes, and more distantly with pathogenic Actinobacillus 
species and with Corynebacterium diphtheriae and several other pathogens. 
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Figure 4. Co-occurrence network representing the strongest correlations between abundance values of bacterial 
taxa, calculated using CoNET for the tonsil samples dataset only. The edges represent positive correlation (green) or 
negative correlation (red). The node representing Streptococcus suis is coloured red.
Theoretically, negative correlation between S. suis and its co-occurring pathogens and 
Lactobacillus spp. could hint at bacterial antagonism, but also at different niches. Although 
the species L. crispatus, L. fermentum and L. vaginalis have been found in the intestine and 
oral cavity, the species L. reuteri is most often retrieved from the intestine but not from 
the oral cavity  [23] although L. reuteri is a substantial component of the biofilms that line 
parts of the pig upper digestive tract and can adhere to cells of the stratified squamous 
epithelium [28]. In these biofilms and during planktonic growth in liquid media, L. reuteri 
produces the antimicrobial compound reuterin [29] that has a broad-spectrum antimicrobial 
activity against different Gram-negative and Gram-positive bacteria, including Streptococcus 
salivarius [30]. To directly test if L. reuteri might display antagonism towards S. suis via the 
production of reuterin, four S. suis strains representing the serotypes 2, 7, 9 and 14 were 
incubated with reuterin concentrations ranging from 0.25 to 64 mM, a range during which 
most sensitive bacteria are killed by reuterin [30]. We found that none of the S. suis strains 
were killed or inhibited by reuterin under the conditions used in our micro broth dilution 
assays (data not shown).
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Discussion
Streptococcus suis bacteria are among the most predominant bacteria associated with pigs 
and are economically relevant bacteria that cause serious porcine diseases and increased 
mortality especially a few weeks after weaning. On the other hand, also asymptomatic pigs 
are colonised by S. suis, in the upper airways and upper gastrointestinal tract including the 
tonsils and small intestine [1]. We were interested to find out if the tonsillar and small intestinal 
colonies of S. suis could be part of a consortium of porcine pathogens and if interactions 
between bacteria could be involved in suppressing (negative correlations, antagonism) or 
promoting (positive correlation, symbiosis) virulence of S. suis.
To be able to assess the relative abundance of S. suis and other members of the porcine 
microbiota, pyrosequencing was used to profile the bacterial communities using abundance 
of the 16S rRNA gene. The microbial diversity in terms of most abundant identified taxa were 
similar to previous data where 16S profiling of the porcine tonsil [7, 31] and intestine [32] 
had been carried out. One important insight of our analysis was that, although S. suis was 
enriched in the tonsil, its abundance on the tonsils of individual piglets was highly variable, 
and two piglets showed high intestinal colonisation by S. suis. Unfortunately, we did not 
possess sufficiently detailed metadata to state if these piglets showed clinical symptoms of 
intestinal infection by S. suis.
Perhaps surprisingly, a comparison of enrichment of specific bacterial taxa in the tonsillar 
and intestinal areas showed that the tonsil, a lymphoid tissue organ, harboured a higher 
proportion of enriched bacteria. A similar trend was observed when microbiomes of the 
human GI tract were compared; this study included tonsil samples and stool samples [33] 
instead of the small intestinal samples that we included in our study. It therefore appears 
that our data fall well into the diversity spectra that have been reported by other studies, and 
therefore appear to be of general value.
LEfSE analyses of bacterial taxa enriched in piglets with high, low or no S. suis load and 
network-based analyses suggested that Lactobacillus species, most notably L. reuteri, could 
be antagonists of S. suis. Alternatively, the observed anti-correlation between abundance 
of S. suis versus Lactobacillus spp. could be based on differential niche occupation in the 
studied piglets. LEfSE analysis revealed a strong L. reuteri-S. suis anti-correlation when all 
microbiota samples from the tonsillar and small intestine areas were analysed together. 
However, LEfSE analysis did not show this anti-correlation when only the tonsillar samples 
or intestinal samples were analysed. This absence of statistical anti-correlation was less 
likely to be caused by differences in sample sizes (32 intestinal vs. 49 tonsillar samples) but 
might have been a result of low abundance of S. suis in the intestine and low abudance of 
L. reuteri in the tonsil areas. S. suis was observed at low frequencies in the intestine of three 
piglets, and in different regions, whereas L. reuteri was most abundant in the small intestine. 
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Additionally, the differential intestinal abundances may have been influenced by differential 
abundance of microbes per intestinal region. Unfortunately, the sample sizes per region 
were low (duodenum 11 samples, jejunum 10 samples, and ileum 11 samples) and it was not 
possible to obtain statistically significant enrichment results by LEfSE analysis for any taxon 
across the three regions.
We thus assayed for direct antagonism between L. reuteri and S. suis in a bioassay using 
reuterin, the broad-spectrum antibiotic compound produced by L. reuteri, and found that 
S. suis is not sensitive to reuterin at concentrations 3-4 times higher than those shown to kill 
other bacteria including S. salivarius. We therefore assumed that the observed anti-correlation 
between L. reuteri and thus possibly also other lactobacilli, and S. suis was probably not due 
to direct bactericidal effect of reuterin against S. suis. It could be that the observed anti-
correlation was at least substantially influenced by differential niche occupation of S. suis 
and L. reuteri. Alternatively, L. reuteri might, through the production of reuterin, directly affect 
abundances of other bacteria that are positively correlated with S. suis, thereby indirectly 
mediating anti-correlations. And there may be other (in)direct factors that we are not aware 
of, including differential impact on microbial taxa via host AMPs and other molecules.
Both the LEfSE and network analyses supported the notion that S. suis may be part of a 
consortium of opportunist pathogens, of which several of the species belonging to the genera 
Actinobacillus, Actinomyces, Pasteurella and Streptococcus are known to cause respiratory 
disease [34, 35]. The pathogenicity of intranasally or orally administered Actinobacillus minor, 
A. porcinus, and A. indolicus has been studied in colostrum-deprived gnotobiotic piglets, 
and under these conditions with a limited natural microbiota disease was only observed 
sporadically [36].  It is therefore possible that these pathogens promote the virulence and 
infection capacity of S. suis and/or other members of this consortium. This finding was very 
relevant to us since it answered one of our main research questions: Can we find evidence 
that the pathogenicity of S. suis can be promoted by other microbes? This finding has 
practical applications, for instance, it suggests that in vivo S. suis pathogenicity may be 
better studied in experiments where the endogenous microbiome is taken into account. The 
influence of additional opportunistic pathogens on the outcome of S. suis infections also 
offers an explanation why controlled infection bioassays and natural infections of pigs by 
S. suis show variable results [37]. We consider that the impact of polymicrobial infections 
and virus-S. suis co-infections in pig populations warrants more attention. Our data may 
contribute to a better understanding of the composition of bacterial consortia potentially 
involved in polymicrobial disease, and may help to select bacterial candidates to explore this 
further in a context of S. suis virulence and pig infection.
The LEfSE tonsil- and intestine- specific analyses and co-occurrence data still suggested that 
some bacterial groups might be natural antagonists of S. suis (and the pathogenic bacteria 
it associates with). To test this in direct assays, following up on the reuterin bioassays, we 
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decided to use culture-based analysis of porcine microbial communities, employing a robotic 
system, in order to screen thousands of porcine microbiota members for the production of 
compounds that kill or substantially inhibit the growth of S. suis. The results of this approach 
are reported in the next chapters of this thesis.
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Supplemental Information
 
#  animal sow pen sex feed prior  to 
weaning 
weaning age 
(d)  
weaning weight 
(kg)  
pool  
t1  
pool  
t2  
1 6714 2987 1 m n 25 5,8 A1 A2 
2 7094 3078 1 f n 22 6,7 A1 A2 
3 7009 3080 1 m n 24 6,6 A1 A2 
4 6884 2985 1 f n 24 6,7 A1 A2 
5 7084 3078 2 m y 22 7 B1 B2 
6 6961 2799 2 f y 24 6,7 B1 B2 
7 6877 2985 2 m y 24 6,8 B1 B2 
8 6662 2996 3 m n 25 6,1 A1 A2 
9 6511 2829 3 f n 27 6,2 A1 A2 
10 6804 2814 3 f n 24 5,6 A1 A2 
11 7173 3075 3 m n 21 6,2 A1 A2 
12 7086 3078 4 m y 22 6,5 B1 B2 
13 6498 2829 4 m y 27 7 B1 B2 
14 6962 2799 4 f y 24 6,2 B1 B2 
15 6718 2987 4 m y 25 6,8 B1 B2 
16 7152 3004 5 m y 21 7,1 B1 B2 
17 6825 2824 5 f y 24 6,9 B1 B2 
18 6397 2915 5 m y 27 7,1 B1   
19 6721 2987 5 f y 25 6,7 B1 B2 
20 6383 3074 6 m n 29 5,1 A1 A2 
21 6952 2799 6 m n 24 5,7   B2 
 
 
Table S1. Animals sampled using tonsil swabs for collection of oropharyngeal microbiota. For subsequent 
screening, samples were pooled (A1, A2, B1, B2) based on their animals’ intake of feed prior to weaning and the 
sampling time point (9d or 30d post-weaning). Animal 6397 had died due to a streptococcal infection between day 9 
and 30 post-weaning, 6952 served as a replacement but was allocated incorrectly to the B2 pool.
Table S2. Animals sampled for collection of small intestinal and oropharyngeal microbiota. Colours are used to 
group animals that belong to same litter from one sow. For the creation of individual intestinal microbiota isolate 
collections, two pools of ileum content from either weaned (pool A) or not-weaned (pool B) animals were used.
 
Pig #  Age (d)  Weight (kg)  Sex Sow /  pen Weaned I leum sample pool  
2 34 6.8 m 1109 / 25  yes A 
3 20 7.1 m 333 / 15  no B 
4 27 9.4 m 333 / 15  no B 
5 34 8.5 m 333 / 28  yes A 
6 21 6.1 m 98 / 17  no B 
7 28 7.6 m 98 / 17  no B 
8 35 7.8 m 98 / 25  yes A 
9 15 4.9 m 33 / 15  no B 
10 25 6 m 33 / 15 no B 
11 32 7.6 m 33 / 28  yes A 
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Figure S1: Graphical representation of relatedness, pen of housing and sex of the animals that were sampled using 
tonsil swabbing for the collection of oropharyngeal microbiota (see Table S1). Boxes numbered 1 to 6 represent the 
sampled pens, each in which a total of 10 animals were grouped based on their intake of solid feed prior to weaning. 
Each sampled animal is represented by its number and sex, while colours and dashed lines indicate and link piglets 
born to the same sow. 
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Importance
Streptococcus suis is an important porcine and zoonotic pathogen for which there is no 
effective cross-protective vaccine. Str. suis is the cause of significant economic losses to the 
pig production industry worldwide, and there is a need for alternative strategies to prevent 
colonisation and invasive disease, especially in young pigs. We have explored the microbiota 
of healthy piglets with the aim to find commensal bacteria that can specifically kill or inhibit 
the growth of Str. suis. Here we describe the identification and characterization of two 
short antimicrobial peptides secreted by a commensal Staphylococcus pasteuri strain that 
effectively inhibit a wide range of Str. suis strains. Until recently, this family of Staphylococcal 
peptides was considered only to be cytolytic against eukaryotic cells. We demonstrate that 
the biological activity of these peptides could affect both microbe-host and microbe-microbe 
interactions, although the antibacterial activity appears to be narrow-spectrum. 
Abstract 
Given that microbes within communities fiercely compete for resources we expected to 
identify bacteria in the microbiota from porcine tonsil or small intestine that could kill or 
inhibit growth of the porcine pathogen Str. suis. A library of 10,150 individually picked 
colonies of tonsil and ileum microbiota was screened for growth-inhibiting activity against 
clinically relevant Str. suis serotypes. One isolate with a narrow spectrum of activity against 
seven serotypes of Str. suis was identified as Staphylococcus pasteuri. The S. pasteuri genome 
sequence revealed two genes located within RNAIII of the staphylococcal agr locus. These 
genes encode 25-amino acid, α-helical amphipathic peptides with high sequence identity to 
staphylococcal delta-lysins. The two delta-lysins were purified from S. pasteuri cultures and 
their antimicrobial and cytotoxic activities were compared with their chemically synthesised 
peptide equivalents. Both S. pasteuri delta-lysins show rapid, narrow-spectrum bactericidal 
activity with an MIC and MBC of 2 μM; there was no significant loss of porcine epithelial cell 
viability at this concentration. The fact that bacteria producing narrow-spectrum AMPs 
against Str. suis can be isolated from the same host niche highlights the potential to harness 
intrinsic competing capacities within the microbiota to enhance colonisation resistance 
against Str. suis. The delta-lysins were cytotoxic to human epithelial cells and PBMCs, and 
caused haemolysis of erythrocytes. Notably, the highly similar delta-lysin from S. aureus 
showed a different spectrum of antimicrobial activity against Str. suis. This study shows that 
delta-lysins may display both antimicrobial activities against competing microbes as well as 
interactions with the host.
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Introduction
Mammalian mucosal surfaces in the gastrointestinal tract and the oropharynx are home to 
a rich community of microorganisms known as the microbiota. One of the well-established 
mutualistic aspects of mammalian host-microbiota relationships is colonization resistance 
against pathogens [1, 2]. Colonization resistance refers to the competition between 
pathogenic microbes and the resident microbiota for niches and nutrients as well as 
the need for pathogens to evade innate immunity elicited by the indigenous microbial 
communities [1]. Direct microbe-microbe competition within the microbiota may involve the 
production of antimicrobial peptides (AMPs), which can prevent colonization of the host by 
pathogenic bacteria or reduce their ability to establish an infection [3-5]. Loss of microbiota 
diversity following antibiotic treatment can increase susceptibility of the host to infections 
by pathogenic, pathobiont or opportunistic bacteria [6-8]. Potential use of the endogenous 
microbiome to protect the host against harmful bacteria has fuelled great interest in 
identifying commensal bacteria that can produce AMPs in situ that effectively inhibit specific 
pathogens [5, 9]. In addition, purified natural or modified AMPs hold great potential as 
therapeutics to combat potentially harmful bacteria [10].
Streptococcus suis is an encapsulated Gram-positive facultative anaerobic microbe, 
frequently present as a member of the porcine microbiota of the oro- and nasopharynx, 
and the intestinal and genital tracts [11-14]. Carriage of Str. suis in adult pigs is usually 
asymptomatic whereas young pigs (weeks 4 to 12) are most at risk from invasive disease [15, 
16], with symptoms such as acute sepsis, meningitis, endocarditis, pneumonia and arthritis 
often being reported [17, 18]. Str. suis is also a zoonotic pathogen and human infections 
worldwide have increased significantly in the past years, with most cases originating in 
Southeast Asia [19]. Currently, no efficacious, cross-protective vaccines exist for Str. suis [20, 
21] and resistance to macrolides, lincosamides, tetracyclines, and sulphonamides has been 
reported for up to 85% of Str. suis isolates in many countries [22]. In some countries Str. suis is 
the primary cause of mortality and morbidity in young pigs and the most frequent reason to 
prescribe antibiotics of the amino-penicillin group as a preventative measure. 
Of major concern is the emergence of strains causing more rapid and severe disease and the 
risk that the burden of both zoonotic and porcine disease will increase as plans for continued 
reduction of antibiotic use in livestock are implemented across Europe [23]. Thus Str. suis 
problems on farms indirectly contribute to the spread of antibiotic resistance and alternative 
strategies for controlling this disease are needed [24]. 
Since adult pigs are usually asymptomatic carriers of Str. suis, we reasoned that healthy pigs 
might harbour members of the microbiota that could suppress outgrowth of Str. suis and 
reduce risk of invasive disease. To identify AMP-producing members of the microbiota that 
inhibit the growth of Str. suis but not of other commensals inhabiting the same niche, we used 
CHAPTER 5
124
a high-throughput screening assay on isolated bacteria from the porcine tonsil and small 
intestine. Here we describe the detailed characterisation of a Staphylococcus pasteuri isolate 
producing two α–helical delta-lysins with high sequence identify to other staphylococcal 
delta-lysins that display narrow-spectrum antimicrobial activity against Str. suis.
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Material and Methods
Animals and sample collection
We used two separate groups of piglets for the collection of biological samples from the 
tonsil and small intestine (see Chapter 4). 
Tonsil samples: Piglets (breed TEEZN) (see Chapter 4: Table S1, Figure S1) were bred and 
housed under specific pathogen free (SPF) conditions at Varkens Innovatie Centrum (Sterksel, 
The Netherlands). Animals were weaned between 21 and 29 days of age, with an average of 
24 days for the sampled pigs. Tonsil swabs were obtained from 20 piglets at days 9 and 30 
post-weaning, by brushing both palatine tonsils thoroughly for 20s with a sterile toothbrush. 
The top of the toothbrush was cut off and transferred to a tube containing 4 mL sterile, 
cold phosphate-buffered saline (PBS) and kept at 4°C. The samples were homogenized by 
thorough vortexing and divided into 1 mL aliquots, either with or without 20% (v/v) glycerol. 
Samples were stored at -80°C within 4 hours of collection. 
Intestinal content and tonsil tissue: Piglets (breed Topigs20 F1, all boars) (see Chapter 4: Table 
S2) were raised on a SPF farm (Van Beek Varkens BV, Lelystad, The Netherlands). Animals 
were weaned at 28 days of age. When aged 3 – 5 weeks, piglets were anaesthetized and killed, 
after which the abdominal cavity was opened and ~20 cm sections of three different locations 
of the small intestine (duodenum, jejunum, and ileum) were clamp-closed and removed. The 
luminal content (~2 mL) from the intestinal sections was collected by gentle squeezing and 
split into two cryotubes, either with or without 20% glycerol. All samples were directly frozen 
in liquid nitrogen and stored at -80°C. 
Bacterial strains and culture conditions
Isolates of Streptococcus suis comprising eight different serotypes, including the un-
encapsulated strain J28 and its parental strain S10, were obtained from Central Veterinary 
Institute (Lelystad, Netherlands) and are listed in Table 1. All Streptococcus strains were 
cultured without agitation at 37°C with 5% CO2 in Todd-Hewitt Broth (THB) (Oxoid, Basingstoke, 
UK), broth with vigorous shaking at 37°C. Bacterial isolates from porcine microbiota were 
grown in THB, in THB supplemented with K2HPO4 (36 mM), KH2PO4 (13.2 mM), sodium citrate 
(1.7 mM), MgSO4 (0.4 mM), (NH4)2SO4 (6.8 mM) and 4.4% glycerol (THB freezing medium), 
or in BHI. The following culture media were used for other tested organisms; MRS (VWR 
International, Leuven, Belgium) for Lactobacillus strains, BHI for all Staphylococcus strains 
and Listeria monocytogenes, Luria-Bertani (LB) (Merck, Darmstadt, Germany) for Salmonella 
enteriditis, and trypticase soy yeast extract medium (BD, Erembodegem-Dorp, Belgium) for 
Enterococcus faecalis. All bacteria were cultured at 37°C and agar (1.5% w/v) was added to 
culture media for bacterial growth on plates.
Isolate library creation and inhibition screening assay
Tonsil samples were pooled based on the animal’s feeding behaviour prior to weaning (has 
eaten solid feed or not yet) and the time point of sample collection (9 days or 30 days post-
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weaning), resulting in 4 separate pools. Only the ileum content was pooled from all the 
intestinal samples. Pooled microbiota samples were each plated directly onto THB agar 
Q trays, which were incubated overnight (~18 h) aerobically at 37°C. Single colonies were 
isolated from THB agar Q trays using a Genetix QPIX II-XT (Molecular Devices, Berkshire, UK) 
colony-picking robot and inoculated into 96-well microtiter plates containing THB freezing 
medium. The plates were incubated overnight at 37°C and subsequently stored at -80°C.
Individual colonies were replicated from these 96-well microtiter plates onto THB agar plates 
using a 96-pin microplate replicator (Boekel Scientific) and grown overnight at 37°C. Plates 
were exposed to UV light (λ=312 nm) for 30 min to kill the bacterial cells. Soft THB agar (0.75% 
w/v agar) was cooled to 50°C and seeded with a Str. suis target strain (approximately 1 x 106 
CFU mL-1) from an overnight culture and a 35 mL aliquot was rapidly transferred to overlay 
each plate. The seeded soft-THB agar was allowed to solidify and dry, and growth inhibition 
zones were detected following overnight incubation at 37°C. Protease sensitivity of the 
antimicrobial compound was evaluated to ensure activity was due to a peptide and not due 
to non-specific fermentative metabolites such as lactate or acetate. A selection of colonies 
were grown overnight and exposed to UV light,  a 1 µL solution (>600 mAU mL-1) of proteinase 
K (Qiagen) or trypsin (Sigma) was spotted next to each colony and plates were incubated for 
1 h at 37°C prior to applying the Str. suis seeded agar overlay. 
Crude peptide extraction and agar diffusion assay
Selected isolates from porcine microbiota that showed activity in the screening overlay assay 
against specific Str. suis strains, were further characterized using a modification of the agar 
diffusion assay [25]. Glycerol stocks of isolates that had shown growth-inhibitory activity to 
Str. suis were used to inoculate 5 mL THB or BHI media, which was incubated overnight at 
37°C. From this culture, THB or BHI agar plates were inoculated with an appropriate dilution 
of bacteria to obtain a lawn of growth following overnight incubation at 37°C. A volume of 5 
mL sterile NaCl 0.9% solution was added and bacteria were detached from the agar surface 
by 5 min incubation at room temperature on a horizontal shaker followed by gentle scraping 
with a sterile plastic T-shaped spreader (VWR International, Amsterdam, The Netherlands). 
The cell suspension was collected in sterile 15 mL Falcon tubes and centrifuged for 15 
min at 3200 x g at 4°C. Supernatant was filtered using a 0.2 μm sterile syringe filter (Merck 
Millipore,  Darmstadt, Germany) to obtain cell-free culture supernatant (CFS). Bacterial cell 
pellets were resuspended in 70% 2-propanol (IPA), 0.1% trifluoracetic acid (TFA) and stirred for 
4 hours at 4°C. The IPA-TFA cell extract (CE) was obtained by centrifugation for 15 min at 10.000 
x g at 4°C, and filtered using a 0.2 μm sterile syringe filter. To partially purify the antimicrobial 
peptide from the CE, the IPA-TFA was removed by rotary evaporation, and the remaining 
sample applied to a 2g, 12 mL, Strata C18-E solid phase extraction column (Phenomenex, 
Cheshire, UK) pre-conditioned with methanol and equilibrated with water. The column was 
washed with 40% ethanol and the antimicrobial activity eluted in stepwise concentrations of 
IPA with 0.1% TFA, and each elution fraction was collected. Appropriate nutrient agar (0.75% 
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w/v agar) was cooled to 50°C and seeded with a selected target bacterium (approximately 1 x 
106 CFU mL-1). A volume of 25 mL was rapidly transferred to sterile Petri dishes and allowed to 
solidify and dry, after which wells (4.6 mm diameter) were made using a sterile glass Pasteur 
pipette. A volume of 50 µL or 100 µL of the CFS, CE or reverse-phase HPLC fractions (obtained 
as described below) was dispensed into the wells and the plates were incubated at 37°C 
overnight. Antimicrobial activity was determined by the presence and size of clearly visible 
zones of growth inhibition around the wells.
Whole-genome sequencing and identification of the strain inhibiting growth of Str. suis 
Total DNA was extracted from isolate #26 and whole-genome sequencing was performed 
as described elsewhere (refer to Genome Announcement) (NCBI WGS submission ID: 
SUB1512943). To identify the isolate, the complete 16S rRNA gene sequence was derived 
from the whole genome sequence using RNAmmer 1.2 [26]. The tuf and gap gene sequences 
[27, 28] were retrieved after annotation of the genome using RAST [29, 30]. Phylogenetic 
neighbours and their corresponding 16S rRNA gene sequences were found using the 
EzTaxon server (http://www.ezbiocloud.net/eztaxon) [31]. Using the Phylogeny.fr web server 
software suite (http://www.phylogeny.fr/) [32, 33],  gene sequences were aligned (T-coffee), 
the alignments were trimmed and curated (Gblocks), and a phylogenetic tree was estimated 
using the Maximum Likelihood criterion (PhyML v3.0) with 500 times bootstrapping. 
Genome mining for antimicrobial peptide encoding genes
The web-based tool BAGEL3 (http://bagel.molgenrug.nl/) [34] was used to mine the S. 
pasteuri whole genome sequence for putative bacteriocin or antimicrobial peptide encoding 
genes. Amino acid sequences of two putative antimicrobial peptides were used as input for 
helical wheel representation using the tool available on http://rzlab.ucr.edu/. PEPFOLD 1.5 
[35, 36] was used for de novo three-dimensional conformation prediction of the peptides.
Staphylococcus pasteuri peptide purification
Five mL of BHI medium was inoculated with 25 µl of isolate #26 (Staphylococcus pasteuri) 
from a -20°C glycerol stock and incubated overnight at 37°C with agitation at 125 rpm, and 
was used to inoculate 1 litre of BHI medium which was then grown overnight. The culture 
was harvested by centrifugation (8000 rpm, 20 minutes, 4°C), and the cell-pellet was 
resuspended in 150 mL of 70% IPA 0.1% TFA and stirred for 3-4 hours at room temperature. 
The antimicrobial peptides were first partially purified from cells using a Strata C18-E solid 
phase extraction column eluted with 70% IPA 0.1% TFA as described above and the IPA-TFA 
was removed by rotary evaporation. The eluent was applied in 249 µl aliquots to an analytical 
Proteo Jupiter RP-HPLC column (4.6 x 250 mm, 4µ, 90Å, Phenomenex, Cheshire, UK) running 
a 30-62% acetonitrile 0.1% TFA gradient for 5 minutes followed by a 62-75% gradient over 35 
minutes. Eluent was monitored at 214 nm and fractions were collected at 1 minute intervals.
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Synthetic peptides
Peptides were synthesised using Microwave-assisted Solid Phase Peptide Synthesis (MW-
SPPS) performed on a LibertyBlueTM CEM microwave peptide synthesiser, according to the 
amino-acid sequences predicted from the hld genes. Both peptides were synthesised on an 
Fmoc-L-Lys(BOC) HMBP-Chemmatrix® resin (PCAS BioMatrixInc, Quebec, Canada).
Peptides were purified using RP-HPLC on a C4 Vydac (10 x 250 mm, 10 μ, 300Å) column 
(Vydac, California, USA) and eluted using a gradient of 30% acetonitrile, 0.1% TFA for 5 
minutes, 30-40% acetonitrile, 0.1% TFA over 5 minutes, followed by 40-60% acetonitrile, 0.1% 
TFA over 40 minutes. The flow rate was 2.5 mL min-1 and eluent was monitored at 214 nm. 
Fractions were collected at 1 minute intervals and fractions containing the desired molecular 
mass were identified using matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-ToF-MS) performed on an Axima TOF2 mass spectrometer (Shimadzu 
Biotech, Manchester UK). Fractions deemed pure were pooled and lyophilised on a Genevac 
HT 4X (Genevac Ltd., Ipswitch, UK). 
Time-course bactericidal assay
A culture of Str. suis S10 was grown overnight in THB at 37°C 5% CO2, diluted 100-fold into 
pre-warmed THB and incubated for 6 h. For the assay, the bacteria were suspended in fresh, 
pre-warmed THB at a density of 5x105 CFU mL-1 and exposed at 37°C to 1 µM (½x MIC) or 4 
µM (2x MIC) of synthetic peptide diluted in THB, or an equal volume of THB as control. At 30 
min intervals, 20 µL aliquots were removed and 10-fold serial dilutions in PBS were plated 
onto THB agar plates, and Str. suis survival was enumerated following overnight incubation 
at 37°C 5% CO2. The experiment was performed in duplicate and average colony forming 
units (CFU) values are presented. 
Transmission electron microscopy
For visual assessment of peptide-induced membrane damage, bacteria were collected in 
exponential growth phase as described above, were exposed to 1, 2 or 8 µM peptide and 
were fixed 30 or 120 min after exposure according to the lysine-acetate-based formaldehyde/
glutaraldehyde ruthenium red-osmium (LRR) fixation procedure [37]. After dehydration using 
ethanol, samples were embedded in Epon and ultrathin sections were cut and placed on 
copper grids. Fixed samples were imaged using a JEOL JEM 1011 transmission electron 
microscope.
Haemolysis assay
To assess haemolytic activity of the delta-lysins towards human cells, human erythrocytes 
from 3 different donors (Sanquin Blood Bank, Nijmegen, The Netherlands) were assayed. 
Erythrocytes were isolated by centrifugation (750 x g, 5 min), washed three times in sterile 
0.9% NaCl solution and resuspended at a density of 2x107 cells mL-1 in Dulbecco’s PBS (dPBS) 
without calcium or magnesium (AppliChem, Darmstadt, Germany). After 1h incubation at 
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37°C with 5% CO2 in the presence of different concentrations of peptide in dPBS , the cells 
were centrifuged (12,000 x g, 15s) and haemoglobin release, indicating cellular damage, 
was measured as absorbance of the supernatant at 405 nm and 600 nm (background) 
(Spectramax M5, Molecular Devices, Sunnyvale CA, USA). Parallel exposure to 0.5% (v/v) 
Tween-20 and dPBS was used to determine 100% and 0% (background) haemolysis, 
respectively. Experiments were performed in duplicate, and represented as mean values 
with SD of the three donors. The LD50 was calculated as the concentration resulting in 50% of 
haemolysis based on these averaged values.
Neutral red uptake assay
IPEC-J2 cells, originating from porcine jejunal epithelium [38], were used to determine 
cytotoxicity of the two delta-lysins for pigs, by assessing porcine cell viability using the 
neutral red uptake assay [39]. Briefly, cells were seeded in a flat-bottom 96-well microtiter 
plate at a density of ~1x105 cells well-1 in 89% Dulbecco’s Modified Eagle’s Medium (DMEM) 
+ GlutaMAX™ (Gibco, Life Technologies), containing 10% heat-inactivated Fetal Bovine 
Serum (FBS) and 100 U mL-1 penicillin and 100 µg mL-1 streptomycin (Invitrogen, Breda, The 
Netherlands). After incubation at 37°C with 5% CO2 for 24 hours cells had reached confluency 
and culture medium was removed and replaced with 200 µL treatment medium (Keratinocyte 
Serum Free Medium (Gibco, Life Technologies)) containing a concentration range of synthetic 
peptide. Following 20 h incubation at 37°C with 5% CO2, the treatment medium was removed 
and 100 µL neutral red solution (40 mg mL-1) was added. After 3 h incubation, neutral red 
solution was removed, cells were washed with 150 µL PBS and neutral red was extracted 
from the cells by adding 150 µL 50% ethanol, 1% glacial acetic acid. The released neutral 
red content, indicative of cell viability, was measured spectrophotometrically at 540 nm 
(Spectramax M5, Molecular Devices, Sunnyvale CA, USA), values from duplicates conditions 
were averaged and normalized to cells treated with PBS only and expressed with the SD as 
percentage viable cells. 
Human peripheral blood mononuclear cell (PBMC) viability assay 
PBMCs were isolated and prepared as previously described [40] with modifications. Buffy 
coats of peripheral blood of 3 healthy donors were obtained from the Sanquin Blood Bank, 
Nijmegen, The Netherlands. Isolated PBMCs were washed and resuspended in Iscove’s 
Modified Dulbecco’s Medium (IMDM) + GlutaMAX™ (Gibco, Life Technologies) supplemented 
with 10% FBS, 100 U mL-1 penicillin and 100 µg mL-1 streptomycin (Invitrogen, Breda, The 
Netherlands) to a final concentration of 1 × 106 cells mL-1 and seeded (100 µL per well) in 96-well 
tissue culture plates. Two-fold serial dilutions of active CE fractions were prepared in sterile 
PBS and 11 μL was suspended per well. After 3 hours of incubation at 37°C 5% CO2, cells were 
harvested and stained using the commercially available Annexin V: Propidium Iodide (PI) 
Apoptosis Detection Kit APC (eBiosciences, Vienna, Austria) according to the manufacturer’s 
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instructions. Viability was assessed by flow-cytometry and data were analysed using FACS 
Diva software. 
DNA extraction and 16S rRNA gene sequence-based microbiota composition profiling
For the oropharyngeal samples, 1 mL aliquots from tonsil-brushed material were freeze-
dried prior to DNA extraction. For the small intestinal content samples, approximately 0.2 
gram of material was used. Total DNA was extracted from these samples using the Repeated 
Bead Beating method as described in [41] using a FastPrep-24 instrument (MP-Biomedicals, 
France), purified using the QIAmp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) and stored 
at -20°C.
Amplicons from the V3 to V6 region of the 16S rRNA genes were generated by 
PCR using forward primer 338F (5’-ACTCCTACGGGAGGCAGCAG-3’) 5’-extended 
with a ‘NNNNNN’ barcode sequence and the titanium sequencing adapter A 
(5’-CCATCTCATCCCTGCGTGTCTCCGACTCAG-3’) at the 5’ end. The ‘NNNNNN’ barcode is a 
unique six nucleotide sequence used for each separate sample. Each reaction was performed 
using the reverse primer 1061R (5’-crrcacgagctgacgac-3’) 5’-extended with the titanium 
sequencing adapter B (5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-3’) at the 5’ end.
PCR reactions were performed using a thermocycler in a total reaction volume of 50 µL 
containing 1x buffer, 5 μL dNTP mix, 3 μL MgSO4, 1 unit of KOD Hot Start DNA polymerase 
(Novagen, Toyobo, Japan), 200 nM of forward and reverse primer, and 2 µL of undiluted or 
10x diluted template DNA. The amplification program comprised an initial denaturation 
step at 95°C for 2 min, and 35 cycles of: denaturation at 95°C for 20 s, annealing at 55°C for 
10 s, elongation at 70°C for 15 s. The size of the amplicons (789 bp) was confirmed by gel 
electrophoresis. Both negative and positive control PCR reactions were run alongside the 
amplification, and yielded no amplicon and an amplicon of the expected size, respectively. 
PCR products were purified using MSB® Spin PCRapace columns (Stratec Molecular GmbH, 
Berlin, Germany) and the PureLink® PCR Purification kit (Invitrogen) with high cut-off buffer B3 
to remove fragments <300 bp. Yield and purity of the DNA was determined using a NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
All PCR amplicons were mixed in equimolar concentrations to 31 ng µL-1 and 5 internal standard 
controls were included. The pooled PCR amplicons were subjected to pyrosequencing, using 
half a picotiterplate on the Genome Sequencer FLX in combination with titanium chemistry 
(GATC-Biotech, Konstanz, Germany).
Pyrosequencing data were analysed with a workflow based on QIIME v1.2 [42], using settings 
as recommended in the QIIME 1.2 tutorial, with the following exceptions: reads were filtered 
for chimeric sequences using Chimera Slayer [43] and OTU clustering was performed with 
settings as recommended in the QIIME newsletter of 17 December 2010 [44] using an identity 
threshold of 97%. Diversity metrics were calculated as implemented in QIIME 1.2. Hierarchical 
clustering of samples was performed using UPGMA with weighted UniFrac as a distance 
measure as implemented in QIIME 1.2. The Ribosomal Database Project classifier version 2.2 
INHIBITION OF S. SUIS BY DELTA LYSINS OF S. PASTEURI FROM PORCINE TONSIL
131
Ch
ap
te
r 5
was performed for taxonomic classification [45]. Additional data handling was done using 
in-house developed Python and Perl scripts (NIZO Food Research, Ede, The Netherlands).
Ethical statement
All animal experiments were approved by the ethical committee of Wageningen UR, The 
Netherlands, in accordance with the Dutch law on animal experiments. The human PBMC 
and haemolysis assays were approved by Wageningen University Ethical Committee and 
performed according to the principles of the Declaration of Helsinki. Written consent was 
provided by the donors.
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Results
Collections of porcine microbiota isolates 
We used two separate groups of piglets for the collection of microbiological samples from 
the tonsil and small intestine, respectively. From one group of 20 piglets tonsil swabs were 
obtained from each animal at days 9 and 30 post-weaning (Chapter 4, Table S1), and from 9 
different piglets the intestinal content and tonsil tissue were collected 1 wk prior to weaning 
(n=3), at weaning (n=3) or 1 wk post-weaning (n=3) (Chapter 4, Table S2). Tonsil samples 
harvested from the first group of animals at the same sampling time point were pooled and 
ileal content from all animals from the second group were pooled. We plated the pooled 
microbiota samples, picked individual colonies using a colony-picking robot, and cultured 
these in 96-well plates, creating two separate isolate libraries originating from the tonsil and 
the ileum. These isolate libraries of individually picked bacterial colonies from tonsillar and 
ileal microbiota were used for antimicrobial activity screening against Str. suis.
Identification of porcine microbiota isolates inhibiting growth of Str. suis 
In total 10,150 colonies were screened for their capacity to inhibit growth of Str. suis serotype 
2 (un-encapsulated mutant; J28), serotype 7 (strain 8039), and serotype 9 (strain 8067) using 
an overlay assay. We selected 86 colonies from the tonsil library and 18 colonies originating 
from the ileum library that displayed inhibition against one or more serotypes of Str. suis in 
the overlay assays, and these were tested further in overlay assays against other strains of 
Str. suis (Table 1). 
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Serotype Strain Virulence Screening 
1/2 15964 ND  
1 6388 HV  
1 6555 / NCTC 428 V  
2 T15 AV  
2 S735 / NCTC 10234 WV  
2 p 1/7 V  
2 3881 / S10 V  
2 J28 (S10 cpsΔEF) AV y 
3 15965 ND  
4 5213 ND  
7 8039 ND y 
9 7997 AV  
9 8067 AV y 
9 8017 AV  
9 7709 ND  
9 C132 ND  
9 5973 AV  
9 22083 R ND  
9 7998 ND  
9 8186 ND  
14 13730 ND  
 
 
Table 1: Streptococcus suis isolates with different serotypes used in this study. Strain 8039, 8067, and J28 were used 
for screening of the isolate banks, encompassing the most prevalent serotypes 2 and 9 as well as an unencapsulated 
mutant. AV = avirulent, V = virulent, HV = highly virulent, ND = not determined. 
We selected 32 tonsil isolates out of the original 86 isolates based on their different colony 
morphologies and consistent inhibitory activity in vitro against a panel of Str. suis strains. In 
total 28 isolates lost Str. suis inhibiting activity after culturing under laboratory conditions and 
23 isolates were only active against three or less serotypes of Str. suis (Table S1). Similarly, from 
the original 18 ileum isolates only a single isolate showed inhibition of multiple serotypes of 
Str. suis. From these tonsil and ileum libraries we selected 7 isolates with the largest zones 
of inhibition, and of which the inhibitory effect was abrogated after protease treatment. We 
identified these 7 isolates by 16S rRNA gene sequencing and characterised them further. 
Here we focus on the detailed characterisation of one bacterial isolate (#26) originating from 
the tonsil,  as in overlay assays it showed consistent growth inhibition of multiple serotypes 
of Str. suis with large, clear inhibition zones (Figure 1A, Table S1). Isolate #26 was identified as 
Staphylococcus pasteuri [46] based on the genome sequence. In the pyrosequencing reads 
obtained from all tonsil samples, the 16S rRNA gene sequence of this isolate was found in 
one tonsil swab sample with 100% identity and in tonsil swabs from 17 out of 21 sampled 
animals with >99% identity (data not shown). Although the high degree of 16S sequence 
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similarity between closely related Staphylococcal species [28] and the possible presence of 
sequencing errors in the ~510 bp reads does not allow for reliable species assignment, this 
confirms the presence of S. pasteuri isolate #26 and closely related isolates in the sampled 
porcine tonsils. 
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Figure 1. A) Overlay assay showing a selection of tonsil isolates (Table S1) with inhibition zones against Str. suis SS2 
S10. Spotting of proteinase K or trypsin (black dots) next to the bacterial colonies locally abolishes this inhibitory 
effect, indicating production of a proteinaceous inhibiting substance. S. pasteuri #26 is indicated with a red asterisk. 
B) Well-diffusion assay with CFS of a high optical density culture of S. pasteuri #26 against nine Str. suis strains 
belonging to 5 different serotypes. Clear zones around the wells indicate inhibition of growth. C) Well diffusion assay 
against Str. suis S10 of CE fractions (50 µL per well) eluted with stepwise increased concentration of IPA from a SPE 
column. Activity is present in the 40% and 50% IPA elution fraction, and in total cell extract (as was applied onto 
the column) but not in other fractions or the flow-through (ft). Whitish halo around the 50% IPA well presumably is 
caused by protein precipitation in absence of IPA. Protein content of these fractions was analysed by Tricine-SDS-
PAGE (Figure S1B).
Antimicrobial activity detection in cell-free supernatant and 70% 2-propanol cell 
extract
The antimicrobial activity of S. pasteuri #26 was abolished by proteinase K and trypsin 
in overlay assays (Figure 1A), indicating the production of a proteinaceous inhibitory 
substance. Antimicrobial activity against multiple serotypes of Str. suis was found in cell-free 
supernatant (CFS) of liquid cultures grown overnight to high optical density (OD600 nm >10) at 
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37°C with aeration by agitation at 225 rpm (Figure 1B), whereas this activity was absent in 
the CFS of cultures grown without aeration by agitation that reached a much lower optical 
density. When the bacteria were grown aerobically overnight on BHI agar plates, and cells 
were removed and washed in saline solution, this supernatant also contained antimicrobial 
activity (data not shown). Most antimicrobial activity was extracted in 70% 2-propanol (IPA), 
0.1% trifluoracetic acid (TFA) crude cells extracts (CE) of bacteria grown either to high OD 
in liquid culture or on agar plates. This suggests that, although some of the antimicrobial 
activity is released into the culture medium, a large part of this activity remains attached 
to the bacterial cell envelope and can effectively be released by extraction with an organic 
solvent such as IPA. The inhibitory substance present in the CFS and CE was likely to be 
a small peptide as shown by Tricine-SDS-PAGE (Figure S1A). To purify the antimicrobial 
fraction, the crude CE was applied to a C18-E solid phase extraction (SPE) column and elution 
of bound material by stepwise addition of increasing concentrations of IPA was performed. 
IPA was removed by evaporation and the eluent fractions were subsequently subjected to 
antimicrobial testing. We only found antimicrobial activity in elution fractions with 40% and 
50% IPA (Figure 1C and Figure S1B) and we used these fractions, after evaporation of IPA, 
for testing the antimicrobial activity against different strains of Str. suis and other bacterial 
species. Fractionation by HPLC on a C12 column of the 40% and 50% IPA samples, and 
subsequent testing of these collected fractions for antimicrobial activity against Str. suis S10, 
showed the presence of different bioactive components (Figure S3A). 
Identification of two hld genes encoding delta-lysins by bioinformatic prediction
To identify genes of S. pasteuri #26 that may encode antimicrobial peptides, total DNA 
was purified and sequenced on an Illumina HiSeq 2500 system (reference to Genome 
Announcement). Two genes encoding putative bacteriocins that could be responsible for 
the antimicrobial activity were identified using BAGEL3, a web-based genome-mining tool 
for the identification of bacteriocins [34].  Further analysis of the genomic context revealed 
that the two putative bacteriocin-encoding ORFs were located within the regulatory RNAIII 
coding region that is part of the conserved staphylococcal accessory gene regulatory (agr) 
locus (reviewed in [47]) (Figure 2A). The agr locus comprises two divergent transcripts called 
RNAII and RNAIII [48, 49], the former being an operon encompassing the genes agrBDCA that 
encode the entire staphylococcal peptide-induced quorum sensing module, and the latter 
playing a complex post-transcriptional regulatory role in virulence. In most staphylococcal 
species the RNAIII also contains a single small ORF annotated as hld [48], encoding the 
delta-lysin peptide known for its haemolytic and cytotoxic activity [50, 51]. However, in S. 
pasteuri the RNAIII is predicted to encode two non-identical copies of delta-lysins of 25 
amino acid residue length; delta-lysin I [MAADIISTIGDLVKLIINTVKKFQK] and delta-lysin II 
[MTADIISTIGDFVKWILDTVKKFAK]. Delta-lysin I and II resemble each other with 19 identical 
residues and 6 amino acid residue substitutions (A2T, L12F, L15W, I17L, N18D, and Q24A). 
Both peptides contain a large proportion of hydrophobic amino acid residues (52%) and 
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secondary structure prediction using PEPFOLD1.5 [35, 36] and helical wheel representations 
(see Methods) predicts that both peptides are likely to form amphiphilic α-helices (Figure 
2B,C). At physiological pH the net charge of the predicted delta-lysin peptides is +1 for 
delta-lysin I, 0 for delta-lysin II, which is similar to other staphylococcal delta-lysins [52]. 
Sequence alignment of the two delta-lysins from S. pasteuri #26 with delta-lysins from other 
staphylococcal species revealed high similarity (Figure 3). Notably, S. pasteuri #26 delta-lysin 
I  is identical to S. warneri delta-lysin I, but their delta-lysin II peptides differ by one residue 
on position 24 (A24T). The delta-lysin II peptide in S. pasteuri #26 is identical to the delta-lysin 
found in S. epidermidis E229 DL [53].
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Figure 2. A) Graphical representation of the molecular arrangement of the agr locus in S. pasteuri #26, with the two 
BAGEL3 predicted genes encoding delta-lysin I and II (1 and 2, highlighted in green) located within RNAIII B) Helical 
wheel representation of delta-lysin I (left) delta-lysin II (right) showing peptide amphipathicity. Hydrophobic amino 
acids (diamond shape) are colour coded from highest (green) to lowest (yellow) hydrophobicity. Hydrophilic amino 
acids (round shape) are shaded from highest (red) to lowest (yellow) hydrophilicity, positively charged residues 
(pentagons) and negatively charged residues (triangles) are shown in light purple. Values depicted are hydrophobic 
moment (HM) and angle of HM, the arrow indicates the HM direction. C) 3D conformation prediction by PEPFOLD1.5 
of delta-lysin I (left) and delta-lysin II (right) , coloured by residue, showing the α-helical peptide structures. 
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Figure 3. Alignment of peptide sequences of delta-lysins from various staphylococcal species, including delta-lysin I 
and II from S. pasteuri #26. Alignment was performed using T-Coffee and visualized with BOXSHADE, with the fraction 
identity threshold for shading set at 1. 
S. pasteuri secretes two highly similar delta-lysins 
To confirm whether the two predicted hld encoded delta-lysins were responsible for the 
antimicrobial properties of S. pasteuri #26, we employed MALDI-ToF-MS to detect and 
characterize these peptides. In colonies of S. pasteuri #26 grown on BHI agar, in CFS, and in 
CE the main peaks identified by MALDI-ToF-MS were identical, and corresponded to a mass-
to-charge ratio (m/z) between 2300 and 2950 (Figure S2). The S. pasteuri hld gene sequences 
were predicted to encode delta-lysin I with a mass of 2760.34 Da and delta-lysin II with mass 
of 2841.37 Da. MALDI-ToF-MS on active CE shows the presence of 2759.52 Da and 2787.56 Da 
masses corresponding to delta-lysin I and 2840.50 Da and 2868.47 Da masses corresponding 
to delta-lysin II (Figure S2). The two masses obtained for each peptide differed by 28 Da, 
which corresponds to absence or presence of a formyl group (HCO-) on the N-terminal 
methionine, respectively. 
In order to establish the proposed antimicrobial activity and mass of the two delta-lysins, we 
purified the natural individual peptides from the 70% IPA 0.1% TFA CE using C4 and C18 HPLC 
columns. Due to the high similarity in physiochemical characteristics of the two peptides, 
analytical columns were required to obtain good separation (Figure 4A). After purification, 
the yield from the CE obtained from 1 L of S. pasteuri #26 culture was approximately 0.8 mg/L 
for delta-lysin I and 4.4 mg/L for delta-lysin II. MALDI-ToF-MS showed that the masses of 
the two dominant HPLC peaks purified from the CE matched the theoretical masses of the 
N-terminal formylated delta-lysins [54-56] and matched the peptides predicted from the hld 
gene sequences (Figure 4B,C and Figure S2). We compared the antimicrobial activity of these 
purified peptides with that of chemically synthesised peptides (see section below).
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Figure 4. A) Chromatogram of RP-HPLC purification of delta-lysins from 70% IPA 0.1% TFA S. pasteuri cell extract. 
The dashed line represents the elution gradient with acetonitrile 0.1% TFA. Fractions were collected every minute 
and assayed for antimicrobial activity on Str. suis S10 indicator plates, showing activity eluting in fractions 23-25 and 
27-32 (grey boxes). Delta-lysins were purified from two pooled fractions of interest (red and blue boxes). B) Overlaid 
reflectron mode MALDI-ToF-MS spectrum of purified delta-lysin I from fraction pool 1 (red) and delta-lysin II from 
fraction pool 2 (blue). Boxed enlargements show protonated masses of formylated delta-lysin I and delta-lysin II, 
respectively.
Trypsin cleavage of purified formylated peptides yielded masses of 1474.7 Da (pos. 1-14) and 
800.4 Da (pos. 15-21) for delta-lysin I and 1538.8 Da (pos 1-14) and 874.5 Da (pos 15-21) for 
delta-lysin II (data not shown), which are identical to theoretical masses predicted by in silico 
digestion. This confirms the trypsin cleavage site in the purified peptides as predicted from 
the hld gene encoded peptides. 
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S. pasteuri delta-lysins have specific antimicrobial activity against seven serotypes of 
Str. suis 
In the initial antimicrobial activity assays, we used the SPE column-purified CE; because the 
exact concentrations of the delta-lysins were unknown, the CE dilution factor that still showed 
antimicrobial activity was taken as a relative measure of inhibitory activity. Interestingly, 
among the 13 different bacterial species tested only Str. suis strains were susceptible (Figure 
5), including strains of serotype 2 and 9 that are most frequently associated with clinical 
infections. Only serotype 7, represented by a single strain originally isolated from a pig with 
streptococcal pneumonia, appeared insensitive to the S. pasteuri CE. S. mutants, S. mitis, S. 
salivarius, S. aureus, S. epidermidis, Lb. plantarum, Lb. rhamnosus, Lb. salivarius, Lb. reuteri, 
E. faecalis, S. enteriditis, L. monocytogenes were not susceptible to the lowest dilution of CE 
tested (data not shown).
To investigate whether any of the Str. suis genes considered to be involved in resistance to 
antimicrobial peptides [57] could influence sensitivity to the delta-lysins we tested several 
isogenic mutants generated in Str. suis S10. These included mutants of the two-component 
systems (TCS) Δ1930, Δ0827 [58], and ΔCiaHR,  as well as a mutant of dltA, which can provide 
some resistance against positively charged antimicrobial peptides via alanylation of teichoic 
acid. However, none of these mutants were more sensitive to the antimicrobial peptides 
present in the S. pasteuri CE. Also, the un-encapsulated mutant J28 did not show a difference 
in susceptibility compared to its parental strain S10 (Figure 5).
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Figure 5. Minimal Inhibitory Concentrations (MIC) of S. pasteuri cell extracts (CE) against several strains of Str. suis 
and a panel of other bacteria. The MIC is represented as a dilution factor of extract, with higher values indicating 
higher bacterial susceptibility. CE applied on a SPE column was eluted subsequently with 40% and 50% IPA and 
both collected fractions were tested for antimicrobial potency.
Synthetic delta-lysins confirm antimicrobial activity of purified peptides
To further confirm that the antimicrobial activity displayed by S. pasteuri was caused by the 
two predicted delta-lysins, we chemically synthesized these peptides. Both synthetic peptides 
had a minimal inhibitory concentration (MIC) of 2 µM, which is also the minimal bactericidal 
concentration (MBC) against Str. suis S10, whereas purified (N-formylated) delta-lysin I and 
delta-lysin II have a MIC of 2 and 4 μM, respectively. The difference in MIC of synthetic and 
purified delta-lysin II could be due to the presence of the N-terminal formyl group that confers 
an overall reduction in net-charge of 1. Combinations of equimolar concentrations of the two 
peptides showed no synergistic activity (data not shown); other ratios of peptide were not 
tested. Microbroth dilution assays with the synthetic peptides confirmed the spectrum of 
activity as determined using the CE (data not shown).
S. pasteuri delta-lysins display immediate bactericidal activity by disrupting the 
membrane 
A time-course experiment performed with Str. suis S10 and each of the synthetic delta-
lysins showed that their bactericidal activity was immediate, from the moment of exposure 
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(Figure 6A). Peptide concentrations of 4 µM (2 x MIC) resulted in complete loss (5 log fold 
reduction) of viable bacteria after 90 min for delta-lysin I and after 150 min for delta-lysin II. 
Additionally, both peptides inhibited growth of Str. suis at a concentration of 1 µM (½ x MIC). 
Bacteria treated for 30 min with a concentration of 8 µM (4 x MIC) delta-lysin show minor 
plasma membrane disturbance, but complete disruption of the membrane was not evident 
(Figure 6B,C,D). Remarkably, delta-lysin appeared to cause partial delocalization of plasma 
membrane, resulting in cytoplasmic accumulation of membrane-like structures (Figure 6E). 
Bacteria exposed to peptides appeared to have areas of increased granulation with higher 
density in the cytoplasmic space compared to untreated bacteria.
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Figure 6. A) Time-kill curve of synthetic delta-lysin 1 and 2 at concentrations of ½ x MIC (1 µM) and 2 x MIC (4 µM) 
against an inoculum of 5 x 105 CFU mL-1 Str. suis S10 in exponential growth phase. Aliquots were collected at regular 
time intervals and serial dilutions in PBS were plated on THB agar for CFU enumeration. All conditions were tested 
in duplicate, average values are depicted. Representative transmission electron microscopy images of Str. suis S10 
exposed to B) PBS (negative control) for 120 min, C) 8 µM delta-lysin I for 30 min, D,E) 8 µM delta-lysin II for 30 min. 
Boxes indicate areas of shown enlargements. Arrows highlight possible membrane-like structure delocalization. 
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Haemolytic and cytotoxic activity of S. pasteuri delta-lysins
Because delta-lysins from S. aureus are known to display haemolytic activity, we tested both S. 
pasteuri delta-lysin I and delta-lysin II for their potency to lyse human erythrocytes. Exposure 
for 1 hour of human erythrocytes in PBS reveals a clear dose-dependent haemolytic activity 
that is very similar for both delta-lysins, although purified (N-formylated) peptides show 
slightly lower maximum haemolysis (Figure 7A,C). The crude cell extract (40% IPA CE) against 
porcine erythrocytes showed a similar dose dependent haemolytic effect (data not shown).
As staphylococci inhabit the oral-, nasal- and gastrointestinal tract, we tested the effects of 
the delta-lysins on a porcine intestinal epithelial cell line, IPEC-J2. A dose-dependent effect on 
epithelial cell viability was observed after 20 h exposure to peptide and no significant impact 
on viability was observed at the concentration of 2 μM (Figure 7B), which was sufficient to 
rapidly kill Str. suis S10.
To be able to directly relate the spectrum of antimicrobial activity results to cytotoxicity, 
we also used SPE column-purified CE to assay cytotoxicity against human peripheral blood 
mononuclear cells (hPBMCs). 40% IPA and 50% IPA CE dilutions ranging from 1/10 to1/2560 
were incubated for 3 hours with freshly isolated hPBMCs. Cells were stained for viability with 
Annexin V, which binds to phosphatidylserine on early apoptotic cells, and propidium iodide 
(PI), which stains permeable, dead cells. This allows for the distinction of live (unstained), 
necrotic (PI only), early apoptotic (Annexin V only) and late apoptotic (both Annexin V and 
PI) cell populations by flow-cytometry. The 50% IPA CE dilutions of 1/10 and 1/40, which 
were inhibiting growth of 95% and 62% of tested Str. suis strains, respectively, have a clear 
cytotoxic effect on hPBMCs, and a 40% IPA CE dilution of 1/10, inhibiting 81% of tested Str. 
suis strains, resulted in an increase of necrotic cells. At lower concentrations of both CE 
fractions no significant cytotoxic effect can be observed.
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Figure 7. A) Haemolytic activity of both synthetic peptides against human erythrocytes from 3 different donors, 
after 1 h exposure. Delta-lysin I LC50 = 2.83 µM and delta-lysin II LC50 = 3.98 µM. Error bars represent SD between 
averaged, normalized haemolysis values per donor. B) Cytotoxic activity of both synthetic peptides against porcine 
IPEC-J2 cells, as measured by neutral red uptake after 20h exposure to a range of peptide concentrations. Error 
bars represent SD of averaged, normalized technical duplicates. C) Haemolytic activity of purified delta-lysins 
against human erythrocytes from 3 different donors, after 1 h exposure. Error bars represent SD between averaged, 
normalized haemolysis values per donor. D) hPBMCs obtained from 3 healthy donors were exposed for 3 h to 
dilutions of 40%IPA and 50%IPA CE, after which cells were stained with Annexin V and PI and analysed using FACS 
for the quantification of cell apoptosis and necrosis. PBS was used as a negative control, DMSO (1% v/v) was used 
as a positve control (ctrl). Each sample was performed in duplicate, error bars depict SD between averaged values 
per donor.
S. aureus delta-lysins possess a different spectrum of antimicrobial activity against Str. 
suis
Considering the high sequence similarity between delta-lysins from several Staphylococcus 
species, we hypothesized that it is unlikely that only S. pasteuri peptides exert an antimicrobial 
effect on Str. suis. Therefore, we tested the known delta-lysin producing S. aureus laboratory 
strain 8325-4 [59] and clinical isolate FPR3757 (USA300) [60], and delta-lysin lacking mutant 
RN6911 (8325–4 Δagr) [61]. An overlay assay and agar diffusion assay with CFS showed agr-
dependent antimicrobial activity of S. aureus against Str. suis S10, but no activity against 
other S. aureus strains (Figure S4). Testing of antimicrobial activity against 12 Str. suis strains 
using an overlay assay showed activity of both S. aureus 8325-4 and FPR3757 against Str. 
suis S10, but the agr mutant RN6911, lacking both RNAII and RNAIII, did not show a zone 
of growth inhibition against this strain (Figure 8). Strikingly, no other tested Str. suis strains 
were susceptible to S. aureus, whereas we observed large zones of inhibition around S. 
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pasteuri #26 (Figure 8). Because agr is known to regulate other toxins beside the RNAIII 
encoded delta-lysin in S. aureus, this result does not exclusively imply that lack of delta-lysin 
causes loss of antimicrobial activity. Therefore, we also tested synthetic S. aureus delta-lysin 
[MAQDIISTIGDLVKWIIDTVNKFTKK] in parallel with synthetic S. pasteuri delta-lysins against 
nine strains of Str. suis. Delta-lysins from S. aureus and S. pasteuri #26 had comparable activity 
against Str. suis strain S10 and 6555, whereas delta-lysin from S. aureus was not active against 
other Str. suis strains (MICs of 64 µM or higher) (Table 2). This susceptibility of Str. suis S10 to 
synthetic delta-lysin is in accordance with the results seen in the overlay assay, while the 
size of the growth inhibition zones does not necessarily correspond to the MIC. We conclude 
that despite the high sequence similarity between these Staphylococcal delta-lysins, their 
spectrum of antimicrobial activity is differential.
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Figure 8. Overlay assay with producer strains S. aureus 8325-4 [59], RN6911 (8325–4 Δagr) [61], FPR3757 (USA300 
JE2)[60] and S. pasteuri #26 spotted on the same BHI agar plate, overlaid with 12 different strains of Str. suis. 
 
 
S.  pasteuri   
hld I  
S.  pasteuri   
hld I I  
S.  aureus   
hld 
Str. suis 15964 (SS1/2) 16 64 64 
Str. suis 6555 / NCTC 428 (SS1) 2 16 8 
Str. suis S10 (SS2) 2 4 2 
Str. suis p1/7 (SS2) 32 >64 >64 
Str. suis 15965 (SS3) 4 >64 >64 
Str. suis 8039 (SS7) 32 >64 >64 
Str. suis 8067 (SS9) 16 16 >64 
Str. suis 5218/22083 (SS9) 16 16 64 
Str. suis 13730 (SS14) 16 n.d. >64 
 
 
Table 2. Minimal Inhibitory Concentration values of synthetic delta-lysin from S. pasteuri #26 and S. aureus against 
nine strains of Str. suis, as determined by microbroth dilution assay. Experiment was performed in duplicate, with 
technical duplicates per condition, averaged values are represented.
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Discussion
Given the lack of an effective vaccine against multiple serotypes of Streptococcus suis [20, 21], 
in combination with the presence of multi-drug resistant strains in pigs [22] and the potential 
of these bacteria to cause zoonotic disease [62], alternative strategies to control this porcine 
pathogen are needed. Bacteriophages, phage lysins [63, 64] and plant extracts [65] are 
among the alternatives that have been investigated to date. Another promising approach 
could be via administration of bacteria producing antimicrobial peptides (AMPs) to suppress 
or prevent the colonization by Str. suis [4]. Such a strategy may be very suitable in young pigs, 
which are most susceptible to Str. suis infections around the time of weaning. The feasibility 
of such an approach was shown for a mixture of five candidate probiotic strains from the 
porcine intestine which inhibited Salmonella enterica in vitro and ameliorated diarrhoea 
when administered as a mixture to  S. enterica infected pigs. In this case, the protective effect 
was hypothesized to be attributed to the production of a bacteriocin by one probiotic isolate 
[66-68]. Recently, the production of bacteriocins by selected avirulent strains of Str. suis that 
can inhibit virulent Str. suis of different sequence types was described as a similar strategy 
[69-71]. We performed a high-throughput screen for AMP-producing bacteria from the 
microbiota of the tonsil and small intestine of piglets and screened for microbes displaying 
antimicrobial activity against Str. suis. 
In healthy piglets we sampled the tonsil and small intestine, niches which can be colonized 
by Str. suis [11, 12, 14]. Microbiota analysis by 454 pyrosequencing of all individual samples 
confirmed the presence of Str. suis in 38 of 40 tonsil swabs, but in only 2 of 10 ileal content 
samples, with varying abundance (see CHAPTER 4). Bacteria were isolated from the samples 
using culture medium and conditions that supported the growth of Str. suis, in anticipation 
of increasing the likelihood of recovering competing, antagonistic bacteria. We screened 
bacterial isolates from tonsil and small intestine of piglets for growth inhibitory activity 
against different Str. suis strains, including a capsule-free cps deletion mutant of Str. suis S10. 
The majority of the initially selected 104 isolates exhibiting an inhibitory effect against Str. suis 
originated from the tonsil samples. This might be due to the apparent higher diversity of the 
microbiota in the tonsils samples compared to the ileum samples (see CHAPTER 4). We can 
not exclude that tonsil samples appeared more diverse because their sampling procedure 
included brushing which is likely to disrupt the tonsil biofilm and release associated bacteria, 
whereas the small intestinal luminal content collection did not involve scraping of mucosally 
adhered microbial populations. Many of the initially selected bacteria lost their Str. suis-
inhibiting activity during culturing under laboratory conditions, possibly due to regulation of 
AMP production in response to environmental conditions and/or quorum sensing regulatory 
mechanisms. Therefore, we carried out further tests with 7 promising candidate isolates that 
showed consistent in vitro antibacterial activity against Str. suis.  
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One isolate (#26) showed consistent growth inhibiting activity against 17 of the 21 tested 
strains of all major clinical serotypes of Str. suis [62] (Table S1). Additionally, this isolate had a 
narrow spectrum of activity, only inhibiting Str. suis and none of the other 13 species tested. 
The specificity may be an advantage when using the inhibitory factor or organism to inhibit 
Str. suis in vivo as it is expected not to have a major effect on the resident microbiota, which 
is considered to have an important role in colonization resistance against pathogens [4, 5]. 
Presence of activity in the cell-free supernatant (CFS) hinted at secretion of this factor, while 
local loss of antimicrobial activity in overlay assays upon protease treatment indicated that 
the inhibiting substance was of a proteinaceous nature.
We identified isolate #26 as Staphylococcus pasteuri, a commensal coagulase-negative 
bacterium in humans and animals and a common colonizer of the intestine and oral cavity 
[46, 72]. The mining of the genome of S. pasteuri strain #26 revealed the presence of two 
putative antimicrobial peptide or haemolysin (hld) encoding genes located within a region 
homologous to the S. aureus regulatory RNAIII. The S. aureus RNAIII has been shown to be 
regulated by the agr peptide-induced quorum sensing system [73], possibly explaining why 
antimicrobial activity was only detected in high-density cultures of S. pasteuri. The agr locus 
is conserved in many staphylococcal species and has also been found in other taxa [47, 74]. 
In S. pasteuri #26 the divergent agr transcripts RNAIII and RNAII and the genes they comprise 
are similar to those of other staphylococci, although the S. pasteuri RNAIII encodes two non-
identical copies of hld genes (Figure 2A), whereas most staphylococcal species encode a 
single hld gene within their RNAIII  [48]. Notably, the phylogenetically close relative S. warneri 
(99.52% 16S rRNA gene sequence identity to S. pasteuri #26) also produces two non-identical 
delta-lysins [56, 75]. 
Staphylococcal delta-lysins have been described to possess haemolytic or cytotoxic activity 
[50-52, 76, 77]. The haemolytic activity we observed for the two S. pasteuri delta-lysins was 
in the same range as that described for S. aureus and S. warneri delta-lysins [52, 56, 76]. 
Although the delta-lysins of S. pasteuri also exerted dose-dependent cytotoxic effects on 
porcine epithelial cells (Figure 7B) there was a prominent difference between the kinetics 
of the antimicrobial and the cytotoxic effects, with all Str. suis bacteria being rapidly killed 
within 90 to 150 minutes, and the cytotoxic effects taking several hours (Figure 7B). Moreover, 
concentrations of CE required to cause necrosis in PBMCs appeared also 2- to 4-fold higher 
than the concentrations required to kill all Str. suis cells.
Our results support the conclusion from other studies that staphylococcal delta-lysins have 
narrow-spectrum antimicrobial activity.  Previously, antimicrobial activity of staphylococcal 
delta-lysin was demonstrated against several strains of Legionella, Bacillus megatherium, S. 
aureus, and Streptococcus pyogenes [53, 56, 78]. Membrane disruption of S. aureus delta-lysin 
is, in part, a result of the high degree of peptide α-helicity [77], which is comparable to that of the 
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two S. pasteuri peptides. Delta-lysins were originally considered to lack antimicrobial activity 
[76] and be directed towards the host, most likely due to their narrow-spectrum antimicrobial 
activity and the limited panels of target bacteria that were tested. Sequence alignment of 
delta-lysins from several staphylococcal species shows a high level of conservation (Figure 
3), and taking into account the similarity in structural and physicochemical properties, one 
can speculate that all these delta-lysins could possess antimicrobial activity against certain 
target bacteria. This is in agreement with our observation that two strains of S. aureus and 
chemically synthesised S. aureus delta-lysin peptide can effectively inhibit growth of Str. suis 
S10 but not of other tested Str. suis strains. 
Delta-lysin is a member of the group of staphylococcal phenol-soluble modulin (PSM) 
peptides, and is sometimes referred to as delta-toxin or PSMγ  [55, 79]. PSMs are involved in 
virulence and inflammation, but also have a role in the commensal lifestyle of staphylococci 
by facilitating growth and bacterial spreading on epithelial surfaces [80, 81]. Activation of 
agr is important in biofilm growth and regulation of genes associated with the switch from 
planktonic to biofilm lifestyle. Indeed, PSMs have important roles in biofilm formation and 
structuring [82]. Staphylococcal delta-lysins can kill Streptococcus pyogenes via synergistic 
interactions with host-derived antimicrobial peptides [83], and similarly, staphylococcal 
PSMα can give the producer strain a competitive advantage against other (pathogenic) 
bacteria, such as Streptococcus pyogenes [84]. Both N-formylated as well as deformylated 
PSMs are recognized by the human formyl peptide receptor 2 (FPR2/ALX), leading to host 
immune activation [85, 86]. Thus PSMs appear to have multiple roles in (in)direct bacterial 
competition and in host colonization [81]. 
To investigate whether S. pasteuri also can produce other PSMs, we searched for peptide 
sequence homology and AgrA binding motifs using MEME (http://meme-suite.org/). This 
revealed the presence of genes encoding PSMβ1 and PSMβ2 orthologues in the whole 
genome sequence of S. pasteuri #26, but we did not find homologs of other PSMs. Exactly 
corresponding masses to these PSMβs, as predicted from the gene sequence, were not 
detected by MALDI-ToF-MS in BHI agar grown colonies or in CE (Figure S2), nor in Tricine-SDS-
PAGE analysis of active CFS and CE (Figure S1). As the majority of masses detected exactly 
match delta-lysins I and delta-lysin II, we propose that they are responsible for the observed 
antimicrobial and cytotoxic effects of the CFS and CE.
The level of PSM production and FPR2/ALX activation by a given staphylococcal strain 
correlates closely with its virulence potential [86, 87]. Of all PSMs, PSMα peptides have the 
strongest leukolytic, pro-inflammatory, chemotactic, and surfactant activities. The apparent 
absence of genes encoding PSMα and some well-known S. aureus cytotoxic molecules 
associated with virulence, such as alpha-toxin, might at least partially explain why S. pasteuri 
is not reported as a cause of infection or disease in pigs. 
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Theoretically, delta-lysins might be toxic to the producer strain but the genes pmtABCD, 
encoding the dedicated ATP transporter required for peptide export and immunity, are found 
in all PSM-producing staphylococci [88]. Homology searches revealed that S. pasteuri also 
contains pmtABCD homologs, likely explaining why S. pasteuri delta-lysins have no effect on 
S. aureus or vice versa (Figure S4). 
Our results demonstrate that bacterial isolates producing (narrow-spectrum) antimicrobial 
compounds against Str. suis can be found by screening isolates of the microbiota that 
inhabit the same niche. We hypothesized that, for instance in the case of weaning-associated 
complications with Str. suis in piglets, such bacteria could be used to, temporarily, shift the 
microbiota towards a more antagonistic composition, thereby repressing the colonization 
and outgrowth of Str. suis in the oropharynx and small intestine. S. aureus, which produces 
other toxins capable of damaging the host, is commonly found as a harmless commensal of 
the nasal cavity suggesting that the S. pasteuri strain described here is a promising candidate 
for follow-up experiments in vivo. However, the safety of using these AMP-producing bacteria 
to antagonise Str. suis colonization in vivo still needs to be established. Additionally, this study 
shows that the biological activity of these peptides is not exclusively restricted to competing 
microbes but extends to interactions with the host epithelium and immune cells, making 
their ecological function difficult to predict. 
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B3 0.4 0.8
B4 
B5 
B6 
B7 
B8 0.4 0.2 0.2
B9 0.4 0.2
B10 
B11 
C1 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8
C2 0.8
C3 0.4
C4 
C5 
C6 
C7 
C8 
C9 0.2 0.8
C10 0.4
C11 
C12  
D1 0.8 0.4 0.8 0.8
D2 0.8
D3 0.8
D4 
D5 0.2 0.4
D6 0.4 0.8 0.2 0.8
D7 
D8 0.4
D9 
D10 
E1 0.8 0.4 0.8 0.2 0.8
E2 0.4 0.4 0.2 0.8
E3 0.4 0.8
E4 0.4 0.2 0.4
E5 0.4 0.4 0.2 0.8
E6 0.4 0.4 0.2 0.8
E7 0.4 0.4 0.2 0.4
E8 0.8
E9 0.6 0.4 0.2 0.8
E10 0.4 0.2 0.4
E11 0.4 0.4 0.4 0.2 0.8
E12 0.8 0.6 0.4 0.2 0.8
F1 0.8 0.4 0.8 0.2 0.8
F2 0.8 0.4 0.8 0.2 0.8
F3 
F4 0.4 0.4 0.2 0.8
F5 0.4 0.2 0.8
F6 0.4 0.2 0.8
F7 0.4 0.4 0.2 0.8
F8 0.4 0.8
F9 0.4 0.4 0.2 0.8
F10 0.4 0.4 0.2 0.8
F11 0.4 0.4 0.2 0.8
F12 
G1 0.8 0.4 0.4
G2 0.8 0.4 0.8 0.2 0.8
G3 0.8 0.4 0.4 0.2 0.8
G4 0.4
G5 0.4 0.4 0.2 0.8
G6 0.2 0.8
G7 0.4 0.2 0.8
G8 0.8 0.4 0.4 0.2 0.8
G9 
G10 0.4 1.0 0.8 0.4 0.6 0.4 0.2 0.2 0.4 0.8
G11 0.8 0.4 0.4 0.2 0.8
G12 0.8 0.6 0.4 0.2 0.8
H1 0.8 0.8 0.8 0.2 0.8
H2 0.8 0.4 0.8 0.2 0.8
H3 0.8 0.4 0.8 0.2 0.8
H4 0.8 0.4 0.8 0.2 0.8
H5 0.8 0.4 0.8 0.2 0.8
Table S1.  Growth inhibition of Str. suis strains (see Table 1, strains used in screening boxed in blue) by the initially 
selected 86 tonsil microbiota isolates, scored according to relative size of the inhibition zone on a relative scale 
from 0 (no inhibition) to 1 (maximum inhibition as seen in this overlay assay). Many isolates lost their original 
antimicrobial activity after culturing under laboraty conditions. Data were obtained from duplicate experiments. 
The isolate in well G10, identified as S. pasteuri (#26), showed growth inhibition against multiple serotypes of Str. 
suis (see also Figure 1) 
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Figure S1. Tricine-SDS-PAGE [89] of S. pasteuri #26 A) CFS or total CE, indicating the abundance  of mainly small 
peptide(s). B) S. pasteuri #26  CE was applied to SPE columns and elution fractions (stepwise increased IPA 
concentration from 10% to 70%) and total CE (T) were analysed using Tricine-SDS-PAGE. Antimicrobial activity 
against Str. suis was detected in 40% and 50% IPA fractions (Figure 1C). Human LL-37 was included as a reference  for 
molecular weight of small peptides. 
A 
B 
L1 L2 CFS CFS 
1:10 
CE CE 
1:10 
L2 50 60 70 T 10 20 30 40 LL37 
15 kDa 
10 kDa 
14.4 kDa 
4.49 kDa 
10 kDa 
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Figure S2. MALDI-ToF-MS spectra obtained from A) multiple colonies of S. pasteuri #26 grown for 24 h on BHI agar 
and B) 70% IPA 0.1% TFA bacterial cell extract (CE) of a S. pasteuri BHI culture. The following masses are of interest: 
1a (2787.56) delta-lysin I with formylated N-terminal methionine, 1b (2759.52) delta-lysin I with deformylated 
N-terminal methionine, 1c (2356.27) delta-lysin I fragment (residue 1-22), 2a (2868.47) delta-lysin II with formylated 
N-terminal methionine, 2b (2840.50) delta-lysin II with deformylated N-terminal methionine. In addition to these 
masses for singly protonated molecules, corresponding peaks for [M+Na+] (+22) and [M+K+] (+39) adducts can be 
seen. Predicted peptides were identified according to the experimental masses using FindPept (http://web.expasy.
org/findpept/)
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Figure S3. Chromatograms of RP-HPLC fractionation of 40% and 50% IPA SPE column fractions of S. pasteuri #26 
CE. Each collected fraction was tested for antimicrobial activity against Str. suis S10, active fractions are indicated 
by red boxes.
A
B
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Figure S4. A) Overlay assay with producer strains S. aureus 8325-4 [59], RN6911 (8325–4 Δagr) [61], FPR3757 
(USA300 JE2)[60] and Str. suis S10 against each other. A volume of 10 µL overnight culture was spotted onto BHI 
agar plates and incubated overnight at 37 °C with 5% CO2, after which plates were exposed to UV light for 30 min and 
overlaid with soft nutrient agar (0.75% w/v) at 45°C inoculated with approximately 106 CFU/mL target strain. Growth 
inhibition zones were imaged after 20 h incubation at 37 °C with 5% CO2. Experiment was performed in duplicate and 
representative results are shown. B) Agar diffusion assay with CFS from overnight cultures in BHI broth of producer 
strains S. aureus 8325-4 [59], RN6911 (8325–4 Δagr) [61], FPR3757 (USA300 JE2)[60] and S. pasteuri #26. Soft THB 
agar  (0.75% w/v) at 45°C was inoculated with with approximately 106 CFU/mL from an overnight culture of the target 
strain. After solidification of the agar, wells (4.6 mm diameter) were punched and 50 μL CFS was dispensed per well. 
Growth inhibition zones were imaged after 22 h incubation at 37 °C with 5% CO2.
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Abstract
Many members of the mammalian microbiota may produce non-ribosomally synthesized 
secondary metabolites that have the potential to modulate microbe-microbe and microbe-
host interactions. Such small molecules may be responsible for direct microbial antagonism 
and as such could play a role in colonisation resistance by commensal species against 
pathogenic microbes. Previously, we screened the microbiota from healthy piglets for 
isolates that displayed direct antagonism against Streptococcus suis, an important swine 
pathogen that causes economic losses worldwide. Here a common Rothia nasimurium 
isolate from the porcine tonsil that was able to inhibit the growth of S. suis and other 
bacteria is described. Genome mining revealed the presence of a putative non-ribosomal 
peptide synthetase (NRPS) gene cluster that showed identical organization of modules 
and domains to the Streptomyces vlm cluster involved in the biosynthesis of valinomycin, 
a cyclododecadepsipeptide ionophore antibiotic. In silico analysis hinted at recent 
acquisition of this biosynthetic gene cluster. The antimicrobial compound was purified 
from R. nasimurium cultures and identified using MALDI-ToF MS, LC-MS/MS, and NMR as 
valinomycin. Antimicrobial, cytotoxic and immunomodulatory effects of valinomycin were 
investigated. This study shows that commensal bacteria from mammalian microbiota may 
produce NRPS-derived molecules that impact other microbes as well as the host, and could 
help further elucidate the exact biological role of valinomycin production by R. nasimurium.
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Introduction
Mammalian mucosal surfaces in the gastrointestinal tract and in the oropharynx are home 
to a rich and diverse community of microorganisms known as the microbiota. Microbe-
host and microbe-microbe interactions within the microbiota can increase susceptibility 
for infection, for example by influencing host immunity and physiology or by creating a 
synergistic habitat for pathogens [1, 2]. Conversely, microbial communities may also provide 
direct colonisation resistance against pathogenic species through a variety of mechanisms 
including the production of small molecules, such as antimicrobial peptides or secondary 
metabolites, thereby conferring a benefit to the host [1, 3, 4]. Non-ribosomal peptides (NRPs) 
are common products of biosynthetic gene clusters (BGCs) among microbes found in soil 
and aquatic environments and were the foundation for most of the currently licensed classes 
of antibiotics [5]. Recently, a remarkable number of BGCs was discovered in the genomes 
and metagenome sequences of human-associated bacteria and the small molecules they 
produce were proposed to have an important role as mediators of complex interactions within 
and between the enteric microbiota and the host [6, 7]. However, relatively few NRPs from 
human-associated bacteria have been characterized in detail. Further efforts to characterise 
the products of such BGCs is likely to provide valuable insights into the interactions that shape 
microbial communities, as well as contribute to a better understanding of the establishment 
of polymicrobial infections and the pathogenesis of diseases [6, 7].
We were interested to characterise commensal bacteria of the microbiota from healthy 
piglets as we reasoned that these could potentially suppress excessive blooms of the 
porcine opportunistic pathogen Streptococcus suis, a common coloniser of the porcine 
oral cavity and small intestine [8, 9]. Here we describe the isolation of a Rothia nasimurium 
strain from porcine tonsil microbiota which is capable of inhibiting the growth of S. suis as 
well as other species of bacteria. The inhibitory activity was protease-, pH- and heat-stable, 
suggesting that the active compound might be the product of a small molecule BGC. A cyclic 
dodecadepsipeptide responsible for the antimicrobial activity was purified and shown to be 
structurally equivalent to the ionophore valinomycin. The non-ribosomal peptide synthetase 
(NRPS) gene cluster encoding the biosynthesis of this antibiotic was identified in the genome 
of the R. nasimurium isolate; in silico analysis revealed signs of recent acquisition of the BGC by 
horizontal gene transfer, while it surprisingly showed only distant evolutionarily relation with 
well-characterized valinomycin BGC from Streptomyces. We tested the effects of valinomycin 
on barrier permeability in a model of the porcine epithelium. To gauge the potential effects 
of valinomycin on inflamed mucosa, we tested the capacity of valinomycin to induce 
apoptosis in mononuclear cells and promote IL-1β secretion in primed macrophages by 
triggering the inflammasome. Decreased barrier permeability, mononuclear cell apoptosis 
and macrophage inflammasome activation all occurred at valinomycin concentrations that 
were tolerated by the producing R. nasimurium strain, while inhibiting other bacteria.
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Material and Methods
Bacterial strains and culture conditions
Bacterial strains used in this study are listed in Table 1. Bacterial isolates from porcine 
microbiota were grown under aerobic conditions at 37°C on Todd-Hewitt Broth (THB) (Oxoid, 
Basingstoke, UK) agar plates or in THB supplemented with K2HPO4 (36 mM), KH2PO4 (13.2 
mM), sodium citrate (1.7 mM), MgSO4 (0.4 mM), (NH4)2SO4 (6.8 mM) and 4.4% glycerol (THB 
freezing medium). Rothia nasimurium was cultured aerobically at 37°C in Brain-Heart Infusion 
(Oxoid, Basingstoke, UK). Isolates of Streptococcus suis of different serotypes and an un-
encapsulated mutant J28 were obtained from the Central Veterinary Institute (Lelystad, The 
Netherlands). All Streptococcus strains were cultured in THB aerobically without agitation 
at 37°C with 5% CO2. The following culture media were used for other tested organisms; 
MRS (VWR International, Leuven, Belgium) for Lactobacillus reuteri, BHI for Staphylococcus 
aureus, Staphylococcus pasteuri and Listeria monocytogenes, and Luria-Bertani (LB) (Merck, 
Darmstadt, Germany) for Salmonella enteriditis and Escherichia coli.
 
Species Strain Serotype Virulence Screening 
Streptococcus suis  15964 1/2 ND 
 
 6388 1 HV 
 
 6555 / NCTC 428 1 V 
 
 T15 2 AV  
 S735 / NCTC 10234 2 WV 
 
 p 1/7 2 V 
 
 3881 / S10 2 V 
 
 J28 (S10 ΔcpsEF) 2 AV x 
 15965 3 ND 
 
 5213 4 ND 
 
 8039 7 ND x 
 7997 9 AV 
 
 8067 9 V x 
 8017 9 AV  
 7709 9 ND 
 
 C132 9 ND 
 
 5973 9 AV 
 
 22083 R 9 ND 
 
 7998 9 ND 
 
 8186 9 ND 
 
 13730 14 ND 
 
Streptococcus mutans DSM 20523    
Streptococcus mitis Is. MS VID    
Streptococcus salivarius Is. Ms Oral D6    
Lactobacillus reuteri ATCC 55730    
Staphylococcus aureus 8325-4 WT    
Staphylococcus pasteuri T#26    
Enterococcus faecalis DMS 20478    
Salmonella enteriditis  NIZO1241    
Listeria monocytogenes EGD-e    
Escherichia coli Nissle 1917    
Escherichia coli Pro 083    
 
	
Table 1. Bacteria used in this study. Streptococcus suis strains J28, 8039 and 8067 were used for the 
initial antimicrobial screening assay of the libraries of porcine commensal isolates. AV = avirulent, 
V = virulent, HV = highly virulent, ND = not determined. 
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Overlay inhibition assay
BHI medium was inoculated from a -80°C glycerol stock of Rothia nasimurium  isolate #4 or 
#32 and incubated overnight at 37°C without agitation. Ten microliters of this culture were 
spotted onto BHI agar plates and these were incubated overnight at 37°C to allow growth of 
bacterial colonies. Plates were then exposed to UV light for 30 min to kill the bacterial cells. 
Proteinase K (Qiagen; 1 ul, >600 mAU/ml) was spotted next to each colony, and incubated at 
37°C for 30 min. Then each plate was overlaid with 20 ml of soft THB agar (0.75% w/v agar) 
at 48°C, inoculated with approximately 1 x 106 CFU/mL of the indicator S. suis strain from an 
overnight culture in THB. Plates were then allowed to solidify and dry, and inhibition zones 
measured after overnight incubation at 37°C.
Well diffusion assay
Appropriate nutrient agar (0.75% w/v agar) was cooled to 50°C and seeded with a selected 
target bacterium (approximately 1 x 106 CFU mL-1). A volume of 25 mL was rapidly transferred 
to sterile Petri dishes and allowed to solidify and dry, after which wells (4.6 mm diameter) 
were made using a sterile glass Pasteur pipette. A volume of 50 µL or 100 µL of the 70% IPA, 
0.1% TFA bacterial extract after evaporation of the IPA (obtained as described below) was 
dispensed into the wells and the plates were incubated at 37°C overnight. Antimicrobial 
activity was determined by the presence and size of clearly visible zones of growth inhibition 
around the wells.
Genome-mining for secondary metabolite synthesis genes
Genomic DNA was extracted from two strains that inhibited growth of S. suis, first designated 
as isolates #4 or #32, and sequenced as described elsewhere (Genome Announcement 
manuscript in preparation) (WGS project deposited at DDBJ/ENA/GenBank under the 
accession LXWF00000000). The web-tool antiSMASH 3.0 [10, 11] was used for identification 
and annotation of secondary metabolite biosynthesis gene clusters, and MultiGeneBlast 
[12] was used for comparative analysis with known valinomycin and cereulide BGCs. The 
valinomycin BGC was submitted to the Minimum Information about a Biosynthetic Gene 
cluster (MIBiG) repository (http://mibig.secondarymetabolites.org/) [13], under accession 
BGC0001341.
Bacterial identification
The complete 16S rRNA gene sequences were predicted from the draft genome sequences 
using RNAmmer 1.2 [14]. The 16S rRNA gene sequences  of the nearest phylogenetic 
neighbours were found using the EzTaxon server (http://www.ezbiocloud.net/eztaxon) [15]. 
With Phylogeny.fr (http://www.phylogeny.fr/)[16, 17],  the 16S rRNA gene sequences were 
aligned (T-coffee), the alignments were trimmed and curated (Gblocks), and a phylogenetic 
tree was constructed using the Maximum Likelihood method and 500 times bootstrapping 
in PhyML v3.0. 
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PCR detection of vlm cluster
Total DNA was isolated and purified from forty 1 mL aliquots of tonsil-brushed material that was 
used for the isolation of porcine microbiota (Chapter 4) following the Repeated Bead Beating 
method as described in [18] using a FastPrep-24 instrument (MP-Biomedicals, France) and the 
QIAmp DNA Mini Kit (Qiagen GmbH, Hilden, Germany). Based on the draft genome sequence 
of Rothia nasimurium, PCR primers were designed for the detection of the vlm gene cluster. 
Primers fl_F (5’-CTTTCCCGTATGGCTGAGAG-3’) and fl_R (5’- CGCGTACCACGTCCATTAAG-3’) 
generated an amplicon that spanned the genetic linkage between the proposed insertion 
site of the vlm cluster and the genome, primers int_F (5’-CTACGTCCCAGTCGGATTATTC-3’) 
and int_R (5’- AGCACAGAGGATAGCCATCTAC-3’) generated an amplicon within the vlm1 gene. 
PCR reactions were performed using a thermocycler in a total reaction volume of 50 µL 
containing 1x GoTaq Flexi buffer, 0.2 mM of each dNTP, 1.5 mM MgCl2, 1.25 u GoTaq G2 Hot 
Start DNA polymerase (Promega, Madison (WI), USA), 1 µM of forward and reverse primer, and 
1 μL of undiluted template DNA (0.5 – 1.3 ng/50 μL). The amplification program comprised 
an initial denaturation step at 95°C for 2 min, and 30 cycles of: denaturation at 95°C for 1 
min, annealing at 59.5°C for 30 s, elongation at 72°C for 30 s. The size of the amplicons was 
confirmed by gel electrophoresis. 
Epithelial Barrier Function
NPTr cells, originating from newborn pig trachea [19] were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) plus GlutaMAX™ (Gibco, Life Technologies), supplemented with 
10% fetal calf serum (FCS) (PAA) and 100 U mL-1 penicillin/ 100 µg mL-1 streptomycin (Sigma, 
Zwijndrecht, The Netherlands) in a humidified atmosphere with 5% CO2 at 37°C. A volume 
of 500 µL (2 x 104 cells) was seeded in each 24-well filter (0.4 mm) inserts (Becton Dickinson 
Labware, Franklin Lakes, NJ, USA) and cultured for 1 week with medium replacement every 
3 days. At t = 0 the media was replaced with DMEM without serum or antibiotics (800 µL 
basolateral, 200 µL apical), and then stimulus (20 µL valinomycin in MeOH + 180 µL DMEM) 
was added apically, reaching a final MeOH concentration of 5% in all wells. Trans-epithelial 
resistance (TER in Ω x cm2; indicates barrier to passive ion flux) was continuously measured 
over time using the cellZscope® (Nanoanalytics, Münster, Germany) across the filter-grown 
monolayers of NPTr cells. TER values were normalized per well to 100% at t = 0. Each condition 
was measured in triplicate and data represented as mean ± SEM.
Cytotoxicity assay
To assess cytotoxicity of valinomycin against human peripheral blood mononuclear 
cells (hPBMCs), hPBMCs were isolated and prepared as previously described [20], with 
modifications. Buffy coats from peripheral blood of 3 healthy donors were obtained from 
the Sanquin Blood Bank, Nijmegen, The Netherlands. Isolated hPBMCs were washed and 
resuspended at 1*105 cells per well in 96-well tissue culture plates  in Iscove’s Modified 
Dulbecco’s Medium (IMDM) (Gibco, Life Technologies) with 5% FCS and penicillin/
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streptomycin and exposed to valinomycin concentrations ranging from 0.1 to 1000 nM. 
Following treatment for 18 h in a humidified atmosphere with 5% CO2 at 37°C, cells were 
harvested and then stained using the commercially available Annexin V: Propidium Iodide (PI) 
Apoptosis Detection Kit APC (eBiosciences, Vienna, Austria) according to the manufacturer’s 
instructions. Using flow cytometry (FACS CantoII, BD Biosciences) the proportions of viable, 
dead and early- and late-apoptotic cells were determined (BD FACSDiva software). Values 
from each donor, with each condition measured in duplicate, were normalized to total cells 
in the monocyte gate, averaged for all donors and are represented as mean ± SD.
IL-1β quantification
Wild type C57BL/6 mice were obtained from Charles River, UK.  Nlrp3-/- mice on a C57BL/6 
background were produced by Millennium Pharmaceuticals. Primary bone-marrow derived 
macrophages (BMDM) were prepared and cultured for 6-9 days as previously described 
[21]. BMDMs were plated in 96-wells plates (200.000 cells per well), primed with 200 ng mL-1 
ultrapure LPS from Escherichia coli O111:B4 (InvivoGen) for 3 hours at 37 oC and stimulated 
with Valinomycin for 4 or 18 hours.
Secreted IL-1β was measured by ELISA in the culture supernatants according to the 
manufacturer’s instructions (OptEIA Mouse IL-1β Set, BD Biosciences).
Immunofluorescence microscopy
WT and Nlrp3-/- LPS-primed primary macrophages were stimulated with valinomycin 10 
μM or nigericin 5 μM (Sigma) for 18 hours, then fixed in -20°C methanol for 5 minutes, after 
washing with PBS, non-specific labeling was blocked by incubation at 37°C for one hour in 
5% BSA (Sigma) containing 0.1% saponin (Sigma).  ASC was labeled with anti-ASC primary 
(1:500, AL177; Enzo) and Alexa-fluor 568 secondary antibody (1:1000, anti-rabbit Alexa-fluor 
568 (Invitrogen). Cells were counterstained using DAPI mounting medium (Vecta Labs) and 
ASC-speck quantification was performed by counting the ASC specks from around 1000 cells 
per treatment, from randomly selected fields.
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Results 
Rothia nasimurium isolated from porcine tonsils inhibits growth of multiple strains of S. 
suis 
Previously, we described a high-throughput screening assay to detect antagonist bacteria 
against Streptococcus suis from the porcine microbiota (see Chapter 5). Two bacterial isolates 
(#4 and #32) originating from porcine tonsil biofilm strongly inhibited growth of S. suis strains 
that represented the serotypes 1/2, 1, 2, 3, 4, 7, 9 and 14 (Figure 1 A). Phylogenetic analysis 
of the full-length 16S rRNA gene sequence, which was identical for isolates #4 and #32, 
identified them as members of the genus Rothia with the closest related species at 97.9% 
sequence identity being Rothia nasimurium [22] (Table S1 and Figure S1). From here on, we 
refer to isolates #4 and #32 as Rothia nasimurium.
Isopropanol (70% v/v), TFA (0.1% v/v)-extracted and solubilised components from bacterial 
pellets of isolates #4 and #32 showed dose-dependent antimicrobial activity against S. 
suis S10 (Figure 1 B). Agar well diffusion assays with these extracts showed variability in 
the susceptibility of tested S. suis strains, with absence of the polysaccharide capsule 
(mutant J28) leading to a more sensitive phenotype (Figure 1 C). Of the other bacteria 
tested Streptococcus mutans, Streptococcus salivarius, Lactobacillus reuteri, Staphylococcus 
aureus, Staphylococcus epidermidis, Enterococcus faecalis, Salmonella enteriditis, Listeria 
monocytogenes and Escherichia coli were not susceptible in agar well diffusion assays, 
whereas growth of Streptococcus mitis was inhibited up to a dilution of 1/32 (data not shown). 
Treatment of the extract with proteases confirmed that the antimicrobial activity was resistant 
to proteinase K and trypsin. Furthermore, heating at 100°C for 20 min did not diminish the 
antimicrobial activity of the extract (data not shown). MALDI-ToF mass spectrometry on the 
bacterial colonies indicated that the majority of molecules present have a mass to charge 
ratio (m/z) smaller than 2500 Da (data not shown).  
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Figure 1. A) Overlay assay showing consistent inhibitory activity around the colonies of Rothia nasimurium isolate 
#4 and #32 against multiple serotypes and strains of S. suis. Spotted proteinase K above (#4) or below (#32) the 
colonies did not abolish growth inhibition of S. suis around the colonies of R. nasimurium. Growth inhibiting effect 
of Rothia nasimurium cell extracts prepared in 70% IPA 0.1% TFA, determined using B) a micro-well dilution assay 
against S. suis S10. OD600 nm was measured after 18 incubation at 37°C, 5% CO2, showing a concentration dependent 
reduction of bacterial growth, represented as mean values of four replicates with SD, and C) an agar well diffusion 
assay against nine S. suis strains including the capsule-deficient mutant J28. The Minimal Inhibitory Concentration 
(MIC) is represented as 1 divided by the highest extract dilution factor that still showed a zone of growth inhibition, 
and ranges from 1/16 to 1/512.
R. nasimurium isolates possess non-ribosomal peptide synthetase gene clusters with 
similarity to vlm and ces
To gain insight in the molecular and genetic basis underlying the ability of the two R. 
nasimurium strains to inhibit growth of S. suis, genomic DNA was purified and sequenced 
(Genome Announcement manuscript in preparation). The web tool antiSMASH 3.0 [10, 11] was 
used for identification and annotation of secondary metabolite biosynthesis gene clusters in 
the draft genome sequence of the two Rothia nasimurium strains. In both strains, two putative 
non-ribosomal peptide synthetase (NRPS) gene clusters were detected, of which one was 
predicted to be involved in the production of a siderophore. Bioinformatic analysis of the 
second NRPS cluster revealed that its two encoded NRPS proteins comprise four modules 
in total, with the domains A1-KR1-T1-C2-A2-T2-E2-C3 and A3-KR3-T3-C4-A4-T4-TE (Figure 2). The 
organization of the modules and domains of these two NRPS genes is identical to those found 
in the vlm cluster involved in the biosynthesis of valinomycin, a cyclododecadepsipeptide 
ionophore antibiotic produced by several soil-dwelling Streptomyces species [23-27] and 
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the cereulide biosynthetic genes (ces) found in Bacillus amyloliquefaciens, B. subtilis and B. 
pumilus isolates [28].
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Figure 2. A) Graphical representation of the NRPS cluster identified by in silico analysis of the draft genome sequence 
of Rothia nasimurium, including the approximate size of the detected cluster and the predicted NRPS structural 
genes. The cluster (in blue) consists of orfA encoding a discrete type II thioesterase (TEII), two structural synthetase 
encoding genes orf1 and orf2, ABC transporter encoding genes orfB and orfC and a 4’-phosphopantetheinyl 
transferase (PPTase) encoding gene orfD. Underneath is depicted the organization of the four modules, their 
corresponding enzymatic domains and the predicted incorporated monomers attached to the thiolation domains. 
The wavy line represents the phosphopantetheine arm of the primed T domain. Predictions were made using 
AntiSmash [10, 11]. Binding sites of primer pairs used for detection of the cluster are indicated (flF and flR spanning 
the junction between chromosomal DNA and NRPS cluster, intF and intR amplifying within the NRPS cluster). Genes 
orfA12BCD were later renamed to vlmA12BCD (see main text) B) GC profile (top) and GC content (bottom) of the 
Rothia nasimurium genomic scaffold containing the NRPS cluster, as generated by the tool on http://tubic.tju.edu.
cn/GC-Profile [29]. The segmentation points in GC profile and shift in GC content are 142 bp upstream of gene orfA 
(TTE) and 592 bp downstream of gene orfD. C) Orientation of disA and radA in other Rothia species.
The substrate specificity of the adenylation (A) domains was predicted in silico from the 
amino acid sequence encoded by orf1 and orf2 [30, 31]. This prediction was supplemented 
by a phylogenetic comparison of the A domains from R. nasimurium, known valinomycin 
producers Streptomyces tsusimaensis and Streptomyces fulvissimus, as well as the cereulide 
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producing bacterium Bacillus cereus [26, 32, 33]. The R. nasimurium A domains were most 
similar to the Streptomyces A domains from the vlm NRPS (see Figures S2 and S3) and, based 
on the conserved features of the biosynthesis of valinomycin and cereulide [26, 32, 33], are 
predicted to recognize and activate the substrates α-ketoisovalerate (Kiv), l-valine (l-Val), 
pyruvate, and l-Val. 
Modules 1 and 3 encoded by the biosynthetic cluster contain A domains that preferentially 
activate and load α-keto acids onto the T domain [26]. Using NADPH as a redox cofactor, 
the ketoreductase (KR) domains in these modules then catalyse the stereospecific reduction 
of the T-domain-tethered α-keto acyl group to an α-hydroxyacyl group. The KR domain in 
module 1 would therefore reduce α-Kiv to d-α-hydroxyisovalerate (d-Hiv), and the KR domain 
in module 3 would reduce pyruvate to l-lactate (l-Lac), as proposed by Li et al. [34].
The condensation (C) domains catalyse the condensation reaction between the peptidyl 
chain tethered to the phosphopantetheinyl arm of the upstream T domain to the amino 
acid bound to the downstream T domain, thereby elongating the peptidyl chain [35].  The 
C domains in module 2 and 4 (Figure 2, C2 and C4) were classified by the bioinformatic tool 
NaPDoS [36] as the LCL subtype,  with l-specificity for the peptidyl donor and l-specific for 
the aminoacyl acceptor, catalyzing the peptide bond formation between two l-amino acids. 
The C domain in module 3 is of the DCL subtype, showing d-specificity for the peptidyl donor 
and l-specificity for the aminoacyl acceptor [37]. Domain C3 lies immediately downstream 
of the E2 domain, and thus catalyses chain elongation onto d-Val which results from the 
epimerization of l-Val by E2 in module 2 [38]. 
Assuming that this synthetase follows the general linearity principles of known vlm NRPS 
clusters, it would form three tetradepsipeptides with the subunits d-Hiv, d-Val, l-Lac, l-Val, 
as monomers or as dipeptides, which then undergo cyclization by macrolactonization by the 
terminal thioesterase (TE) domain [25, 26, 32, 39].
Gene orfA lies upstream of orf1 and orf2 and encodes a discrete type II thioesterase (TEII) that 
displays 49% identity to S. tsusimaensis TE protein sequence [25], and may have a similar 
function in optimizing NRP assembly by hydrolysing misprimed substrates from T domains 
[40, 41]. We predicted that orfD encodes a PPTase that is involved in catalysing the transfer of 
the 4’-phosphopantetheine group of coenzyme-A to the T domain by ester bond formation, 
thus priming the T domains for subsequent tethering of activated amino acids during peptide 
assembly [42, 43].
The proteins encoded by downstream genes orfB and orfC are predicted to function as an 
ATP-binding protein and ABC transporter permease, respectively. Amino acid sequences of 
OrfB and OrfC share highest identity with proteins CesC and CesD, respectively, from Bacillus 
as best BLAST hits against a manually curated bacterial ABC transporter database [44] and 
against all protein sequences in the MIBiG database [13]. CesC and CesD are annotated as 
putative ABC transporters associated with the plasmid-borne cereulide synthetase cluster 
from Bacillus cereus, and have been found to be essential for export and biosynthesis of 
cereulide [45, 46]. Interestingly, the encoded protein OrfB shows 44.4% identity and 65.5% 
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similarity to CesC protein sequence (YP_009080546.1) and OrfC shows 29.7% identity and 
65.8% similarity to CesD protein sequence (YP_009080547.1); OrfC also bears the same 
predicted six transmembrane helical regions typical for an ABC transporter permease (Figure 
S4) [47, 48]. 
No genetic elements involved with regulation of expression of the NRPS cluster could be 
detected in the immediate vicinity of the operon. 
The NRPS cluster in R. nasimurium has a GC content of 48.7%, which is markedly lower than 
the overall GC content of the genome of this isolate (57.98%), as can be seen from the GC 
profile (Figure 4B)[29]. The NRPS cluster appears to have inserted between chromosomal 
genes disA and radA, and compared to the genomes of R. mucilaginosa, R. dentocariosa and 
R. aeria, the orientation of disA has inverted (Figure 4C).
Purification and characterization the antimicrobial compound from R. nasimurium 
identifies it as valinomycin
Antimicrobial activity was detected in R. nasimurium bacterial cells extracts made in 70% IPA, 
0.1% TFA and to a greater extent in extracts with 100% MeOH (data not shown). We purified the 
antimicrobial compounds from MeOH extracts using the solvents Et2O and MeCN followed by 
reverse-phase HPLC, and characterized the purified molecules by MALDI-ToF-MS and 1H- and 
13C-nuclear magnetic resonance (NMR)  (Supplemental Information, Figures S5-S8). We found 
three compounds that were also detected in commercial valinomycin with an m/z [M+H+] 
of 1111, 1125 and 1139 (Figure S6 and S7). Based on the identity in HPLC retention times, 
and detected masses and principally identical 1H- and 13C-NMR spectra between purified 
commercial valinomycin fractions and our purified compounds (Figure S8), we concluded 
that this R. nasimurium isolate produces the dodecadepsipeptide valinomycin. 
Rothia nasimurium and its associated vlm cluster is commonly present in the sampled 
tonsils
Considering the similarities of the NRPS gene cluster with vlm from Streptomyces and the 
detection of valinomycin produced by R. nasimurium, we decided to rename the responsible 
gene cluster vlm. PCR was used to confirm that the vlm cluster was present in the total DNA 
purified from porcine tonsil swab samples from which valinomycin-producing strains R. 
nasimurium #4 and #32 were originally isolated (See Chapter 4). Although Rothia species are 
frequently identified in porcine tonsillar microbiota [49, 50], we wondered if the valinomycin-
producing R. nasimurium could also be found in other pigs. To investigate this, we designed 
one PCR primer set (FLANK) to amplify the region spanning the intersection (i.e. GC content 
segmentation point) upstream of the vlm cluster with the Rothia genomic DNA, and a 
second set of primers (INT) to amplicon to generate an amplicon within the vlm cluster 
(Figure 2). The Rothia nasimurium vlm amplicons were detected in the DNA of tonsil swab 
samples from 17 of 21 sampled pigs (Table 2). In some samples, only the INT amplicon was 
detected. The microbiota composition of these tonsil samples was also determined using 
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454 pyrosequencing, and a high percentage of 16S reads with >99% and >99.4% identity to 
the 16S sequence of R. nasimurium were identified in the vlm-positive samples (Table 2).
piglet
sample # 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62
% reads >99% id. 0.18 0.19 0.06 0.12 0.19 0.09 0.13 0.07 0.08 0.10 0.02 0.18 0.26 0.05 0.06 0.04 0.32 0.02 0.56 0.16
% reads >99.4% id. 0.03 0.00 0.00 0.02 0.00 0.00 0.02 0.02 0.00 0.00 0.00 0.02 0.09 0.02 0.02 0.02 0.02 0.00 0.03 0.02
vlm FLANK ++ + +/- +/- + ++ + + - +/- - - ++ +/- + +/- + - + -
vlm INT ++ + + +/- + + + + + + + + ++ + + + + +/- + +
piglet 6397 6952
sample # 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82
% reads >99% id. 0.56 0.10 0.06 0.03 0.14 0.18 0.29 0.18 0.18 0.07 0.28 0.12 0.18 0.09 0.10 0.00 0.07 0.10 0.08 0.53
% reads >99.4% id. 0.05 0.00 0.00 0.00 0.00 0.00 0.04 0.03 0.02 0.00 0.02 0.02 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00
vlm FLANK ++ +/- +/- - +/- +/- + + + +/- + - - + - - ++ +/- + +
vlm INT ++ + + +/- + + + + + + + + +/- + +/- +/- ++ + + +P
CR
6383
py
ro
 
se
q.
py
ro
 
se
q.
PC
R
6498 6962 6718 7152 6825 6721
6877 6662 6511 6804
7173 7086
6714 7094 7009 6884 7084 6961
Table 2. Presence of vlm cluster in the R. nasimurium genome detected in sampled porcine tonsils determined 
by PCR, semi-quantified from high (++, dark red), medium (+, orange) and low (+/-, light yellow) to absent (-, light 
blue) by intensity of the band corresponding to the expected amplicon on an agarose gel. The percentage of 454 
pyrosequencing reads with >99% and >99.4% identity to R. nasimurium 16S sequence are indicated for each sample, 
coloured from largest (dark green) to smallest value (white).
The valinomycin-producing strains of Rothia are less susceptible to its antibacterial 
activity than non-producing Rothia species and S. suis 
Antibacterial activity of valinomycin, especially against Gram-positive bacteria, has been 
described quite extensively, although the exact biological function of this ionophore has not 
been elucidated [51] [52]. We hypothesized that the production of valinomycin could provide 
Rothia nasimurium a competitive advantage by inhibiting the growth of competing microbes, 
for instance other species within the Rothia genus. First, we performed a microbroth dilution 
assay with R. nasimurium isolate #4 and #32, and reference strains R. nasimurium CCUG35957, 
R. dentocariosa DSM43762 and R. mucilaginosa DSM20746 to assess the valinomycin 
concentrations that are tolerated by the producer strains relative to those tolerated by other 
Rothia strains. These reference Rothia strains do not inhibit each other’s growth, nor do they 
inhibit the growth of S. suis S10 (data not shown), and mining of the available genomes of 
R. dentocariosa and R. mucilaginosa did not reveal the presence of a vlm NRPS cluster, nor 
were we able to detect the cluster by PCR in DNA from strain CCUG35957 (data not shown). 
We observed a higher than 100-fold higher minimal inhibitory concentration (MIC) for 
valinomycin in R. nasimurium strains #4 and #32 (>100 µM) as compared to the reference 
strain CCUG35957 (1 µM) (Figure 3A). Furthermore, R. dentocariosa appeared to be quite 
resistant to valinomycin, with a MIC of >100 µM, whereas R. mucilaginosa was found to be 
more susceptible (MIC 1 µM) (data not shown). Interestingly, the optical density of the culture 
of R. nasimurium #4 and #32 after 24 h incubation is reduced significantly to about 40% at 
concentrations of 1 µM and above. Concentrations of  valinomycin of 1 µM and above also 
completely inhibited growth of S. suis (Figure 3B), while growth of S. suis S10 was significantly 
reduced at 100 nM valinomycin. Additionally, bacterial colony morphology of R. nasimurium 
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#4 and #32 was altered in the presence of valinomycin concentrations that inhibit the growth 
of the reference strain CCUG35957 (Figure 3C). 
C
A B
Figure 3. A) R. nasimurium and B) S. suis microbroth dilution assay with valinomycin. Optical density at 600 nm 
was measured after 24 h incubation at 37 °C in a humidified atmosphere with 5% CO2, data was normalized to the 
control and is represented as average values from three independent experiments with technical duplicates ± SD, *** 
indicates P < 0.0001 and * indicates P < 0.05 compared to control treatment, as determined by one-way ANOVA and 
Tukey’s Multiple Comparison Test). 500 µg mL-1  streptomycin was used as a positive control. C) Effect of valinomycin 
on growth and plaque morphology of valinomycin producer Rothia nasimurium isolate #32 and reference strain R. 
nasimurium DSM15694. Ten microliter of valinomycin solution (concentration ranging from 10 mM to 1 µM) in MeOH 
were spotted on a BHI agar plate, and after solvent evaporation these spots were overlaid with 7.5 uL droplets of 
overnight bacterial culture. Plates were incubated for 48 h at 37°C in a humidified atmosphere with 5% CO2.
Valinomycin increases permeability of epithelial monolayers and induces dose-
dependent apoptosis in PBMCs
It is known that in epithelial cells Na2+/K+-ATPase enzyme activity and intracellular K+ 
homeostasis are required for tight junction formation [53]. We hypothesized that the K+ 
ionophore valinomycin produced by mucosal-associated Rothia nasimurium might affect the 
barrier function of the epithelium through altered tight junction formation or cell apoptosis. 
When 10 µM valinomycin was added to a confluent monolayer of porcine tracheal epithelial 
cells, the trans-epithelial resistance (TER) gradually decreased over 12 to 24 h, indicating a 
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loss of barrier integrity (Figure 4A). Incubation of NPTr cells with 10 µM valinomycin for 18 
hours led to modest but significant decrease of 15% of neutral red uptake indicating that the 
viability or transport capacity of epithelial cells was reduced (Figure S8). 
As Rothia species inhabit the same niche as oral and respiratory pathogens which can trigger 
inflammation and recruitment of monocytes and neutrophils to the sites of infection, we 
investigated whether valinomycin was cytotoxic for peripheral blood mononuclear cells. 
Perturbation of K+ homeostasis has been shown to be associated with apoptosis [54], with 
valinomycin being an important effector of this pathway of induced cell-death [55, 56]. After 
18 h exposure of freshly isolated human PBMC to valinomycin we observed a significant 
dose-dependent effect on cell viability and apoptotic cells at valinomycin concentrations 
of 1 nM and higher (Figure 4B), indicating that PBMCs are substantially more sensitive to the 
cytotoxic effects of valinomycin than epithelial cells.  
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Figure 4. A) Trans Epithelial Resistance (TER), a key parameter of epithelial tightness, of NPTr cells treated with 
different concentrations of valinomycin, represented as mean values of technical triplicates ± SEM, normalized 
per replicate to t=0 (*** indicates P < 0.0001 compared to control treatment, as determined by one-way ANOVA 
and Dunnett’s Multiple Comparison Test). B) Cytotoxicity of 18h exposure to valinomycin on human PBMC’s, using 
fluorescent staining with Annexin-V and propidium iodide and measurement by flow-cytometry (n = 3, mean ± SD, * 
indicates P < 0.05 *** indicates P < 0.0001 of viable cells compared to treatment control, as determined by one-way 
ANOVA and Tukey’s Multiple Comparison Test).
Valinomycin induces NLRP3-independent secretion of IL-1β in LPS-primed ex vivo bone 
marrow-derived macrophages
Potassium efflux has been suggested as a common signal leading to NLRP3 inflammasome 
activated maturation of Il-1b. To test whether valinomycin would promote Il-1b release and 
inflammasome assembly, we tested its effects in LPS-primed WT and Nlrp3-/- bone-marrow 
derived macrophages (BMDM). Valinomycin stimulation triggered NLRP3-dependent 
IL-1β secretion at 4 and 18 hours (Figure 5A-B). Accordingly, ASC specks, indicative of 
inflammasome assembly, were observed in Valinomycin-stimulated WT BMDMs, whereas 
Nlrp3-/- BMDMs rarely displayed ASC specking (Figure 5C-D). This finding indicates that 
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valinomycin is capable of stimulating the production of the pro-inflammatory cytokine IL-1β 
in a NLRP3-dependent manner, possibly due to its effects on potassium efflux.
A B
C D
Figure 5. A,B) IL-1β secretion by WT and Nlrp3-/- BMDMs treated with different concentrations of valinomycin. 
A) 4 hours incubation and B) 18 hours incubation. C) ASC-speck formation after BMDM stimulation with 10 μM 
valinomycin for 18 hours. D) Quantification of speck formation. (For A, C and D n = 3, for B n = 2, mean ± SEM, * 
indicates P < 0.05 as determined by student’s t-test, † indicates P < 0.05 as determined by one-way ANOVA and 
Tukey’s Multiple Comparison Test).
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Discussion
Reducing usage of antibiotics in animal husbandry is highly relevant. One potential strategy 
to suppress outgrowth of porcine pathogens such as Streptococcus suis is by introducing 
or stimulating outgrowth of porcine commensals that efficiently antagonise S. suis but not 
other commensals. Here we show that two Rothia isolates of the porcine tonsil microbiota, 
with R. nasimurium as the closest relative, inhibit in vitro growth of S. suis. We purified the 
Rothia-derived compound that inhibited growth of S. suis and showed it to be the antibiotic 
valinomycin. Sequence analysis of the draft genome of this R. nasimurium isolate showed 
presence of two NRPSs. Products of functional NRPS in Rothia have not been described 
before, although biosynthetic gene clusters tentatively originating from this genus were 
found in human metagenomic data [6]. To our knowledge, this is the first time a commensal 
bacterium from mammalian microbiota has been shown to produce the ionophore antibiotic 
valinomycin. Previously, the presence of vlm NRPS gene clusters and the production of 
valinomycin has only been attributed to members of the Streptomyces genus [23-27] and 
isolates belonging to the Bacillus pumilus group [28]. 
The small size of the growth inhibition zones around the colonies of Rothia nasimurium seen 
in the overlay assay or around the wells in the agar diffusion assay are likely to be caused by 
slow diffusion of valinomycin into the surrounding agar due to its highly hydrophobic nature 
[57]. Therefore, the different growth rates and media compositions of the panel of target 
bacteria that were assayed using the agar diffusion method make it difficult to compare 
inhibitory activities. We tested a panel of twelve bacterial species in agar well diffusion 
assays, in which only the growth of Gram-positive species S. suis and S. mitis was clearly 
inhibited by R. nasimurium cell extracts (data not shown). We showed different susceptibility 
to valinomycin of species within the Rothia genus. It was previously reported that valinomycin 
has a wider spectrum of antibacterial activity against Gram-positive bacteria than Gram-
negative bacteria [51, 52]. Therefore, our findings do not completely support the assumed 
broad-spectrum activity of valinomycin.
Despite the fact that the R. nasimurium and Streptomyces fulvissimus NRPS’s are not very similar 
in protein sequence, the purified compounds produced by R. nasimurium are characterised 
by identical HPLC retention time, matching MALDI-ToF-MS spectra, and highly similar NMR 
spectra with commercial valinomycin from S. fulvissimus. In addition to valinomycin (m/z 
[M+H+]=1111), we detected a smaller amount of structural variants of valinomycin with one 
(+14 Da) or two (+28 Da) additional CH3 groups in purified fractions of the R. nasimurium 
isolates described here and the commercial valinomycin derived from S. fulvissimus (Figure 
S6 & S7). Recently, the same variants of valinomycin were also identified by automated search 
algorithms in the extract of a S. fulvissimus strain [58]. It is not uncommon to find very similar 
structural variants of cyclododecadepsipeptides that differ in one of the three four-residue 
comprising units, as is described for bacillistatin, where one of the 3S-methylvaleric acid 
moieties being replaced by a 4-methylvaleric acid [59, 60]. Similarly, such chemo-diversity 
of cereulide from B. cereus has recently been described and was proposed to be attributed 
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to relaxed proof-reading of the NRPS complex [61]. To further elucidate the composition 
and identity of molecules produced by the R. nasimurium  vlm cluster, we collaborated 
with Pieter Dorrestein at University of California San Diego to employ LC-MS/MS and mass 
spectrometry imaging (MSI) (see Supplemental Information for methods). Although this work 
is still in progress, initial results confirmed the production of valinomycin by R. nasimurium 
isolate #4 and #32 when cultured on BHI agar plates (Figure 6 AB). Additionally, we observed 
masses corresponding to montanastatin, a cyclooctadepsipeptide with the structure, cyclo-
(d-Hiv-d-Val-l-Lac-l-Val)2 [62] (Figure 6 A). Montanastatin and valinomycin were both found 
to be produced by a soil-dwelling Streptomyces anulatus, while the former did not show any 
antimicrobial activity [62].
Figure 6. A) Network of masses predicted to belong to structurally related molecules detected by LC-MS/MS in 
R. nasimurium cultures, including valinomycin (yellow circle) with m/z [M+H+]=1111.63 B) Temporal and spatial 
visualization of the production of valinomycin by R. nasimurium #4 and #32 colonies cultured for 1 to 4 days on BHI 
agar plates (top), as measured by IMS (bottom). (see Supplemental Information for detailed methods)
The vlm cluster in R. nasimurium has a much lower GC content than the average for the 
genome of this isolate (Figure 4B). The median GC content of valinomycin-producing 
Streptomyces griseus (17 assemblies) is 72.6% and the GC content from combined vlm 
sequences of multiple Streptomyces is 70% [27], while Bacillus cereus (208 assemblies) has 
a median GC content of 35.2%, with the plasmid encoded ces gene cluster (ref|NG_036207.1) 
having a median GC content of 35.6%. This may imply that vlm cluster in R. nasimurium, 
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having an average GC content of 48.7%, may have been acquired from a Firmicute origin. In 
several Bacillus species, the vlm-like ces operon is located on large plasmids [45] which may 
contribute to the horizontal gene transfer of the ces operon to other species. Analogously, the 
vlm clusters in Streptomyces tsusimaensis (ATCC 15141) and in S. fulvissimus (DSM 40593) are 
flanked by putative transposase encoding genes, which could also facilitate horizontal gene 
transfer [25, 63]. The R. nasimurium appears to lack such flanking transposase gene, but with 
the limited availability of ces- and vlm-like clusters from different species the assignment 
of the origin of the vlm cluster in R. nasimurium remains speculative. It has been proposed 
that the vlm gene cluster and the ces gene cluster may share a relatively distant common 
ancestor, and that these two gene clusters have since evolved independently [27]. However, 
the low GC content of the R. nasimurium vlm cluster in combination with the genetically 
linked ces-like transporter genes could hint at yet a different evolutionary path, which may 
involve combinatorial recombination events to generate novel mosaic-like recombinant 
clusters. Compared to other NRPS gene clusters, which tend to evolve very rapidly towards 
the production of different chemistry [64], the product of the Rothia vlm cluster has remained 
evolutionarily stable over long periods of time, which is remarkable and indicates that 
valinomycin could be seen as a ‘living fossil’ among natural products. 
We detected the Rothia genome-encoded vlm NRPS cluster in 19 out of 21 sampled pigs, 
suggesting valinomycin-producing Rothia nasimurium was a common member of the tonsil 
microbiota, at least on the farm where these pigs were sampled. Because the ionophore 
activity of valinomycin is reported to be antimicrobial and cytotoxic, we further explored 
its possible effects at mucosal sites where Rothia is colonising the host in mixed biofilm 
communities. Although valinomycin is highly hydrophobic, limiting its diffusion in vivo, it is 
quite resistant to proteolysis and might aggregate in bacterial biofilms, potentially leading to 
substantial local concentrations. Experiments employing LC-MS/MS to detect and quantify 
valinomycin or variants thereof in duplicate porcine tonsil swab samples (See Table 2) have 
been planned, but at the time of printing these results were not yet available. Presence of 
valinomycin in these samples could then possibly be correlated with the abundance of 16S 
rRNA gene reads belonging to Rothia nasimurium and/or the PCR-based detection of the vlm 
cluster in the same sampled animals.
Cytotoxicity of valinomycin to eukaryotic cells is considered to be due to the efflux of  K+ from the 
cell leading to a drop in the transmembrane inner membrane potential, thereby uncoupling 
electron transfer from oxidative phosphorylation in mitochondria [65-67]. Interestingly, the 
chemical stressor dinitrophenol (which uncouples oxidative phosphorylation) has been 
shown to increased gut permeability and immune cell recruitment [68], suggesting that 
valinomycin might have similar effects at mucosal sites, and potentially may have a role 
in releasing nutrients that could aid R. nasimurium colonization. Indeed, we observed an 
increased permeability of porcine epithelial monolayers at valinomycin concentration of 
10 µM, which may be attainable in vivo given its insensitivity to proteases and potential to 
accumulate in biofilms. At this concentration neutral red uptake by epithelial cells was only 
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reduced by 15% over 18 h, suggesting they are much more resistant to apoptosis than other 
cell types reported in the literature. We did find that PBMC’s were substantially more sensitive 
to valinomycin than epithelial cells, suggesting valinomycin producing Rothia species could 
play a role in polymicrobial infections by inducing apoptosis in immune cells recruited to 
inflamed mucosa. The reason for the differential cytotoxicity to epithelial and immune cells is 
not known but may be due to epithelial cells generating high potassium gradients via Na+/K+ 
ATPases in the basolateral membrane, which export 3 sodium ions from the cell in exchange 
for 2 potassium ions. 
Efflux of K+ from immune cells such as macrophages is responsible for triggering the 
assembly of the NLRP3 inflammasome in the cytoplasm, a macromolecular complex 
responsible for the maturation of IL-1β, a potent pro-inflammatory cytokine [69]. Indeed, our 
observations indicate that increasing valinomycin concentrations stimulates the assembly of 
the inflammasome and production of IL-1β in a process mediated by the NOD-like receptor 
NLRP3.
The mammalian microbiota has great potential to produce NRPS-derived small molecules 
with a variety of biological activities that could possibly modulate microbe-host and microbe-
microbe interactions [7]. However, relatively few microbiota-derived NRPS products have 
currently been described, and the focus is mainly on harmful effects on the host.  For example, 
colibactin is a DNA-damaging molecule produced by certain enterobacteria including E. coli 
phylotype B2, which is increased in abundance in inflammatory bowel disease patients [70, 
71]. Tilivalline, a NRP toxin causing apoptosis in human cells, is produced by pathobiont 
strains of Klebsiella oxytoca associated with antibiotic-induced colitis. It is notable that 
colibactin and tilivalline are produced in dysbiotic intestinal environments and tilivalline is 
implicated in the pathogenesis of disease [72].
To our knowledge this is the first time a commensal bacterium from mammalian microbiota 
has been shown to produce the ionophore antibiotic valinomycin. We showed that a 
Rothia nasimurium strain from the porcine tonsil biofilm can produce valinomycin, which 
could limit the growth other bacteria, such as the pathogen S. suis and other Rothia 
species. Previously, a competitive advantage of K+ ionophore producers over (mainly Gram-
positive) bacteria in alkaline (pH >8) and potassium rich environments (such as insect gut, 
decaying plant material or manure) has been proposed as one ecological function of this 
ionophore [52]. Additionally, we demonstrated that valinomycin may cause increased barrier 
permeability and trigger inflammation and IL-1β release. We hypothesize that valinomycin 
production could be a niche factor [73] that aids R. nasimurium survival in the environment 
and colonization of epithelial surfaces by interacting with other microbes as well as with the 
host. This competitive colonization advantage might explain the maintenance of the large 
vlm cluster while this causes inevitable toxicity of higher concentrations of valinomycin to R. 
nasimurium itself. However, assessing the effects on colonisation and competitiveness with 
other microbes within the tonsil biofilm, the implications on host physiology and immunity, 
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and in vivo could help elucidate the exact biological role of valinomycin production by R. 
nasimurium.
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Supplemental figures
	
Rank Name Strain Accession 
Pairwise 
Similarity(%) 
Dif f/Total  
nt  
Completeness(%) 
1 Rothia nasimurium CCUG 35957(T) AJ131121 97.89 31/1467 100 
2 Rothia endophytica YIM 67072(T) KC806052 97.78 33/1488 100 
3 Rothia marina JSM 078151(T) FJ425908 97.64 34/1441 99.04 
4 Rothia amarae JCM 11375(T) AY043359 97.09 42/1442 98.26 
5 Rothia terrae L-143(T) DQ822568 97.00 43/1432 98.29 
6 Kocuria polaris  CMS 76or(T) JSUH01000031 96.56 51/1484 100 
7 Kocuria rosea DSM 20447(T) X87756 96.48 52/1476 100 
8 Rothia mucilaginosa ATCC 25296(T) ACVO01000020 96.43 53/1484 100 
9 Kocuria halotolerans YIM 90716(T) DQ979377 96.30 55/1485 100 
10 Kocuria koreensis  P31(T) FJ607312 96.29 55/1481 100 
11 Kocuria atrinae P30(T) FJ607311 96.25 55/1468 100 
12 Rothia dentocariosa ATCC 17931(T) CP002280 96.09 58/1485 100 
13 Kocuria sediminis FCS-11(T) JF896464 95.94 58/1428 97.54 
14 Kocuria palustris DSM 11925(T) Y16263 95.86 60/1451 99.32 
15 Micrococcus terreus V3M1(T) FJ423763 95.81 62/1479 100 
16 Kocuria kr ist inae DSM 20032(T) X80749 95.79 62/1471 100 
17 Arthrobacter crystallopoietes DSM 20117(T) X80738 95.78 62/1470 100 
18 Kocuria turfanensis HO-9042(T) DQ531634 95.76 61/1440 98.63 
19 Arthrobacter pascens DSM 20545(T) X80740 95.72 63/1473 100 
20 Kocuria flava HO-9041(T) EF602041 95.69 62/1440 98.63 
21 Kocuria himachalensis K07-05(T) AY987383 95.67 63/1456 100 
22 Arthrobacter woluwensis DSM 10495(T) X93353 95.56 65/1463 100 
23 Micrococcus aloeverae AE-6(T) KF524364 95.46 64/1410 97.04 
24 Rothia aeria GTC 867(T) AB071952 95.44 61/1338 92.55 
25 Arthrobacter phenanthrenivorans Sphe3(T) CP002379 95.41 68/1480 100 
26 Arthrobacter cumminsii DMMZ 445(T) X93354 95.34 68/1460 100 
27 Kocuria salsicia 104(T) GQ352404 95.32 67/1432 98.09 
28 Arthrobacter methylotrophus TGA(T) AF235090 95.31 68/1451 99.32 
29 Nesterenkonia flava CAAS 251(T) EF680886 95.31 66/1408 97.39 
30 Arthrobacter globiformis NBRC 12137(T) BAEG01000072 95.21 71/1482 100 
31 Arthrobacter mysorens LMG 16219(T) AJ639831 95.21 70/1461 100 
32 Micrococcus lactis DW152(T) FN673681 95.21 68/1419 97.06 
33 Micrococcus luteus  NCTC 2665(T) CP001628 95.21 71/1481 100 
34 Arthrobacter siccitolerans 4J27(T) CAQI01000001 95.14 72/1483 100 
35 Nesterenkonia lutea YIM 70081(T) AY588278 95.11 72/1473 100 
  
	 Table S1. Based on the complete 16S rRNA gene sequence of the Rothia nasimurium isolate, the top 35 phylogenetic 
neighbours were identified using the EzTaxon server. (http://www.ezbiocloud.net/eztaxon) [15]. The species marked 
in bold font were included for the building of a phylogenetic tree (Figure S1).
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Figure S1. Bootstrapped phylogenetic tree based on curated 16S rRNA gene sequence comparison (see methods 
section), showing that isolate #32 is closely related to R. nasimurium. However, members of this group include R. 
endohytica, R. marina, R. amarae, and R. terrae, which cannot reliably be distinguished by phylogenetic approaches 
using only the 16S rRNA gene sequence. 
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Figure S2. Protein sequences of the adenylation domains encoded by vlm (S. fulvissimus, S. tsusimaensis), ces 
(B. cereus), and vlm (R. nasimurium  #32) were trimmed, aligned and a phylogenetic tree was constructed using 
Phylogeny.fr (http://www.phylogeny.fr/) [16, 17] with 500 times bootstrapping. Rothia A domains are more similar 
to Streptomyces vlm than to B. cereus ces A domains, which can partly be explained by the different substrates 
recognised by these domains. Accession numbers of proteins that were used are AGK81693 and AGK81692 (S. 
fulvissimus), ABA59547 and ABA59548 (S. tsusimaensis), ABD14711 and ABD14712 (B. cereus).
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Vlm1_A1(S_tsus)    TTYGTL VHAGIVVVPLN AAVIFFTSGSTGAPKG HAAG PVWGMAE GHLQVRGACVTREYF FRTGDL GRAKQILIVNGLNFDLSEVE VLRRIGI LGKIQR
Vlm1_A1(S_fulv)    TTYGTL VHAGVVVVPLS AAVIFFTSGSTGAPKG HAAG PVWGMAE GHLLVRGACVTREYF FRTGDL GRAKQILIVNGLNFDLSEVE VLRRIGI LGKIQR
CesA_A1(B_cer) LSYQEM ILGGFLPTPLG IVLNLLTSGSTGVPKC HVGG PTFGMSE GRFQIHGPTVMNGYF FDSGDL GRKKDMIVVHGANYYNYEIE VARKMGI SGKITR
R1_A2(R_nas) LQYNEL IRLGAVYVPLR PIYIMYTSGSTGTPKG FDAS NGYGPTE GELYVGGQGVSQGYL YRTGDL GRQDHQVKIRGFRVELAEVE LEVSLPD NGKVDR
Vlm1_A2(S_tsus)    YTFAQL ARLGAAYVPVR PAYIMYTSGSTGRPKG FDAS NGYGPTE GELHVGGRGVALGYV YRTGDL GRADHQVKVRGFRVELSEIE LERLLPD NGKVDR
Vlm1_A2(S_fulv)    YTYAEL ARLGAAYVPVR PAYIMYTSGSTGRPKG FDAS NGYGPTE GELHVGGRGVALGYV YRTGDL GRVDHQVKVRGYRVELSEIE LERLLPD NGKVDR
CesA_A2(B_cer) MTYEDV LKAGGAYLPID LAYIIYTSGSTGNPKG FDVS NLYGPTE GELCLGGICVAKGYM YRTGDL GRIDNQVKIRGFRIELGEIE VKKTLPQ NGKVDR
R2_A1(R_nas) LTYREL QLAGATAVPVT PAVILFTSGSTGIPKG HVVG PEWGMSE GRFQVRGVTRLVEYF FDTGDL GRDVDRIIINGVNLQNVDIE LMRQFGT IGKIQR
Vlm2_A1(S_tsus) LSYAGL LLAGAVAVPVT PAVILFTSGSTGTPKG HVVG PEWGMSE GHFQVRGLTRLVEYF FDTGDL GRGADLIIVNGVNIQNVDLE LRREFSL IGKIQR
Vlm2_A1(S_fulv) LPYAGL LLAGATAVPVT PALILFTSGSTGTPKG HVVG PEWGMSE GHFQVRGLTRLVEYF FDTGDL GRGADLIIVNGVNIQNVDLE LRREFSL IGKIQR
CesB_A1(B_cer) LTYKMI VLGGFIPVPIT DAILLFTSGSTGNPKG HVGG PVWGMSE GRLQIKGKNVLEGYY YDTGDL GRGKDIIIINGVNFNGTEIE IIEKFGV IGKIQR
R2_A2(R_nas) LSYIDL ARIGCSYVPLD EAYVIFTSGTTGRPKG FDAS NGYGPTE GELYVGGEGLSTGYV YRTGDF GRRDDQVKIRGHRVELASVR LRKELPP SGKVDT
Vlm2_A2(S_tsus) LTYGEL LKAGGAYVPLD EAYVMFTSGTTGLPKG FDAS NGYGPTE GELYVGGEGLALGYV YRTGDW GRRDGQVKVRGHRVELNAVR VRRLIPP SGKVDV
Vlm2_A2(S_fulv) ITYREL LKLGGAYVPID EAYVMFTSGTTGRPKG FDAS NGYGPTE GELYVGGEGLALGYV YRTGDW GRRDGQVKVRGHRVELNAVR VRRLVPP SGKVDV
CesB_A2(B_cer) LTYAEL LKVGAIYLPID TAYIMYTSGSTGKPKG FDAA NGYGPTE GELCVGGDGVAKGYV YRTGDY GRVDNQVKIRGFRIELEAIM AKKHLAE NGKVQY
consensus          ltyael lraGavyvPv ayimfTSGsTG PKg dag ayG tE Gel vgG av  gYl yrtGDl GR d qvkvrG  lel eve l r m GKvqr
motif LTYxEL  LKAGxAYVPID  LAYxxYTSGSTGxPKG FDxS NxYGPTE  GELxlxGxGLARGYW YRTGDL GRxDxQVKIRGxRIELGEIE LPxYMVP NGKVDR
S L L            T                                         K I      L
Figure S3. Conserved core domains from aligned protein sequences of the adenylation domains from Vlm1 and 
Vlm2 (S. fulvissimus, S. tsusimaensis), CesA and CesB (B. cereus), and Vlm1 and Vlm2 (designated R1 and R2) (R. 
nasimurium) and consensus motifs for these core as described by [74] and [75]. Rothia A domains are more similar 
to Streptomyces Vlm than to B. cereus Ces A domains, even if the A domain is involved in recognition and activation 
of the same l-Val residue (R2_A2).
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Figure S4. Consensus topology of the putative ABC transporter permeases A) CesD (YP_001967167.1) from B. cereus 
and B) gene vlmC product from R. nasimurium as predicted by TOPCONS [48]
A 
B 
Figure S5. MALDI-ToF-MS spectrum of crudely purified valinomycin and structural variants from MeOH R. 
nasimurium extract, using sequential Et2O and MeCN solvent steps. This spectrum is representative for multiple, 
independent extractions.
CHAPTER 6
194
Figure S6. A) Chromatogram of analytical HPLC of purified bacterial extracts from R. nasimurium #4 and #32. 
Fraction 1 (retention time = 14.7 min) and fraction 2 (retention time = 15.7 min) were further purified. Commercial 
valinomycin from Streptomyces fulvissimus (VLM) was used as a reference. B) Chromatogram of HPLC purified R. 
nasimurium fractions 1 and 2, with the MALDI-ToF-MS mass of the purified molecule assigned to each peak (see 
Figure S7 for the MALDI-ToF-MS spectra for these fractions).
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Figure S7. MALDI-ToF-MS spectrum of A) R. nasimurium purified valinomycin (molecular formula C54H90N6O18) 
(fraction 1, see Figure 6) with the most prominent ion adducts m/z [M+H+]: 1111, m/z [M+Na+]: 1133 and m/z [M+K+]: 
1149, B) R. nasimurium purified valinomycin variant (fraction 2, see Figure 6) with the most prominent ion adducts 
m/z [M+H+]: 1125, m/z [M+Na+]: 1147 and m/z [M+K+]: 1163. The shift of +14 could be indicative of an additional CH2 
group.
A
B
CHAPTER 6
196
Figure S8. NMR spectra of HPLC purified fractions 1 and 2 from R. nasimurium extracts (red and dark green) and 
commercial valinomycin from S. fulvissimus (orange and bright green).
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Figure S9. Effect of valinomycin on NPTr cell viability, measured by the neutral red uptake assay. (n=3, mean ± SD, 
** indicates P < 0.01 compared to control as determined one-way ANOVA and Dunnett’s Multiple Comparison Test).
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Supplemental information
Extraction and crude purification of peptide
BHI medium was inoculated from a -80°C glycerol stock of R. nasimurium and incubated 
overnight at 37°C without agitation. BHI plates containing 1.25% agar were inoculated 
with a volume of 200 µL of the overnight bacterial culture and incubated for 48 h at 37 °C to 
create a lawn of bacterial growth. A volume of 15 mL cold 70% v/v isopropanol (IPA) 0.1% v/v 
trifluoracetic acid (TFA) or 100% methanol (MeOH) was then added to each agar plate and 
the bacteria were removed by gentle scraping with a sterile T-spreader (VWR International, 
Amsterdam, The Netherlands). The bacterial suspensions were pooled and collected in sterile 
50 mL Falcon tubes (Eppendorf, Hamburg, Germany), vortexed thoroughly and incubated on 
a rotary shaker for 6 h at 4°C.  To remove insoluble matter the suspension was centrifuged for 
25 min at 12.000 x g at 4 °C and the supernatant was filtered using a 0.2 μm cellulose acetate 
sterile syringe filter (Whatman, GE Healthcare). After removal of IPA by rotary evaporation, 
the solution was used for agar well diffusion assays as described above. For the purification, 
the cell-free solution was evaporated to dryness by rotary evaporation and 1 mL MeOH and 
1 mL Milli-Q water were added to the residue, followed by sonication to aid re-solubilisation. 
Approximately 5 volumes of diethyl ether (Et2O) were added and the suspension was 
sonicated thoroughly. The Et2O solution was filtrated (589
3 Blauband, Schleicher & Schuell) 
to remove precipitates and the solvent removed by rotary evaporation. The precipitate was 
subsequently resuspended by thorough sonication in acetonitrile (MeCN) and MeOH with 
elimination of insoluble precipitates by filtration at each step and solvent removal by rotary 
evaporation. The residue was dissolved in 1 mL MeOH and loaded onto a C18-E solid phase 
extraction column (Strata, Phenomenex), which had been conditioned with Milli-Q water. 
The column-bound molecules were eluted with stepwise increasing concentrations from 
10% to 100% of MeOH and the collected 10 mL fractions were analysed using MALDI-ToF-MS 
(Bruker). The elution fractions containing peptides of interest without impurities were pooled 
and solvent was removed by evaporation. These crudely purified peptide preparations were 
stored at -20°C. 
Peptide purification and characterization 
Crudely purified peptides were further purified via preparative high pressure liquid 
chromatography (HPLC). Analytical HPLC and MALDI-ToF-MS were employed to assess purity 
of the separated peptide fractions. Commercial valinomycin from Streptomyces fulvissimus 
(abcam, Cambridge, UK) was used as a reference molecule for MALDI-ToF-MS and NMR 
analysis and for establishing optimal HPLC conditions. 
Preparative reverse-phase HPLC
Column: WatersTM XBridgeTM BEH130 C18, 10 x 250 mm, 5 µm
Pump: WatersTM 600 Pump
Detector: WatersTM 996 Photodiode Array Detector
CHAPTER 6
198
Buffer A: 99.9% H2O, 0.1% TFA
Buffer B: 99.9% MeOH, 0.1% TFA
Purified fractions were collected manually. Spectra were processed as follows: the raw data 
were exported using the Waters Empower 3 software and imported in Microsoft Excel. The 
baseline (blank) was subtracted and negative absorbance values were corrected to 0 (zero).
Analytical reverse-phase HPLC
Column: Phenomenex Luna® C18, 4.6 x 150 mm,  5 µm, 100Å 
Agilent 1100 Series
Pump: G1310A Isocratic Pump
Detector: G1314A Variable Wavelength Detector
Buffer A: 99.9% H2O, 0.1% formic acid
Buffer B: 99.9% MeOH, 0.1% formic acid
Gradient: 
Time (min) Flow (mL min-1) %B 
0 1.2 30 
10 1.2 100 
25 1.2 100 
26 1.2 30 
32 1.2 30 
 
Spectra were processed as follows: the raw data were exported using the Agilent ChemStation 
software and imported in Microsoft Excel. The baseline (blank) was subtracted and negative 
absorbance values were corrected to 0 (zero).
MALDI-ToF-MS
Instrument: Bruker MicroflexTM 
Matrix: α-cyano-4-hydroxycinammic acid in MeCN:H2O:TFA (50:47.5:2.5) (10 mg mL-1)
Target: MSP AnchorChip 600/96 microScout (Bruker Daltonics)
NMR
HPLC purified fractions  1 and 2 from commercial (abcam, Cambridge, UK) and R. nasimurium 
extracted valinomycin were dissolved in a minimal volume of CD3OD and analysed by 
1H- and 
13C-NMR on a Bruker Avance III HD 600 MHz instrument equipped with a 1.7-mm cryogenically 
cooled 13C/1H DCH probe head. 
LC-MS/MS
LC-MS/MS experiments were performed on an Vanquish ultra-high performance liquid 
chromatography (UHPLC) system coupled to a Q-Exactive mass spectrometer (Thermo 
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Fisher Scientific, Bremen, Germany). A C18 core-shell column (Kinetex, 50 x 2 mm, 1.8 um 
particle size, 100 A pore size, Phenomenex, Torrance, USA) with a flowrate of 0.5 mL/min 
(Solvent A: H2O + 0.1 % formic acid (FA), Solvent B: Acetonitrile (ACN) + 0.1 % FA) was used for 
LC separation. Herby a linear gradient from 0-0.5 min, 5 % B, 0.5-4 min 5-50 % B, 4-5 min 50-
99 % B, flowed by a 2 min washout phase at 99% B and a 2 min re-equilibration phase at 5 % 
B was used. For MS and MS/MS measurements the electrospray ionization (ESI) parameters 
were set to 35 L/min sheath gas flow, 10 L/min auxiliary gas flow, 2 L/min sweep gas flow and 
400 °C auxiliary gas temperature. The spray voltage was set to 3.5 kV, the inlet capillary was 
set to 250 °C and a 50 V S-lens radio frequency (RF) level was applied. MS/MS spectra were 
recorded in data dependent acquisition (DDA) mode. Both MS1 survey scans (150-1500 m/z) 
and up to 5 MS/MS scans of the most abundant ions per duty cycle were measured with a 
resolution (R) of 17,500 with 1 micro-scan in positive mode. The maximum ion injection time 
was set to 100 ms and a MS/MS precursor selection windows was set to 3 m/z with 0.5 m/z 
offset. Normalized collision energy was stepwise increased from 20 to 30 to 40 % with z = 2 as 
default charge state. MS/MS experiments were automatically triggered at the apex of a peak 
within 2 to 15 s from their first occurrence. A dynamic exclusion was set to 5s. Ion species 
with unassigned charge states as well as isotope peaks were excluded. Thermo raw data files 
were converted to mzXML in centroid mode using MSConvert (part of proteowizard) for the 
downstream data analysis. 
Molecular networking
A Molecular network of all LC-MS/MS runs was created with the online workflow at GNPS 
(http://gnps.ucsd.edu) [76]. Herby similar MS/MS from the same precursor mass were 
clustered with MS-Cluster [77] with a precursor mass tolerance of 0.02 Da and a MS/MS 
fragment ion tolerance of 0.02 m/z. Consensus spectra that contained less than 2 spectra 
were discarded. A network was then created where edges were filtered to have a cosine 
score above 0.7 and more than 6 matched peaks. The edges between two nodes were kept 
in the network only when each of the nodes appeared in each other’s respective top 10 most 
similar spectra. The spectra in the network were searched against GNPS’s spectral libraries. 
The library spectra were filtered in the same manner as the input data. All spectra library 
matches were required to have a score above 0.6 and at least 6 matched peaks and were 
manually validated.
MALDI-ToF MS Imaging (MSI)
After the cultivation of Rothia #4 and #32 isolates on thinlayer BHI agar, colonies were 
transferred to a stainless steel MALDI target plate and a 1:1 mixtures of CHCA and DHB was 
sieved onto the target as described previously [78]. After trying the sample over night at 37° 
C the target plate was transferred to a Autoflex MALDI-TOF mass spectrometer equipped 
with a Nd:YAG smartbeam2 laser (Bruker Daltonics, Bremen, Germany). For MALDI imaging 
experiments, the laser width was set to “wide”. For each raster spot of 300×300 µm, 1000 laser 
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shots (200 shots random walk) with a relative laser energy of 50% at a frequency of 1000 Hz 
were acquired. TOF measurements were herby performed in positive reflectron mode. The 
mass spectrometer was herby set to a suppression of matrix ions below 300 m/z. The TOF 
mass range was set to 300-2800 m/z with a detector gain multiply of 12. The mass spectra 
were recorded and further visualized using FlexImaging 4.1 (Bruker, Daltonics, Bremen, 
Germany).
Neutral red uptake assay
Viability of NPTr cells [19] was quantified using the neutral red uptake assay to determine 
cytotoxicity of valinomycin to epithelium [79]. Briefly, cells were seeded in a flat-bottom 96-
well microtiter plate at a density of ~1x105 cells well-1 in 89% Dulbecco’s Modified Eagle’s 
Medium (DMEM) + GlutaMAX™ (Gibco, Life Technologies), containing 10% heat-inactivated 
Fetal Bovine Serum (FBS) and 100 U mL-1 penicillin and 100 µg mL-1 streptomycin (Invitrogen, 
Breda, The Netherlands). After incubation at 37°C with 5% CO2 for 24 hours cells had reached 
confluency and culture medium was removed and replaced with 200 μL treatment medium 
(Keratinocyte Serum Free Medium (Gibco, Life Technologies)) containing a concentration 
range of valinomycin. Following 18 h incubation at 37°C with 5% CO2, the treatment medium 
was removed and 100 µL neutral red solution (40 mg mL-1) was added. After 3 h incubation, 
neutral red solution was removed, cells were washed with 150 µL PBS and neutral red was 
extracted from the cells by adding 150 µL 50% ethanol, 1% glacial acetic acid. The released 
neutral red content, indicative of cell viability, was measured spectrophotometrically at 540 
nm (Spectramax M5, Molecular Devices, Sunnyvale CA, USA), values from triplicate conditions 
were averaged and normalized to cells treated with PBS only and expressed with the SD as 
percentage viable cells. 
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Host-Defense Peptides
The increase and spreading of antibiotic resistant bacteria is an urgent global health problem 
[1]. As a consequence, existing antibiotics are becoming increasingly ineffective against 
multi-drug resistant (MDR) pathogenic bacteria leading to increased morbidity, mortality 
and overall healthcare costs in both human and veterinary medicine. Several alternatives to 
conventional antibiotics have been proposed for therapeutic applications to reduce the risk 
of infections by pathogenic bacteria. Antimicrobial peptides (AMPs), also referred to as host-
defense peptides (HDPs) due to their other biological defense functions, are among the more 
promising broad-spectrum antimicrobial compounds and have received substantial scientific 
interest [2-4]. Although naturally occurring peptides differ widely in potency and spectrum of 
activity, their direct antibacterial activity is typically modest compared to most conventional 
antibiotics. Several approaches to optimize naturally occurring AMPs or to design novel AMPs 
have been explored with the aim to deliver potent, broad-spectrum antibiotics in a more 
cost-effective manner [5]. However, many AMPs suffer from poor absorption into host blood 
or tissue, low in vivo peptide stability and proteolytic degradation, and systemic cytotoxicity 
to the host. Given these limitations AMPs currently hold most promise as topical treatments 
for skin and wound infections caused by pathogenic bacteria [6, 7]. Chapter 2 aimed to 
investigate whether frog skin AMPs could be effective for treating skin infections caused by 
MDR pathogenic bacteria, while minimizing the impact on commensal bacteria. We showed 
that several naturally occurring peptides and some amino-acid substituted analogues 
of temporin-1DRa displayed promising differential activity against pathogenic bacteria 
compared to commensal or probiotic lactic acid bacteria. These peptides, or modifications 
thereof, could be interesting candidates for further development as novel therapeutics for 
skin infections. Several bionanotechnological tools have been described that could open 
up avenues towards innovative therapeutic applications of AMPs, such as nanofibers, 
nanoparticles, and biofilms [8]. The combination of these nanostructures with potent AMPs, 
might be further developed into a formulation to be used as successful topical treatment of 
skin infections by pathogenic bacteria. One example would be treatment of recurrent skin and 
wound infections by the opportunistic pathogen Staphylococcus pseudintermedius in dogs. 
Infections caused by methicillin-resistant strains of S. pseudintermedius (MRSP) have proven 
very difficult to treat as they are resistant to essentially all antimicrobial agents available in 
veterinary medicine [9, 10]. In these situations, the topical application of narrow-spectrum 
AMPs, for example formulated in a polymeric hydrogel, as a complement to conventional 
antibiotic therapy may provide a more effective way to reduce S. pseudintermedius infections 
in dogs.
Despite initial enthusiasm about using AMPs to treat infections with antibiotic resistant 
pathogens, it is now recognised that a broad range of diverse resistance mechanisms can be 
present in bacteria [11, 12]. One well-described resistance mechanism involves electrostatic 
repulsion of the generally cationic AMPs, for instance by the incorporation of positively 
charged d-alanyl esters into teichoic acids by gene products of the dlt operon [13, 14]. In 
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Chapter 3, we studied the susceptibility of S. suis to the human cathelicidin LL-37, and also 
included an isogenic dltA mutant in our flow cytometry-based antimicrobial assays. To our 
surprise, no altered susceptibility to LL-37 of the dltA mutant was observed after 30 min or 1 
hour exposure when compared to the wild-type strain S10. Additionally, we evaluated if the 
polysaccharide capsule that forms the outermost surface of many Gram-positive bacteria 
that AMPs have to cross in order to reach the target cytoplasmic membrane, was involved 
in susceptibility to AMPs. Our hypothesis was that capsule composition or lack of a capsule 
might shield the membrane and thus impact on susceptibility to AMPs. However, the capsule 
did not influence the susceptibility of S. suis to LL-37, as determined by testing serotype 2 
and a capsule-negative mutant J28, and strains belonging to serotype 7 and 9 (Chapter 3).
To confirm that certain genetic factors responsible for (modification of) surface molecules 
may influence the susceptibility of bacteria to the cationic AMP LL-37, we used an available 
selection of isogenic deletion mutants of the Gram-positive bacterium Lactobacillus 
plantarum WCFS1 obtained from NIZO Food Research (Ede, The Netherlands). This selection 
included a dltX-D mutant and several mutants lacking individual or multiple capsular 
polysaccharide (cps) encoding gene clusters [15-17]. We found that the mutants lacking all 
capsular polysaccharide gene clusters (cps1-4), the gtcA3 mutant, and the dltX-D mutant were 
more susceptible to killing by LL-37 in a microbroth dilution assay (data not shown). The gene 
product of gtcA3 is involved in the glycosylation of teichoic acids, and altered expression 
of this protein was previously proposed to be implicated with altered immunomodulatory 
properties of L. plantarum WCFS1 in vitro [18]. However, mutants of individual cps clusters 
did not show an altered susceptibility to LL-37. These data suggest that bacterial resistance 
towards cationic AMPs, such as LL-37, is a complex phenomenon involving multiple different 
processes and/or molecules.
Bacterial resistance towards AMPs is an important consideration to make when developing 
AMPs into therapeutic applications, as it has been shown to cause cross-resistance in the 
target bacterium to other antibiotics [19-21]. Furthermore, AMPs such as LL-37 could be 
used by certain bacteria as environmental cues to become more virulent or invasive [22-24]. 
In Chapter 3 we performed microarray gene expression profiling to describe the generic 
and adaptive resistance mechanisms that could be activated in the important porcine 
pathogen Streptococcus suis in response to the human cathelicidin LL-37. Because of the 
global problems imposed by S. suis on pig husbandry (see next section), and the increasing 
pressure to reduce antibiotic chemotherapy to control S. suis, there is an interest in using 
alternatives approached including the application of AMPs. We observed that exposure of 
S. suis to sub-lethal concentrations of LL-37 induces a complex response comprising general 
stress responses (including heat shock proteins) as well as what seems to be increased 
expression of a potential AMP transporter that might be regulated by a two-component 
system; an homologous system present in Bacillus species mediates resistance to AMPs [25, 
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26]. Additionally, expression of 3 surface proteins were increased substantially, one of which 
plays a role in adhesion to epithelial cells. These findings raise the possibility that sub-lethal 
concentrations of LL-37 function as an environmental cue for S. suis leading to induction of 
virulence-associated genes inside the host. If such a response would indeed occur under 
natural in vivo conditions, it would suggest that the interplay between pig immune response 
and shifts of S. suis from a commensal to a pathobiont lifestyle might be mediated by external 
factors including porcine infections by different pathogens. It also shows that applying 
exogenous AMPs to avoid S. suis infections will not be straightforward. 
In practice, the use of pure AMPs alone will probably be insufficient for controlling S. suis 
in the swine industry, aside from the fact that it would be prohibitively expensive due to 
the large amounts of AMPs required and the associated high costs of peptide synthesis. We 
reasoned that the modest antimicrobial activity of many naturally occurring AMPs to some 
bacteria results in a balance between the host and different bacterial taxa within the host-
colonizing microbiota. From the literature information, and taking report biases into account, 
we hypothesized that at least some pathogens appear to be more sensitive to common AMPs 
than commensals. Under this hypothesis, AMPs contribute to lowering bacterial numbers 
and modulating numbers of more (pathogenic) or less (commensal) sensitive species, 
and negative interactions between commensal and pathogenic species would then avoid 
outgrowth of pathogenic bacteria. S. suis is a natural occupant of the upper respiratory tract 
and the proximal intestine in pigs. Therefore, we also carried out microbiota analysis of 
porcine tonsils and small intestine to identify bacteria that would directly antagonise S. suis. 
This research forms the second part of the thesis (Chapters 4-6).
Streptococcus suis infection and colonisation resistance
The second part of this thesis focussed on an alternative strategy involving bacterially 
produced AMPs to control Streptococcus suis infections in piglets. As mentioned above, S. 
suis is an important swine pathogen associated with morbidity and mortality in weaning 
piglets worldwide, causing large economic losses to the pig production industry [27, 28]. In 
adult pigs S. suis is usually carried asymptomatic and it is frequently found as a member of 
the microbiota of the oro- and nasopharynx, and at relatively lower abundances of the small-
intestinal tract microbiota [28-33]. Clinical infections are mainly seen in piglets 2–5 weeks 
post-weaning and in growing pigs, less frequently in suckling piglets and adult animals [34, 
35]. Different mechanisms for pathogenesis have been proposed, but it is generally accepted 
that in pigs the palatine tonsils are a primary site where S. suis colonizes and replicates, which 
may lead to invasion of the mucosal tissues and dissemination into the lymphatic system or 
blood [27, 36]. Translocation of S. suis across the gastro-intestinal mucosal barrier has also 
experimentally been shown to be a possible route of infection [37, 38].
Several stress-related factors are known to correlate with the development of S. suis 
clinical disease, such as crowding, sudden weather change, mixing or moving of animals, 
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and vaccination [27]. Additionally, co-infection with other pathogenic microbes (e.g. swine 
influenza virus or porcine reproductive and respiratory syndrome virus (PRRSV)) has been 
described as important predisposing factor for increased susceptibility to S. suis [39-42]. 
Moreover, a change of diet towards more complex carbohydrates, such as starch, has been 
hypothesized to contribute to outgrowth of and infection with S. suis; it was previously shown 
that the expression of virulence genes is determined by the available carbohydrate source 
[43]. This, together with our observation that increasing concentrations of LL-37 AMPs also 
induced expression of S. suis virulence genes, shows that the interplay between microbiota, 
host immunity and S. suis infections is very much dependent on external, intertwined factors.
Microbiota profiling analysis suggests that tonsil populations of S. suis are part of a 
pathogen complex 
Microbial colonisation of a mammalian host starts directly after birth, initially forming an 
compositionally unstable microbiota that develops into a more stable adult-like microbiota 
over time. Environmental factors and nutrition are an important determinant in shaping 
the microbiota during early life, with weaning associated changes having significant effects 
[44-46]. As little was known about which specific bacterial taxa might have an impact on S. 
suis abundance, we have investigated co- and anti-occurrence of bacterial taxa with S. suis 
in the porcine small intestine and tonsil (Chapter 4). The 16S profiling study provided our 
first glimpse of bacteria that were enriched or underrepresented in correlation with S. suis 
abundance. All the piglets that were sampled for the collection of tonsillar and small intestinal 
microbiota, formed a relatively heterogeneous group in terms of sex, sow, bodyweight, feed 
intake, housing pen and age at weaning. In addition, we sampled piglets from two different 
breeds raised on two separate specific-pathogen free (SPF) farms with low incidence of S. 
suis related morbidity (Chapter 4, Supplemental Information). Accordingly, the collected 
microbiota samples are unbiased for a particular phenotype but all originate from healthy 
piglets around the time of weaning.
According to our microbiota profiling results, S. suis abundance was among others positively 
correlated with the relative abundance of well-known respiratory pathogens, and negatively 
with multiple Lactobacillus species. The positive correlations between S. suis and porcine 
pathogens belonging to different species from multiple different genera confirmed our 
hypothesis that the occurrence of S. suis invasive disease in colonised pigs is dependent on 
the commensal microbial community structure and most likely the presence of a complex 
of other pathogens. The existence of a microbial complex, responsible for polymicrobial 
infections in pigs, had been suggested previously by Brockmeier et al. [47] and Hansen et al. 
[48]. This idea and our findings are supported by the apparent difficulty to experimentally 
induce invasive infections in pigs after intranasal inoculation or aerosol exposure to S. suis 
without predisposing animals by inducing mucosal damage [49, 50]. Studies of colonisation 
and transmission of S. suis have been performed without inducing mucosal damage but 
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then systemic infection occurred only sporadically [51]. Also in porcine gastro-intestinal 
challenge models, translocation and systemic infection of S. suis was only observed at 
relatively low frequencies (13-27% of animals) [37, 38]. Our finding is of scientific interest but 
also of applied relevance, because it provides a possible explanation for the lack of a good 
and robust animal model for experimental S. suis infection. For future strategies to control S. 
suis, it is of interest to study S. suis infections in the context of a pathogenic complex, where 
the different pathogens may differentially impact on an animal’s health status and immune 
system [52]. It is noteworthy to consider that, if under natural conditions, accumulations of 
AMPs do indeed induce S. suis virulence genes, AMPs induced by pathogens that co-occur 
with S. suis may indirectly promote expression of S. suis virulence.
The LEfSE and network analyses of the microbial taxa co-occurring with S. suis showed a 
strong negative correlation with multiple Lactobacillus species, with the strongest negative 
correlations observed between L. reuteri and the pathogen complex including S. suis, 
Actinobacillus, Actinomyces, and Pasteurella species. Exploration of where L. reuteri occurs 
most often (based on its 16S rRNA gene sequence abundance) suggested that this anti-
correlation could be caused by it being relatively highly abundant in the small intestine, 
whereas S. suis and the associated pathogens were most abundant in the palatine tonsils. 
The main antimicrobial compound produced by L. reuteri is reuterin, a mixture of the hydrated 
and nonhydrated form of 3-hydroxypropionaldehyde and its dimer [53]. Sensitive species 
are killed by reuterin in the micromolar range, including Streptococcus salivarius which is 
killed at dosages between 10-20 µM [54]. However, we observed no decreased growth of S. 
suis at dosages ranging from 1 to 64 µM of reuterin, lending support to the notion that the 
negative co-occurrence of L. reuteri and S. suis was mainly determined by differential niche 
occupation or indirect effects rather than direct antagonism via the production of reuterin 
(Chapter 4). However, at least three of the other Lactobacillus species that displayed anti-
correlation with three “bins” of S. suis load (high, low or no S. suis) and bacteria that could 
be part of the presumptive pathogen-complex, are also known to colonise the oral cavity. It 
is also possible that the observed negative correlation of lactobacilli with S. suis abundance 
is caused by one or more immune-mediated colonisation resistance mechanisms [55, 56]. 
Of course, there may be other presently unknown factors that directly or indirectly cause the 
negative correlation we observed between abundance of S. suis and Lactobacillus species.
The research described in Chapter 4 demonstrated that the porcine microbiome contains 
bacteria that might display direct or indirect microbial antagonism against S. suis, thereby 
playing an important role in colonisation resistance against this and possibly other 
(respiratory) porcine pathogens. To further validate this hypothesis, we applied high-
throughput culture-based approaches to find individual bacteria belonging to the porcine 
tonsillar and small intestinal microbiomes that displayed potent narrow-spectrum growth-
inhibiting activity towards S. suis through the production of AMPs or secondary metabolites. 
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We believed that this strategy would be complimentary to the culturing-independent 
microbiota-profiling approach for understanding the interplay between members of the 
endogenous microbiota and S. suis (see Figure 1).
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Figure 1. Schematic overview of the culture-dependent approach described in Chapters 5 and Chapter 6 (left) 
and the culture-independent approach described in Chapter 4 (right) to identify antagonistic bacteria against S. 
suis within the porcine microbiome.
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Culture-dependent approach led to the identification of seven isolates that inhibit S. 
suis
Together with the group of Colin Hill at University College Cork, Ireland, a high-throughput 
approach using a robotic colony picking system was employed to isolate individual bacterial 
colonies originating from the microbiota of the palatine tonsils and small intestinal content 
of healthy piglets. The culturing conditions, like nutrient agar and aerobic atmosphere, that 
we used favoured the growth of S. suis. We isolated a total of 10,150 individual bacterial 
colonies from two pooled libraries of microbiota originating from the tonsils and small 
intestinal content samples, which were subsequently screened for growth inhibiting activity 
against three serotypes of S. suis using soft-agar overlay assays (see Figure 1). Isolates 
that showed clear zones of inhibition were selected for further characterisation, such as 
protease sensitivity to check if the antimicrobial compound was proteinaceous or due to the 
production of non-specific fermentative metabolites, such as acetate or lactate (Chapter 5). 
From the tonsil and small intestinal isolate libraries, 7 colonies with consistent in vitro activity 
displaying the largest zone of inhibition against more than one S. suis serotype were selected. 
These isolates were identified by alignments of their 16S rRNA gene sequence and/or MALDI-
ToF MS Biotyping (data not shown) (Table 1). 
 
Isolate # Location Closest  Species 16S rRNA Identity  
MALDI-ToF MS 
Biotyping 
4 Tonsil Rothia nasimurium  97.89 % (-) / (+) 
5 Tonsil Staphylococcus aureus * 99.20 % # (++) 
26 Tonsil Staphylococcus pasteuri 99.86 % (++) 
31 Tonsil Streptococcus gallolyticus subsp. pasteurianus  99.73 % (++) 
32 Tonsil Rothia nasimurium  97.89 % (-) / (+) 
14 † Ileum Streptococcus gallolyticus subsp. pasteurianus  99.73 % (++) 
G Tonsil Streptococcus ursoris  98.11 % # n.d. 
 
 
Table 1. Identification of isolates that displayed consistent growth inhibition of S. suis in overlay assays. Closest 
phylogenetic match based on the 16S rRNA gene sequence was identified using the EzTaxon server [57]. MALDI-ToF 
MS Biotyping identification probability score: (++) = secure genus identification, probable species identification, 
(+) = probable genus identification, (-) = unreliable identification. n.d. = not determined; # = partial 16S rRNA gene 
sequence (~500 bp) used for alignment identification; * = this Staphylococcus aureus group includes species that 
are not distinguishable based on 16S rRNA gene sequence alone; † = impure colony.
Three candidate antagonistic isolates (belonging to two species) were described in 
detail in this thesis. Chapter 5 described the characterisation of isolate #26, identified as 
Staphylococcus pasteuri, of which BAGEL3, a web-based tool for genome mining for putative 
bacteriocin genes [58], predicted the presence in the draft genome of two small ORFs 
encoding small antimicrobial peptides with high sequence similarity to Staphylococcal 
delta-lysins. We purified these two delta-lysins from bacterial cultures, and compared their 
antimicrobial and cytotoxic activities with their chemically synthesized peptide equivalents. 
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Our results support the conclusion from previous studies that Staphylococcal delta-lysins may 
have narrow-spectrum antimicrobial activity against several strains of Legionella, Bacillus 
megatherium, Staphylococcus aureus, and Streptococcus pyogenes [59-61]. Interestingly, the 
highly similar synthetic delta-lysin from S. aureus displayed a different spectrum of activity 
against a panel of S. suis strains when compared to the S. pasteuri synthetic peptides. The 
delta-lysin from S. aureus was initially considered to possess only haemolytic and cytotoxic 
activity [62-64]. However, based on current knowledge,  delta-lysins, which are part of the 
group of staphylococcal phenol-soluble modulin (PSM) peptides [65, 66], appear to have 
roles in both host colonization and direct competition with a narrow spectrum of bacterial 
species [67].
Chapter 6 focussed on the characterisation of porcine tonsil isolates #4 and #32, for which 
Rothia nasimurium (Actinobacteria) was identified as the closest phylogenetic neighbour. 
This species is distantly related to Streptomyces, soil bacteria that are well-known producers 
of antibiotics [68]. Genome mining for biosynthetic gene clusters using AntiSmash 3 [69, 
70] showed the presence of a non-ribosomal peptide synthetase (NRPS) gene cluster 
that codes for an NRPS assembly line organization identical to vlm from Streptomyces 
[71-75] and ces from Bacillus [76, 77]. Based on the sequences and substrate specificity 
predictions of its adenylation domains, this NRPS cluster was predicted to synthesize a cyclic 
dodecadepsipeptide consisting of the amino acids l-valine and d-valine, d-hydroxyvaleric 
acid and l-lactic acid. Mass spectrometry and nuclear magnetic resonance (NMR) analyses 
identified the purified peptide as valinomycin, a potassium (K+) ionophore or high-affinity K+ 
transporter that facilitates the movement of K+ ions through phospholipid membranes [71, 
72, 78, 79].
To our knowledge, NRPS gene clusters or NRPS-derived compounds have not been 
described in the genus Rothia. Moreover, valinomycin was, until now, only known to be 
produced by soil-dwelling Streptomyces species [71-75] and possibly also isolates belonging 
to the Bacillus pumilus group, although in the latter case the employed detection method 
was not suitable for reliable secondary metabolite identification [76]. Based on different G+C 
content of the NRPS gene cluster (48.7%) compared to the rest of the R. nasimurium genome 
(57.98%), we assumed it was relatively recently acquired from a Firmicute origin. Analysis of 
the genome sequence did not reveal any obvious features of a mobile genetic element that 
might explain how this R. nasimurium isolate acquired the vlm gene cluster. However the 
NRPS gene cluster in R. nasimurium is located between the genes disA and radA (Chapter 
6, Figure 4), and compared to genomes of R. mucilaginosa, R. dentocariosa and R. aeria, the 
orientation of disA has been inverted in the valinomycin producing R. nasimurium isolate. 
DisA (DNA integrity-scanning protein) is a non-specific DNA binding protein associated with 
DNA repair [80] and production of cyclic diadenosine monophosphate (c-di-AMP) [81]. The 
second messenger c-di-AMP has been linked to DNA repair [82] and regulation of the ktrAB 
operon that encodes a potassium transporter [83]. RadA (Radiation sensitive gene A), a highly 
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conserved protein in bacteria, is a member of the RecA/RadA/Rad51 protein superfamily and 
plays a critical role in homologous DNA recombination and DNA repair [84]. Furthermore, 
RadA can act as an antagonist of DisA by physical interaction to inhibit its c-di-AMP synthesis 
[85]. It is remarkable that these genes involved in DNA integrity and DNA recombination are 
in such close proximity to the inserted vlm gene cluster, and it is tempting to speculate that 
their reorientation could be related to a past recombination event.
Species belonging to the genus Rothia are found in diverse habitats ranging from soil and 
sediments to the respiratory and intestinal tracts of humans and other mammals [86-91]. 
Rothia spp. are not considered to be obligate pathogens, but R. dentocariosa has been 
associated with dental and periodontal ailments, and rare cases of systemic infection 
such as peritonitis [92] or endocarditis [93, 94]. Rothia mucilaginosa is often present in high 
abundance in the lung of cystic fibrosis patients [95] and usually treated as part of the normal 
oral microbiota, but its significance in pulmonary disease may be underestimated due to 
possible misidentification of the infecting microbe [96]. Mining the available genomes of R. 
dentocariosa (8) and R. mucilaginosa (20) did not reveal the presence of a putative NRPS 
cluster predicted to produce valinomycin. This was confirmed by the absence of S. suis S10 
inhibition in overlay assays by type strains R. nasimurium CCUG 35957, R. dentocariosa  DSM 
43762, and R. mucilaginosa DSM 20746 (data not shown). Based on biochemical, phenotypic 
and phylogenetic evidence on an unknown murine bacterial isolate, Collins et al. [86] 
proposed the novel species Rothia nasimurium, setting it apart from other members of 
the genus Rothia. There are, however, differences between the type strain R. nasimurium 
CCUG 35957T referred to by Collins et al. and the R. nasimurium isolates described in this 
thesis. When considering the 97.89% 16S rRNA gene sequence similarity, the difference in 
GC content (56% for R. nasimurium CCUG 35957T as determined by [86] vs. 57.98% for R. 
nasimurium #32) and the distinctive property of valinomycin production, one could argue 
that the strain we describe here could form a new species within the Rothia genus. Additional 
experimental evidence, such as biochemical characterization and cellular fatty acid analysis, 
would be required to make such a taxonomic decision and is outside the scope of this thesis.
Not all of the identified active isolates (see Table 1) were described in detail in this thesis. 
Isolate #31, for example, was identified as Streptococcus gallolyticus subsp. pasteurianus by 
16S rRNA gene sequence analysis and MALDI-ToF MS Biotyping, and its observed growth-
inhibiting activity against S. suis may be due to several factors. We ran BAGEL3, a web-based 
tool for genome mining for putative bacteriocin genes [58], on the draft genome sequence of 
isolate #31. BAGEL3 identified three putative bacteriocin encoding gene clusters: two were 
predicted to encode for linear azol(in)e-containing peptide (LAP) and one for an unmodified 
class II bacteriocin (data not shown). Additionally, initial analysis of the draft genome sequence 
using PHAST [97] identified 1 intact, and 4 incomplete or questionable phage DNA sequences. 
We did not experimentally attempt to isolate lytic phages from this isolate, but phages that 
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selectively target S. suis could be interesting candidates for therapeutic applications [98, 99]. 
Most antimicrobial activity against S. suis was found in extracts of bacterial cells made in 70% 
2-propanol 0.1% TFA, and not in cell-free culture supernatant of overnight liquid cultures or 
agar plate-grown bacterial cultures (data not shown). Tricine SDS-PAGE of this active fraction 
revealed the prominent presence of a peptide with a mass of ~5 kDa, which is in accordance 
with one of the BAGEL3 predicted LAPs. These initial results might suggest the presence of a 
small hydrophobic antimicrobial compound, such as a bacteriocin, rather than a lytic phage 
that is responsible for the observed antimicrobial effect of isolate #31 against S. suis. Further 
characterisation of this Streptococcus gallolyticus subsp. pasteurianus isolate is required to 
determine the exact nature of its antimicrobial effect against S. suis and the potential effects 
on host cells. This isolate might prove to be an interesting candidate, alone or in combination 
with the other isolates described in this thesis, for in vivo inhibition and reduction of S. suis 
in piglets.
The findings described in Chapter 5, Chapter 6, and in the section above, show that very 
diverse molecules, produced by phylogenetically unrelated bacteria that are part of the 
natural porcine microbiome, may display antimicrobial activity towards S. suis. Inspection 
of 16S rRNA gene sequence abundance showed that S. pasteuri was present in the tonsil 
samples of 18 out of 21 assayed piglets although at different abundances. Reads of 16S 
sequences with >99.4% identity to the valinomycin-producing R. nasimurium isolate were 
present in tonsil samples of 13 out of 21 sampled piglets. The S. pasteuri and R. nasimurium 
isolates identified in the culture-dependent approach as direct antagonists of S. suis did not 
show clear anti-correlation with S. suis abundance as described in Chapter 4.
Also, our culture-based screens did not identify any Lactobacillus antagonists of S. suis. 
This could strengthen the differential niche occupation theory, that where S. suis nearly 
exclusively occurs in the tonsillar areas, potentially antagonistic lactobacilli such as L. reuteri, 
a species that antagonises diverse bacteria through secretion of the bacteriocidal compound 
reuterin, hardly occur in the tonsillar areas. However, at least three other lactobacilli that 
displayed anti-correlation with S. suis abundance do occur in the oral cavity. It is likely 
that the growth conditions that were used during the culturing of microbiota isolates and 
agar overlay assays, in particular the media optimised for S. suis growth, were unsuitable 
for proper growth of Lactobacillus species; these species generally require different media 
for growth under laboratory conditions and are less tolerant to oxygen. For future studies, it 
would be of interest to obtain a combination of culture media favouring Lactobacillus growth 
and overlay agars that favour simultaneous growth of S. suis. Isolation and characterisation 
of Lactobacillus strains from the porcine tonsil or small intestine may lead to novel insights 
about the molecular mechanisms behind the observed anti-correlation with S. suis.
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Effects of AMPs on host cells
It is difficult to know at which concentrations the delta-lysins and valinomycin are produced by 
S. pasteuri and R. nasimurium, respectively, in the porcine oropharynx and/ or small intestinal 
tract and if such concentrations are high enough to actually inhibit S. suis. Detection and 
quantification of these molecules in tonsil or intestinal content samples by LC-MS/MS would 
be a suitable approach to shed light on the levels of delta-lysin or valinomycin production in 
vivo. We could show that the delta-lysins and valinomycin also pose some toxicity to the host, 
although the concentrations at which host cells (especially epithelial cells) show symptoms 
of damage are substantially higher than the concentrations at which S. suis killing is achieved 
(Chapter 5). Both valinomycin and delta-lysin were often described as molecules that 
primarily display cytotoxic or haemolytic effects on host cells [62, 63, 100-103], although the 
antimicrobial, antiviral and antitumor activities of valinomycin have also been reported [73]. 
Yet, it remains unclear what the exact biological and ecological role of these molecules might 
be, and in what manner they confer benefit to the producing S. pasteuri or R. nasimurium 
bacteria. Chapter 6 aimed to expand the knowledge on valinomycin production by a 
commensal bacterium, such as R. nasimurium, and explored several possible effects this 
ionophore may have in vivo. Figure 2 shows a schematic overview of the potential roles of 
valinomycin production by R. nasimurium in the tonsil or small intestine. Broad-spectrum 
antimicrobial activity has been reported for valinomycin [103], and we observed growth 
inhibition of all tested strains of S. suis in a well-diffusion assay by valinomycin-containing 
extracts of R. nasimurium. However, most other bacteria that we tested were not susceptible, 
and similarly, a 100-fold difference in MIC was observed for pure valinomycin between 
closely related Rothia species (Chapter 6). Apparently, some bacteria are better able to 
resist the antimicrobial action of valinomycin, and this differential susceptibility may also 
be of importance in vivo. We also showed that valinomycin was able to reduce epithelial 
cell barrier function, induce apoptosis in epithelial cells, and induce inflammation and IL-1b 
production in macrophages, although epithelial cells were resistant to higher concentrations 
of valinomycin than immune cells. As shown in Figure 2, the exact biological function and 
effects of valinomycin production by R. nasimurium in vivo remains unclear, and is likely 
to depend on multiple environmental factors, such as K+ concentration, bacterial density, 
nutrient availability, host defense molecules, etc.
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Figure 2. Simplified graphical representation of possible roles of valinomycin production by Rothia nasimurium on 
host mucosal surfaces. (1) valinomycin has an antimicrobial effect on S. suis and potentially on other pathogenic 
bacteria, (2) production of valinomycin could give R. nasimurium an advantage over competing microbes, (3) 
valinomycin may be involved in signalling within the Rothia biofilm community, possibly via induced potassium 
release, (4) cytotoxic effects on epithelial cells may cause inflammation and release nutrients for R. nasimurium, 
(5) the triggering of host inflammation responses may extend beyond the epithelial layer (6) R. nasimurium may 
promote infection by S. suis and other pathogens by damaging the epithelial cells or increasing barrier permeability.
Combining different approaches to find novel bacterial antagonist against S. suis
Both approaches we undertook to identify microbial antagonists of S. suis have limitations and 
advantages.  The outcome of culture-dependent identification of AMP producing antagonists 
of S. suis may be subject to several factors such as the selectivity of the culture conditions, 
number of screened colonies, and selection of target strains of S. suis. Furthermore, the genes 
that are responsible for the production of the antimicrobial compound may be regulated 
differently under laboratory growth conditions compared to in vivo. This might partly explain 
why many isolates that we initially selected, lost their ability to inhibit the growth of S. suis 
after continued culturing under laboratory conditions. One main advantage of the culture-
dependent approach is the relative simplicity of isolating and purifying the antimicrobial 
compounds and linking this directly to the producing bacterial strain that can be characterized 
genetically. Culture-independent approaches, however, provide indirect information about 
bacterial antagonism and the 16S rRNA gene is in most cases unsuitable for the identification 
of bacteria to the species level. In addition, it offers evidence on the presence and abundance 
of bacterial taxa, but it does not provide any functional information.
The research described in this thesis demonstrates the suitability of culture-based 
approaches to identify natural products that can kill pathogenic bacteria. Together with 
the microbiota profiling results, a picture emerges where S. suis is part of a polymicrobial 
community, possibly occurring in biofilms, that may contain other pathogenic bacteria as 
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well as antagonistic species. It is likely that in newborn piglets, biofilm microbial composition 
depends on initial colonisation via the sow, the environment and the feed. Overcrowding 
and suboptimal ventilation may promote growth of pathogens, whereas more optimal initial 
growth conditions, including good animal welfare and hygiene practices, and healthy sows, 
may promote growth of bacteria that better suppress outgrowth of S. suis and other pathogens 
[104, 105]. It would thus be of interest to change focus of future research on suppressing S. suis, 
from the point of view of a single-pathogen problem to one of a polymicrobial nature, where 
S. suis is part of a complex of respiratory pathogens, bacteria, viruses and maybe fungi, that 
colonise the upper respiratory tract including the tonsillar areas. The bacterial part of the 
pathogen complex may be dispersed further into the upper GI tract via the piglet’s feeding. 
Infection of piglets by S. suis via the tonsils might thus originate from bacterial (and viral) 
pathogens that entered via inhalation, and actual infection could be dependent on infection 
pressure by S. suis and other pathogens. Infection in the first weeks upon weaning may be 
stress-induced but may also be a result of a sudden shift from milk oligosaccharides to starch 
[43] in those pathogens that use CcpA to control carbohydrate metabolism. Moreover, it is 
likely that consumption of solid feed in addition sow’s milk leads to a change in the microbiota 
composition. To illustrate this, LEfSE analysis showed that in a group of 21 animals that 
might have consumed solid food before weaning, based on an ambiguous visual inspection 
of the colour of their feces, three bacterial species (Actinomyces denticolens, Fusobacterium 
nucleatum and Streptococcus ferus) were enriched in the tonsillar areas compared to piglets 
that only appeared to have consumed sow’s milk prior to weaning (Chapter 4). Polymicrobial 
infections of this nature are expected to be influenced by farm practices as well as pig contact 
with microbes colonising diverse biotic (sows and other piglets) and contaminating abiotic 
surfaces including the air circulation, walls and floor coverings.
Applications with the endogenous microbiota to reduce the risk for S. suis infection in 
piglets
As mentioned previously, a stable and diverse microbiota may confer health benefits to the 
host and provide colonisation resistance against pathogenic bacteria [55, 56]. The research 
described in Chapter 4-6 emphasises that certain members of the endogenous microbiota 
may display direct or indirect antagonism against S. suis. Conversely, co-occurring 
complexes of opportunistic or pathogenic bacteria may promote the outgrowth of S. suis. 
Neonatal piglets become colonised by S. suis as part of their developing natural microbiota 
at farrowing via vertical transmission from the sow [27, 28]. S. suis mostly causes morbidity 
and mortality in piglets post-weaning, a period associated with a high level of stress, dietary 
change to starch-rich feed [27, 34, 35]. During early life the porcine microbiota composition 
is flexible and influenced by environmental factors, and weaning has been shown to have an 
important impact on microbiota composition [44]. We hypothesise that modulation of the 
microbiota during the early life of a piglet may be used to reduce the risk of S. suis associated 
invasive post-weaning disease. Currently, similar approaches with probiotic supplements are 
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being used in pigs to improve animal performance and overall health, although for most 
applications the underlying mechanism of action that confers the benefits is unknown [106-
109].
As the tonsils and small intestine have been shown to be important niches colonised 
by S. suis, and potentially also provide a point of entry for systemic disease, alteration of 
the tonsillar and small intestinal microbiota is anticipated to have an impact on S. suis 
abundance. One or multiple bacterial isolates that showed direct inhibition of S. suis 
may be administered to piglets through addition to the feed or drinking water, or by oral 
or intranasal application of a bacterial suspension in the period between farrowing and 
weaning. Alternatively, administration of a more complex microbial consortium, composed 
of the most abundant key bacterial taxa found in healthy pigs, could be considered. Given 
that these endogenous bacterial strains were isolated from piglets, there is a high probability 
that they may successfully colonise, or at least remain present in sufficient abundance until 
after the post-weaning period in which piglets are most vulnerable to infections by S. suis. 
The feasibility of such a strategy to reduce S. suis load, and consequently risk for invasive 
disease, could be experimentally shown by using caesarean-derived piglets in a specific-
pathogen free (SPF) clean environment. In that way, the microbiota composition of the 
neonatal piglets is less likely to vary due to the colonisation by sow-associated microbes. 
16S- or whole-genome shotgun sequencing could be used to observe colonisation, changes 
to the microbiota, and determine the effect on S. suis abundance. Obviously, this approach 
may also be suitable for other porcine opportunistic pathogens.
Over the last decade, the fundamental scientific and applied importance of small molecule 
metabolites and peptides in microbe-host and microbe-microbe interactions within the 
microbiota have become clear [110, 111]. In addition to roles in bacterial communication 
[112], these molecules also modulate host health and disease by (in)directly influencing host 
physiology including the development of the immune system in new-borns. Discovering 
these microbiota-derived biologically active small molecules and the genes that encode 
them are essential requirements for understanding the microbiota-host interplay and are 
needed for developing bacterial communities with therapeutic potential to prevent or 
cure infections with bacterial pathogens. Future work in host-microbe interactions should 
therefore include research aimed at elucidating the exact function(s) of bacteriocins or 
secondary metabolites, for instance using isogenic mutants, to assay their expression and 
activity in vivo. Such work requires effective animal models, preferably using the same host 
organism from which the original metabolite- or peptide-producing isolates were sampled. 
Taking an unbiased ecosystem approach, where microbial communities are considered to 
function as complex networks, makes it possible to appreciate the microbial ecology where a 
microbe, such as S. suis, is just one small component of the entire microbiome. Integration of 
multiple unbiased whole-genome-sampling technologies: (meta-)genomics, metabolomics, 
proteomics, and transcriptomics of microbiota and host help to draw a chart of the whole 
microbiome. Such “charts” visualise hidden parts of the microbiome, they may for instance 
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show predicted networks of co-occurring opportunistic or pathogenic bacteria, but may 
also suggest mutualistic interactions between commensals, e.g.  multiple Lactobacillus 
species including known probiotics, that may have (indirect) beneficial effects on the host. 
Combining unbiased -omics platforms with culture-dependent screens therefore appear to 
have true potential to contribute to finding alternatives for conventional antibiotics within 
the endogenous microbiota.
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Summary
The increasing prevalence of antibiotic resistance in pathogenic bacteria and the potential 
future implications for human and animal morbidity and mortality, health-care costs and 
economic losses pose an urgent worldwide problem. As a result, exploration of alternative 
strategies to combat antibiotic resistant bacteria have intensified over the last decades. 
The use of naturally occurring antimicrobial peptides (AMPs) has received considerable 
scientific and commercial interest due to their antimicrobial activity and plethora of possible 
therapeutic applications. The work described in this thesis focused on the study of AMPs and 
other bioactive molecules produced by bacteria as potential alternatives to prevent or treat 
infections with pathogenic bacteria. 
In the first part of the thesis, the antimicrobial potency of eukaryotic AMPs and the responses 
they elicit in bacteria were studied. Chapter 2 described the potential for a selection of 
frog skin AMPs and analogues for development into novel topical therapeutics to treat skin 
infections caused by antibiotic resistant bacteria. We showed that several natural AMPs 
and analogues displayed promising growth-inhibiting activity against multi-drug resistant 
pathogenic bacteria whereas these AMPs or analogues did not inhibit growth of probiotic 
or commensal strains. In Chapter 3 the generic and adaptive resistance mechanisms in 
Streptococcus suis upon exposure to sub-lethal concentrations of a model cationic AMP, the 
human cathelicidin LL-37, were studied. We found significantly altered expression of genes 
associated with two-component signalling, membrane transport and carbohydrate uptake, 
as well as upregulation of genes involved in adhesion, pilus formation, and resistance against 
bacteriocins or small peptides.
The second part of this thesis aimed to increase knowledge about the role of the porcine 
microbiota in S. suis abundance, with the purpose to identify commensal bacteria that 
displayed strong and selective antagonism against this pathogen, possibly via the production 
of AMPs. In Chapter 4 we identified bacterial taxa that show strong positive or negative 
correlations with the abundance of S. suis and other porcine pathogens. The results indicated 
that colonisation by S. suis was correlated with a group of other opportunist pathogens, 
including species belonging to the genera Actinobacillus, Actinomyces, Pasteurella and 
Streptococcus which are are known to cause respiratory disease. The results also revealed 
that the microbiota from the tonsil or small intestine contain bacteria that might display (in)
direct antagonism against S. suis. Based on this result, we screened the tonsillar and small 
intestinal microbiota for isolates that could specifically inhibit the growth of S. suis. Chapter 
5 described the isolation and identification of a Staphylococcus pasteuri isolate producing 
two α-helical peptides that possess narrow-spectrum antimicrobial activity against multiple 
serotypes of S. suis. In Chapter 6 we characterized a Rothia nasimurium strain from the 
palatine tonsil that produces the non-ribosomally synthesized ionophore antibiotic 
valinomycin, and investigated the effects of this cyclic peptide on other bacteria and host 
cells. Chapter 7 summarizes and discusses the key results of the research described in this 
thesis and describes possible directions for future research. 
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This thesis increased the understanding of the role of host- and microbiota-derived 
biologically active small molecules in microbe-microbe and microbe-host interplay. Such 
knowledge may contribute to the development of novel therapeutic solutions to treat 
antibiotic resistant bacteria, such as beneficial microbial communities (i.e. next-generation 
probiotics) or biotechnological applications of natural or modified AMPs.
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Samenvatting
De toename van antibioticaresistentie van ziekteverwekkende bacteriën vormt een urgent 
wereldwijd probleem vanwege de bedreiging van de volksgezondheid, de mogelijke 
toekomstige implicaties voor de humane en veterinaire geneeskunde en de bijkomende 
economische schade. Gedurende de afgelopen decennia is daarom het onderzoek naar 
alternatieve strategieën voor de aanpak van resistente bacteriën geïntensiveerd. Veel 
wetenschappelijke en commerciële aandacht is er voor het mogelijke therapeutische gebruik 
van antimicrobiële peptiden (AMPs) die van nature voorkomen. Dit proefschrift behandelt 
het onderzoek van AMPs en andere door bacteriën geproduceerde bioactieve moleculen 
als mogelijke alternatieven voor het voorkomen of bestrijden van infecties met pathogene 
bacteriën.
Het eerste gedeelte van het proefschrift is gewijd aan de antimicrobiële activiteit van 
eukaryote AMPs en de reacties van bacteriën op deze peptiden. Hoofdstuk 2 beschrijft een 
selectie van AMPs afkomstig van kikkerhuid als een beginpunt voor verdere ontwikkeling van 
deze peptiden tot mogelijk therapeutische toepassing bij de behandeling van huidinfecties 
met resistente bacteriën. We laten zien dat een aantal van nature voorkomende AMPs en 
analoge peptiden veelbelovende antimicrobiële activiteit vertonen tegen verscheidene 
resistente pathogenen, maar niet tegen commensale of probiotische bacteriën. In Hoofdstuk 
3 onderzochten we de reactie en algemene en adaptieve resistentie mechanismes van 
Streptococcus suis na blootstelling aan subletale concentraties van humaan cathelicidine 
LL-37. We vonden significant veranderde expressie van genen die betrokken zijn bij twee-
component-systemen, membraan transport en opname van koolhydraten, alsmede 
een verhoogde expressie van genen die te maken hebben met adhesie, pilus formatie en 
resistentie tegen bacteriocines of kleine peptiden.
Het tweede gedeelte van dit proefschrift heeft als doel om de kennis omtrent de rol van de 
microbiota bij de aanwezigheid en talrijkheid van S. suis in varkens te vergroten, met het oog 
op identificatie van sterke en specifieke antagonisten tegen deze pathogeen (mogelijkerwijs 
door middel van AMP productie). In Hoofdstuk 4 identificeren we bacteriële taxa die sterke 
positieve of negatieve correlatie laten zien met de talrijkheid van S. suis en andere pathogene 
bacteriën.  Kolonisatie van biggen met S. suis correleert met de aanwezigheid van een 
groep opportunistische bacteriën behorende tot de geslachten Actinobacillus, Actinomyces, 
Pasteurella en Streptococcus die vaak betrokken zijn bij respiratoire ziektes in varkens. De 
resultaten laten ook zien dat (in)directe antagonistische bacteriën van S. suis een onderdeel 
van de microbiota in de keelholte en dunne darm kunnen uitmaken. Hierop voortboordurend 
hebben we de microbiota van de keelholte en dunne darm getest op aanwezigheid van 
bacteriën die de groei van S. suis konden tegengaan. Hoofdstuk 5 beschrijft de isolatie 
en identificatie van een Staphylococcus pasteuri stam die twee α-helische peptiden met 
smalspectrum activiteit tegen S. suis uitscheidt. In Hoofdstuk 6 bespreken we een Rothia 
nasimurium stam afkomstig uit de keelholte die de niet-ribosomaal gesynthetiseerde 
ionofoor valinomycine produceert en hebben we de activiteit van dit cyclische peptide op 
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humane en bacteriële cellen onderzocht.  Hoofdstuk 7 vat de belangrijkste bevindingen van 
dit proefschrift samen met aanbevelingen voor mogelijk toekomstig onderzoek. 
Dit promotieonderzoek draagt bij aan kennis over de rol van kleine peptiden met 
biologische activiteit afkomstig van de gastheer of de microbiota in de interacties tussen 
gastheer en microben en microben onderling. Zulke kennis zou bij kunnen dragen aan de 
ontwikkeling van nieuwe, alternatieve oplossingen om antibioticum-resistente bacteriën te 
bestrijden, zoals heilzame microbiële gemeenschappen (volgende-generatie probiotica) of 
biotechnologische toepassingen van natuurlijke of aangepaste AMPs.
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